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chapter 1 
Introduction 
The most relevant literature is reviewed Firstly, an overview of the etiology, 
diagnosis and therapy of ovarian carcinoma is presented Secondly, the aspects 
affecting tumour targeting with radiolabeled monoclonal antibodies are 
addressed In addition, the concept of anti-tumour χ anti effector cell bispecific 
antibodies and the results of in vitro, animal and clinical studies with these 
antibodies are discussed Finally, the aim of the studies described in this thesis 
are depicted 
1 1 Ovarian carcinoma 
In the Netherlands ovarian cancer is the fifth most frequent malignancy among 
females, and the fourth cause of death as a result of cancer in women The 
incidence of ovarian cancer was 1257 cases in 1 9 9 1 , and mortality was 1053 
(1) 
The etiology of ovarian cancer is still unknown Five to ten percent of the 
ovarian cancer cases is considered to be familial (2, 3) The hereditary pattern is 
thought to be autosomal dominant with variable penetration (3) A family 
history of ovarian cancer was associated with a 3 6-fold increased risk for the 
disease (4) Presence of a genetic susceptibility locus for hereditary breast and 
ovarian cancer has been demonstrated on the long arm of chromosome 17 (5) 
Recently, the BRCA1 gene was cloned (6) This gene is expressed in numerous 
tissues, including breast and ovary, and encodes for a 1863 amino acids 
protein The BRCA1 structure resembles to transcription factors that interact 
with DNA to switch other genes on and off Different mutations have been 
detected in five of the eight kindred studied It is expected that different 
mutations will trigger cancer at different ages of onset and will carry different 
likelihoods of triggering breast or ovarian cancer So far, there are no conclusive 
data indicating that the BRCA genes play a role in the oncogenesis of non-
hereditary cancers (7) 
Epidemiological studies identified several factors that may be involved in 
oncogenesis of ovarian cancer exposure to talcum powder, tobacco, alcohol, 
coffee, viral infections (8, 9) In addition, reproductive and menstrual events, 
use of oral contraceptive or ovulation inducing drugs are associated with the 
risk of developing ovarian cancer an decreasing number of ovulations is associ­
ated with a decrease in the relative risk (10, 1 1 , 12) 
More than 5 0 % of the patients present with stage III or IV disease at the time 
of diagnosis The main reason for this finding is the few, aspecific symptoms 
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accompanying the disease· abdominal pain, abdominal distension, gastro-
intestinal complaints and abnormal vaginal blood loss. Screening of the popula-
tion is considered to be of no benefit because of the low prevalence of the 
disease and the low positive predictive value of the available diagnostic 
methods (13, 14) For women with a family history of ovarian cancer annual 
gynaecologie examination is recommended (15) Only in case of the hereditary 
ovarian cancer syndrome annual gynaecologie examination, CA125 determina-
tions and ultrasonography are advised (15). 
Until now, an explorative laparotomy remains the most accurate method for 
establishing the diagnosis in patients suspected of having ovarian carcinoma. 
The extent of the disease can be fully defined (staging) and maximum resection 
of the tumour load has to be pursued (16, 17, 18). The results of a prospective, 
randomized trial indicated prolonged survival after intervention debulking in 
patients with residual disease > 1 cm after primary cytoreductive surgery as 
compared to the group of patients not secondly operated on (19) The value of 
secondary cytoreduction after completion of chemotherapy is not yet clear (20 -
24) 
In the first-line treatment of ovarian carcinoma, cytoreductive surgery is 
followed by systemic chemotherapy Since the 1980's platinum-based combina-
tion chemotherapy (cisplatinum or carboplatin combined with cyclophospha 
mide) has been considered as the treatment of choice (25) With six cycles of 
chemotherapy response rates of 60 70% have been obtained. Results from two 
Dutch randomized studies indicated that platinum-based combination chemo 
therapy enhanced survival by more than 10% at 5 and 10 years compared to 
multi-agent chemotherapy without platinum (26) However, the median overall 
survival is still limited (27) Recently, clinical anti-tumour activity was demon-
strated for the taxanes placitaxel and docetaxel (28 - 30). In phase II trials 
therapy with paclitaxel in previously treated ovarian cancer patients demon 
strated response rates of 20 to 4 8 % (30, 31) Preliminary results from a phase 
III study in previously untreated, suboptimally debulked ovarian cancer patients 
indicated that pachtaxel/cisplatin therapy was associated with an increased 
response rate (79%) as compared to standard cisplatin/cyclophosphamide 
treatment (62%) (32). Improvement of the progression-free interval was 
achieved, while survival analysis is as yet premature. 
However, even when primary treatment results in a complete remission, still 25 
15 
4 0 % of these patients will relapse (33). Retreatment with platinum-based 
combination therapy is appropriate in patients who relapse more than 6 months 
after discontinuation of a platinum-containing regimen (34) In patients with 
platinum-refractory disease, therapy with pachtaxel is considered the treatment 
of choice (34). However, the role of salvage chemotherapy is limited because 
response rates to second-line agents are modest and responses are of short 
duration (34). 
Research continues in order to improve the established modalities for diagnosis 
and therapy and to explore new ones. During the last decades the possible role 
of anti-tumour antibodies (Figure 1) for diagnosis and therapy of ovarian cancer 
has gained great interest. 
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Figure 1. The basic structure of an immunoglobulin and its fragments. The 
immunoglobulin (= antibody) consists of two identical light chains and 
two identical heavy chains linked together by disulphide bonds The 
variable region of the heavy and light chain together form the the antigen 
binding portion (Fab) The Fc portion (which may activate complement) 
binds to Fc receptors on other cells 
carbohy 
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1 2 Radiolabelled monoclonal antibodies 
History 
Assuming that tumours express specific antigens, Ehrlich suggested at the 
beginning of this century that antibodies directed against these antigens could 
be applied for therapy of tumours (35). Specific anti-tumour antibodies could be 
used to deliver drugs, effector cells or radionuclides to tumours in the human 
body. With the introduction of the hybridoma technology by Kohier and Milstein 
(36) it became possible to produce antibodies directed against a single antigenic 
determinant in large quantities. 
Tumour-specific antigens have been identified particularly in virally induced 
tumours in vertebrates. However, in humans tumour-specific antigens have not 
been identified, only tumour-associated antigens have been found. The tumour-
associated antigens are preferentially expressed on a certain tumour type, and, 
are always expressed to a certain extent on other tumours and also on normal 
tissues 
Monoclonal antibodies (MAbs) directed against ovarian carcinoma-associated 
antigens can be applied in several areas. MAbs are used by pathologists for 
differential diagnosis of tumour specimen and MAb-based assays are used for 
detection of tumour-associated antigens shed into the circulation systems In 
addition, tumour targeting can be pursued MAbs against ovarian carcinoma-
associated antigens have been applied in vivo for radioimmunoscintigraphy (RIS) 
and for radioimmunotherapy (RIT). 
Radioimmunoscin tigraph y 
From the late 1970's the applicability of MAbs for tumour detection was 
assessed in RIS studies For this purpose MAbs were labelled with radionuclides 
emitting gamma rays. With the use of a gamma-camera the biodistribution of 
radiolabeled MAbs could be visualized Radionuclides used for these imaging 
studies are iodine-131, iodine-123, indium-111, and technetium-99m. The 
results of RIS with the various MAbs labelled with different radionuclides in 
ovarian carcinoma patients have been reviewed by Massuger et al (37). Buist & 
Kenemans (38) compared the results of RIS with those of the conventional 
imaging techniques used in ovarian cancer patients. RIS data acquired in 580 
patients compiled from 18 studies showed an average sensitivity of 78%, a 
17 
speci f ic i ty of 8 0 % , and an accuracy of 7 7 % (39) . These percentages are similar 
as those obta ined w i t h u l t rasonography and compu ted t o m o g r a p h y . Clinical 
studies indicated that the ef f icacy of ant ibody-gu ided target ing of rad ioact iv i ty 
t owards ovar ian cancer is a f fec ted by several fac tors (Table 1). 
Table 1 Factors interfering with tumour targeting using radiolabeled monoclonal 
antibodies 
Tumour 
Antigen 
Antibody 
Radionuclide 
HAMA development 
localization 
size 
vascularization 
expression 
heterogeneity 
internalization 
circulating antigen 
specificity 
affinity for the antigen 
species (munne/chimeric/human) 
antibody form dgG/F(ab')2/Fab') 
antibody dose 
route of administration 
physical half-life 
energy of photon emission 
labelling chemistry 
non-specific accumulation 
Antigens 
It has been s h o w n that ant i - tumour M A b s preferent ial ly localize in tumour t issue 
after in t ravenous in ject ion Ant ibod ies have to pass some barriers on their w a y 
to the tumour cel l . First, after in t ravenous (i.v ) in ject ion the M A b has to 
migrate f rom the intravascular to the extravascular space The endothe l ium of 
the tumour vascu la ture of ten has a defect basal membrane , resul t ing in 
increased permeabi l i ty . Passage th rough the extracel lular space occurs th rough 
d i f fus ion, w h i c h is coun te rac ted by the interst i t ial pressure Ar r iv ing at the outer 
cell layer of the t umour nest , intercel lular junc t ions may interfere w i t h penetra 
t ion of the M A b in deeper cell layers. The d is t r ibut ion of M A b s w i t h i n tumours 
is af fected by a series of fac tors (40) . Tumour size, t umour vascu lar i ty , blood 
perfusion of the tumour , vascular permeabi l i ty , ant igen d is t r ibut ion w i th in the 
tumour , and the presence of necrosis all interfere w i t h in v ivo ant ibody uptake 
18 
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(41 - 48). In addition, the antigen profile in primary tumours may differ from 
that in its metastases (44, 45). Shedding of antigen into the circulation may 
result in antigen-antibody complex formation after administration of the radio 
immunoconjugate (49), which may alter the biodistribution and tumour uptake 
of the MAb (50) 
Antibody form 
So far, no consensus has been achieved with regard to the use of intact or 
fragmented MAbs in humans (Table 2) Antibody fragments potentially have 
several advantages over intact IgG such as faster blood clearance, resulting in 
higher tumour to non-tumour tissue ratio's (50 - 52) In animal experiments, 
radioimmunotherapy with F(ab')2 fragments showed better results (53, 54) 
However, for clinical radioimmunotherapy, F(ab')2 fragments may be less useful 
because of the lower absolute uptake in the tumour and faster clearance from 
tumour tissue Recently, ovarian cancer patients were simultaneously injected 
ι v. with radioiodmated whole IgG MOv18 MAb and its F(ab')2 fragment (55). At 
two days as well as at six days post injection, tumour uptake was higher for 
whole IgG compared to its fragment. 
Table 2 Several characteristics of the antibody forms 
Molecular weight (kDa) 
Elimination Τ Vi (h) 
Tumour uptake (% ID/kg) 
Tumour/Non tumour ratio 
IgG 
150 0 0 0 
72 
1 - 1 0 0 
1 - 10 
F(ab')2 
1 00 0 0 0 
24 
0 1 - 1 0 
1 - 10 
Fab' 
50 0 0 0 
10 
0 0 1 - 1 
1 - 10 
Antibody species 
So far, most MAbs raised against tumour-associated antigens are from mouse 
origin An important problem associated with the use of these murine MAbs is 
the possible development of human anti-munne antibodies (HAMA). The 
presence of HAMA may lead to faster blood clearance, increased uptake of the 
radioimmunoconjugate in liver and spleen, and reduced tumour uptake at 
repeated injection (56 - 58). These phenomena result from complex formation of 
19 
HAMA with the administered MAb (59). Furthermore, HAMA may interfere with 
in vitro immuno assays (60 - 62) The use of human(ized) and chimeric MAbs 
and the use of antibody fragments may reduce the incidence of HAMA develop 
ment 
Human anti-tumour antibodies are difficult to obtain and are unstable A series 
of humanized antibodies is now becoming available for clinical use After 
repeated administration of radiolabelled and cold human MAb 16 88 up to 1000 
mg no anti-16 88 antibodies could be detected up to 9 weeks post injection 
(63, 64) However, after repeated injections of the human MAb 28A32 as well 
as the human MAb 88BV59, low levels of anti-human antibodies were detected 
(63, 65) New technological developments such as phage display and compie 
mentarity determining regions (CDR)-graftmg may allow the production of 
human and humanized antibodies in the near future (66, 67) 
Chimeric antibodies combine the tumour specific variable regions of a mouse 
MAb with the constant domains of a human immunoglobulin It was shown that 
the immunogenicity of the varaible region of murine antibodies may vary greatly 
(68) In ovarian cancer patients immune responses could not be detected after 
ι ν administration of a cocktail of 1 3 1 l IgG (1 mg), 12SI - F(ab')2 (1 mg) and 
9 Э т
Тс Fab' (1 mg) of chimeric MOv18 (69) However, others reported that 
chimeric antibodies still elicited immune responses (70 72) These results 
suggest that human(ized) and chimeric MAbs are probably less immunogenic 
and therefore are potentially useful for therapy, because they may allow 
repeated administrations 
Route of administration 
Ovarian cancer is mostly confined to the peritoneal cavity In such cases 
regional delivery of the radiolabeled MAb has been suggested to increase 
tumour uptake with decreased toxicity to the dose limiting organ (bone marrow) 
and other critical organs (liver, kidney, gastro-intestinal tract) Dedrick described 
the theoretical and experimental bases for intraperitoneal (ι ρ ) administration of 
drugs (73) Higher concentration at the site of the tumour, slower body clear 
ance, and better tissue penetration were found to be advantages of ι ρ adminis­
tration In nude mice bearing ι ρ tumour grafts simultaneous ι ν and ι ρ 
administration of radiolabeled MAbs resulted in higher uptake in ascitic cells 
after ι ρ injection, whereas MAb uptake in solid tumour deposits after ι ρ 
administration was only temporary higher or showed no advantage over ι ν 
injection (74 - 77) Uptake in normal tissues was lower and, consequently 
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systemic toxicity was suggested to be reduced by i.p. administration (78). 
Clinical studies have indicated that the biodistribution of radiolabelled MAbs in 
patients may be influenced by its route of administration. In gastrointestinal 
adenocarcinoma patients dosimetric calculations predicted effective radiation 
doses to i.p. cancer deposits with reduced risks to normal tissues after i.p. 
administration of 131l-labelled MAb (79). Simultaneous i.p. and i.v administration 
of B72.3 MAb to colorectal carcinoma patients demonstrated systemic adminis­
tration to be more appropriate for large solid tumours, whereas for small 
peritoneal implants the locoregional route seemed to be preferable (80). In 
ovarian carcinoma patients i.v. administration of HMFG2 resulted in higher 
absolute uptake in solid tumour, while i.p. injection resulted in higher antibody 
uptake in ascitic cells (81). Crippa et al. (82) observed that intraperitoneal 
injection of murine MOv18 IgG gave a more favourable biodistribution than via 
the intravenous route. 
Table 3. Radionuclides used for tumour detection with monoclonal antibodies 
Radio­
nuclide 
131 • 
, 2 3 , 
, n l n 
9 9 mTc 
Physical 
half-life 
θ d 
13.3h 
67.4 h 
6.0h 
Photon 
energy (keV) 
364 
159 
173 & 247 
140 
Labelling 
methods 
direct 
direct 
chelate 
direct or chelate 
Costs per 
patient dosage 
low 
high 
intermediate 
low 
Radionuclide 
The radionuclides most frequently used in clinical RIS studies are the gamma-
radiation emitting radionuclides 1 3 1 l , 1 2 3 l , 1 1 1 ln and 9 9 mTc (Table 3). 1 3 1 l has been 
most widely applied. However it is not an ideal radionuclide for RIS due to its 
beta radiation, its relatively long half life and the high-energy gamma radiation. 
Furthermore, radioiodinated MAbs are presumed to be susceptible to dehalo-
genation, which would result in dissociation of the MAb and its radiolabel. 1 2 3 l 
has a more suitable energy for gamma detection, but its use is limited because 
of its high costs and limited availability. n i l n has a suitable halflife and its 
energy is relatively high, resulting in a high radiation burden. The main disadvan­
tage of 1 1 1 ln as a radionuclide for RIS is the high uptake in liver and spleen. 
21 
99mTc is a very attractive radionuclide because it is readily available at low costs 
and has ideal imaging characteristics. However, it short halflife does not permit 
imaging later than 24 h post injection. 
For application in therapeutic studies radionuclides have to meet other require-
ments compared to those for diagnostic studies. The absorbed dose from radio-
immunotherapy with monoclonal antibodies varies as a function of physical 
characteristics of the radionuclide, the penetration of the radioimmunoconjugate 
within tumour and normal tissue and the size of the tumour deposits treated 
(83) In most RIT studies MAbs were labelled with 131l or 90Y, both beta-radi 
ation emitters. Beta-electrons have a range of several cell diameters and are the 
most widely used radionuclides for cancer radiotherapy (Table 4). lodine-131 
has a well established role in the treatment of both benign and malignant 
thyroid disorders It is readily available and it is inexpensive, lodine-131 has a 
suitable half life of 8 days and emits ß radiation leading to an average energy of 
0 61 MeV with a range of approximately 0.1 cm in soft tissue (r90 = 0.83 mm 
r90 is the radius within which 90% of the radiation is delivered) It can be 
directly labelled to MAbs and is cleared rapidly from non-target organs The 
gamma radiation is a disadvantage with regard to whole body radiation, 
although it enables analysis of localization via scintigraphic studies after 
administration of a therapeutic dose. 
Yttnum-90 has the advantage of a higher energy (2.2 MeV) and thus a greater 
radiation range (r90 = 5 34 mm). It has a sufficiently long half-life of 2 7 days 
In addition, this radionuclide emits no gamma radiation. However, it is rather 
difficult to achieve a stable 90Y-labellmg of MAbs. Especially because yttnum-90 
is known to be a bone-seeking agent after dissociation of the metal-chelate 
complex, this particular radionuclide may cause excessive myelotoxicity, 
thereby limiting the maximum dose that can be administered safely (84). 
Furthermore, the DTPA as well as the DOTA chelate used for labelling 90Y to 
MAbs may be immunogenic (85) 
Rhenium-186 seems to be an attractive candidate for radioimmunotherapy. This 
radionuclide emits beta radiation with an energy of 1.07 and 0 93 MeV. It has a 
radiation range of 1 8 mm with a suitable half life of 3 7 days However, it is 
very difficult to couple large amounts of 186Re to MAbs. The development of 
new labelling methods may allow the use of this radionuclide in the near future 
(86, 87) 
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Table 4 Radionuclides used for therapy with monoclonal antibodies 
Radio­
nuclide 
, 3 , | 
90γ 
1 8 6 R e 
Physical 
half-hfe 
8 d 
2 7 d 
3 7 d 
Photon 
energy 
610 keV 
2 27 MeV 
1 07 MeV 
Type of 
radiation 
beta + gamma 
beta 
beta + gamma 
Labelling 
methods 
direct 
chelate 
direct or chelate 
Radioimmuno therap y 
Since gamma camera imaging has demonstrated 'selective' tumour uptake of 
MAbs in patients after administration of radiolabeled MAbs, antibody directed 
radiotherapy has gained more interest The Hammersmith Oncology Group firstly 
reported on antibody-guided radiotherapy in an ovarian carcinoma patient with 
ascites, resulting in disappearance of malignant tumour cells after intraperitoneal 
injection of 1 3 1 l - HMFG2 IgG (88). So far, a limited number of phase l-ll trials 
have been performed aiming at establishing the therapeutic potential of radio 
immunotherapy in ovarian cancer patients (Table 5). 
Epenetos et al. reported on the treatment of 24 patients with recurrent ovarian 
cancer with ι ρ administered 131l-labelled MAbs HMFG1, HMFG2, AUA1 and 
H17E2 (89) HMFG1 and HMFG2 are directed against an epitope (HMFG) on a 
polymorphic epithelial mucin (РЕМ), a high molecular weight transmembrane 
glycoprotein encoded by the MUC1 gene (90 - 92). The epitope recognized by 
the MAbs is also expressed on epithelial malignancies of non-ovarian origin and 
on normal glandular epithelium (93, 94). The MAb H17E2 recognizes placental-
like alkaline phosphatase (PLAP) (95 - 97). The MAb AUA1 recognizes a 40 kDa 
epithelial cell surface glycoprotein present on a wide range of adenocarcinomas, 
including more than 9 0 % of carcinomas of the ovary (98, 99). The 1 3 1 l dose 
labelled to the MAbs as used in this study increased from 740 MBq (20 mCi) to 
7585 MBq (205 mCi). Eight patients with large tumours ( > 2 cm in diameter) 
did not respond to RIT. However, nine out of sixteen patients with small volume 
disease ( < 2 cm in diameter) showed a remission or remained disease-free. 
Analysis of the data on recurrence suggested that doses greater than 5180 
MBq (140 mCi) were more effective than lower doses. 
Ward et al (100) described a comparable group of 12 ovarian cancer patients 
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who received ι p. 2775 - 6290 MBq (75 - 170 mCi) 131l-labelled HMFG2 and 
AUA1 In three out of five patients with ascites not controlled with conventional 
therapies, a temporary ascites control was established. Of the seven patients 
with small volume solid tumour deposits only one patients remained free of 
disease for more than a year. 
Riva et al (101) reported similar results in 10 ovarian cancer patients after ι p. 
administration of 3405 MBq (92 mCi) 131l-labelled HMFG1, HMFG2, H17E2 and 
B72 3 MAb. The MAb B72.3 recognizes the tumour associated glycoprotein 72 
(TAG-72), a high molecular weight glycoprotein with properties of a mucin (102 
- 105) The antigen is expressed on most carcinomas of colon, breast, ovary 
and endometrium RIT resulted in a temporary ascites control in two of the 
patients, while in three other patients a partial response was observed 
Buckman et al reported on i.p. RIT with 925-5550 MBq (15-150 mCi) 1 3 1 l 
labelled 2G3 in 6 ovarian cancer patients with ascites (106). The MAb 2G3 is a 
novel anti-mucin MAb of the IgGI subclass (107) The MAb demonstrated 
consistent reactivity with tumour cells in effusions of patients with breast and 
ovarian cancer (108) Reactivity with lung cancer and melanoma was also 
observed (109). Temporary palliation of ascites was observed in two patients 
who received more than 1850 MBq (50 mCi). 
The therapeutic efficacy of 131l-labelled F(ab')2 fragments of the MAb OC125 
was evaluated in 28 ovarian cancer patients with large volume disease (110) 
The MAb OC125 was obtained after immunizing mice with the OVCA433 
ovarian carcinoma cell line (111). It is directed against the CA125 antigen, 
which is associated with high molecular weight glycoproteins of > 200 kDa 
(112) The antigen is expressed in most (non-mucinous) ovarian carcinomas as 
well as in other malignancies, benign (ovarian) diseases and normal peritoneum 
(113 - 116). The i.p. administration of F(ab')2 fragments of this MAb labelled 
with 740 - 5180 MBq (20-140 mCi) 1 3 1 l did not result in any objective clinical 
response 
In another study 25 ovarian cancer patients received escalating doses of i.p 
administered 90Y-labelled HMFG1 and AUA1 (84) Doses of 185 to 925 MBq 
(5 - 25 mCi) resulted in a partial response in one patient with small volume 
disease, while ten patients with no evidence of disease remained disease free 6 
to 1 5 months after treatment. 
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Seventeen patients were treated with 18eRe-labelled NR-LU-10 MAb (117). NR-
LU-10 is an lgG2 antibody that recognizes a 40 kDa cell surface glycoprotein 
expressed on most carcinomas of epithelial origin (118, 119). Reactivity with 
normal tissue of the gastro-mtestmal tract, pancreas, prostate, bladder, breast, 
kidney and pituitary and salivary glands is also observed (117). Decreased 
tumour size was demonstrated in four of seven patients with tumour deposits 
smaller than 1 cm in diameter. Patients with larger tumour deposits did not 
respond. 
In all these studies the administered activity escalated from a low (non-thera­
peutic) dose (740 MBq (20 mCi)) to doses that may have a therapeutic effect 
( > 3700 MBq (100 mCO), indicating that only a fraction of the entered patients 
received a radioactivity dose that can in potential be effective. Most of the 
patients enroled had bulky disease, ι e. tumour deposits > 2 cm in diameter 
However, based on theoretical considerations and experimental studies it can be 
expected that RIT can only be effective in case of small tumour nodules. 
Furthermore, all patients participating in these trials had failed conventional 
therapeutic regimens and the majority of patients had received multiple second-
line treatment. Despite these drawbacks, responses were observed in patients 
with small volume disease. Reversible gastro-mtestmal toxicity occurred 
However, myelotoxicity was the dose-limiting side-effect. 
Recently, patients with no evidence of disease at second-look laparoscopy 
received 90Y - HMFG1 intraperitoneal^ as adjuvant therapy after primary 
cytoreductive surgery and first-line platin-based combination chemotherapy 
(120). Survival of these patients was improved as compared to a historical 
control group of patients treated in the same hospitals. These results provide 
encouragement to the concept of radioimmunotherapy in ovarian cancer 
patients with small residual tumour. Further (randomized phase III) trials with 
substantial numbers of patients are needed to determine the therapeutic 
efficacy in subsets of patients. 
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1.3 Bispecific monoclonal antibodies 
History 
In 1981 Lotze et al. have shown that the incubation of lymphocytes with inter-
leukine-2 (IL-2) resulted in the generation of lymphokine-activated killer (LAK) 
cells (121). These LAK cells had the ability to kill tumour cells without affecting 
normal cells. Because LAK cells can be isolated readily from the blood, 
expanded and activated ex vivo and readministered to patients in large numbers, 
immunotherapy with LAK cells seemed to be an attractive approach In animal 
experiments, the administration of LAK cells resulted in complete remissions In 
clinical trials the results were less impressive. Response rates have been 
observed in patients with metastatic renal cell cancer and melanoma, but only a 
minority of these patients responded to high doses of IL-2 (122). 
An alternative approach to cellular adoptive therapy would involve the use of 
tumour specific Τ cells. These lymphocytes are probably the most efficient 
component of the immune system for eliminating tumour cells Cytotoxic Τ 
lymphocytes (CTL) express a cell surface antigen receptor complex (TCR/CD3). 
These CTLs are activated when the TCR complex binds to a complex structure 
composed of a tumour cell antigenic epitope presented by a class I major 
histocompatibility complex (MHC) molecule Τ cells demonstrate potent 
cytolytic activity, target specificity and antigenic memory. However, most 
cancer patients do not have significant numbers of CTLs with specific activity 
against their tumour. As a consequence, tumour specific Τ cells can hardly be 
isolated or expanded in vitro. So far, the practical application of CTL 
immunotherapy is limited. 
Concept of bispecific monoclonal antibodies 
In 1985, retargeting Τ cells towards tumour cells using bispecific monoclonal 
antibodies (biMAbs) has been proposed as a new concept for cancer therapy 
(123 - 125). In this approach biMAbs composed of an anti-tumour MAb on one 
hand and a MAb directed against the TCR/CD3 complex on Τ cells on the other, 
are exploited to redirect the cytotoxic activity of cells of the immune system 
towards tumour cells. In vitro studies have indicated that МНС-restriction as 
well as antigen specificity of Τ cells can be circumvented with biMAbs. 
Binding of the anti-T cell MAb to TCR/CD3 complex triggers the CTL activation 
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Figure 2. Bispecific monoclonal antibodies can be biologically obtained by 
fusion of two hybridoma cell lines each producing a parental 
monoclonal antibody. 
I = IL-2 receptor 
flWû =TCR complex 
ay = MHC/amigcn 
ь^ = Tumor cell nntigen 
Figure 3. (A) Cytotoxic T-cells normally kill target cells through recognition 
of an antigen fragment presented by a class I major histocompati­
bility complex. (B) With bispecific monoclonal antibodies (biMAb) 
directed at one hand against the CD3/T-cell receptor complex, the 
cytotoxicity of T-cells can be redirected. BiMAb-directed lysis 
occurs when the biMAb activates the T-cell and the T-cell and 
tumour cell are linked together. 
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Λ 
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machinery (126 - 128). With biMAbs simultaneously binding a tumour cell and 
an activated Τ cell, tumour cell lysis could be obtained using either tumour cell 
lines or freshly isolated tumour cells (129, 130). Simultaneously, tumour growth 
inhibition of those tumour cells which are stencally inaccessible for targeted 
lymphocytes or lack the antigen (bystander killing) may occur resulting from 
cytokine release (tumour necrosis factor, interferon-gamma, IL-2) by Τ cells 
activated by biMAbs (131). 
In vitro studies 
The cytotoxic activity of several effector cell populations in the presence of 
biMAb has been studied. Most studies have been performed with peripheral 
blood lymphocytes (PBLs) as effector cells. The lytic potential of fresh PBLs is 
lower as compared to cultured PBLs exposed to mitogens (IL-2, phytohem-
agglutinm, anti-CD3 MAb)(129, 130, 132). Furthermore, the cytotoxicity of 
retargeted PBLs is variable and donor dependent. Pre-stimulated PBLs demon­
strate a high lytic potential in the presence of biMAbs. The concentration of 
biMAbs required for the targeting and activation of T-cells is extremely low. in 
the order of 1 mg biMAb per 10э T-cells (1 pg/mL) as determined in vitro (128, 
130). 
Animal experiments 
In several preclinical studies the therapeutic potential of biMAbs was studied in 
immuno-incompetent animals with human tumour xenografts. After locoregional 
administration of pre-activated human PBL's retargeted with anti tumour χ anti 
TCR/CD3 biMAbs inhibition of tumour growth was demonstrated in human 
colon carcinoma and intraperitoneal human ovarian carcinoma xenografts (133 -
135) As a control, administration of unconjugated parental MAbs and substitu­
tion of the anti-CD3 portion or the anti-tumour portion of the biMAb with an 
irrelevant MAb did not effect tumour growth (134) 
Systemic administration of anti-tumour χ anti-TCR/CD3 biMAbs in nude mice 
with subcutaneous or intraperitoneal human colon carcinoma xenografts 
resulted in specific tumour localization (132, 136). Renner et al. reported 
tumour cell lysis and cure of mice with s.c. human Hodgkin lymphomas after 
i.v. administration of anti-tumour χ anti-T cell biMAb and pre-activated human 
PBL's (137). In a mouse model with i.p. murine lymphoma prolonged survival 
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and cure was observed solely after a single systemic injection of a low dose of 
biMAb (138). 
Clinical studies 
Clinical experience with anti-tumour χ anti-TCR/CD3 biMAbs is limited. Ten 
patients with grade III or IV malignant glioma received IL-2 cultured LAK cells 
retargeted against the glioma with an anti-CD3 χ anti-glioma biMAb intra­
cavitary in the brain (1 39) Minimal toxicity was observed while in four patients 
treatment resulted in tumour necrosis and in four other patients tumour 
regression was reported 
In another study seven carcinoma patients with malignant ascites or pleural 
exsudâtes received IL-2 cultured lymphocytes retargeted against adeno-
carcinomas with anti-CD3 χ anti-carcinoma biMAb locoregionally (140). Only 
mild treatment-related toxicity, i.e. fever, was observed. With an indirect 
immunoperoxidase technique it was demonstrated that in ascites specific T-
cell/tumour cell clusters were formed within one hour after injection and that 
most tumour cell kill occurred within the first 24 hours of treatment. 
In a multi-centre study sixteen ovarian cancer patients with recurrent disease 
were treated with repeated intraperitoneal administrations of ex vivo expanded 
autologous PBL's targeted with the anti-tumour χ anti-CD3 biMAb OC/TR 
F(ab')2 m the presence of mterleukin-2 (IL-2) and soluble ОС/TR F(ab')2 (141). 
Toxicity consisted predominantly of fever, flu-like symptoms and abdominal 
tenderness. Positive ascites cytology turned negative in all patients. Evaluation 
laparotomy revealed 5 complete remissions, three partial responses and two 
patients with stable disease. However, extra-peritoneal tumour growth was not 
controlled. 
Knowledge about the T-cell mediated tumour cell kill is growing However, 
further research is needed to elucidate many aspects involved in the application 
of biMAbs such as availability of effector cells, binding and activation of 
effector cells, and biological activity of effector cells. The optimal strategy for 
implementation into clinical studies still needs to be defined. Although new data 
are forthcoming, the application of biMAbs for cancer therapy is still in its 
infancy. 
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1.4 Outline of this thesis 
chapter 1 
From the preceding review it is clear that MAbs against ovarian carcinoma offer 
interesting perspectives for diagnosis and therapy of ovarian cancer. However, 
many aspects involved in the applications of the anti-tumour MAbs need to be 
further elucidated. 
The aim of the set of seven studies described in this thesis was to investigate 
the potential of radiolabeled MAbs for diagnosis and to investigate the perspec­
tives of radiolabeled and bispecific MAbs for therapy of ovarian cancer 
First, a patient study was performed to determine the feasibility of imaging 
ovarian carcinoma with 9 9 mTc labelled Fab' fragments of the MAb OV-TL 3, 
using a direct 9 9 mTc labelling technique (chapter 2). 
The use of murine MAbs is complicated because they may elicit a humoral-
response against the administered antibody The development of such human 
anti-mouse antibodies directed against the 9 9 mTc - OV TL 3 Fab' was determined 
with an in-house OV-TL 3 F(ab')2-based sandwich type IRMA This HAMA 
response was compared with the response after administration of 1 1 l l n - DTPA 
OV-TL 3 F(ab')2 (chapter 3). 
One of the major limitations of the Fab' fragments for tumour detection is their 
relatively high kidney uptake, hampering tumour detection in the vicinity of the 
kidneys In mice bearing human ovarian carcinoma xenografts it was tested 
whether the target to background ratio could be improved by using a chelator 
for labelling the 9 9 mTc radionuclide with the Fab' fragments that will be cleaved 
in the kidneys (chapter 4) 
As a prelude to radioimmunotherapy, the effect of the route of administration on 
the biodistribution of radioiodinated MAb was studied in mice bearing either 
subcutaneous or intraperitoneal ovarian carcinoma xenografts (chapter 5) 
Intraperitoneal administration of an escalating dose of chimeric MOv IgG in 
patients suspected of having ovarian cancer was performed to obtain data on 
the pharmacokinetics and biodistribution enabling estimation of radiation 
absorbed doses in normal and tumourous tissues (chapter 6). 
In ovarian carcinoma bearing mice the potential to target tumours after intra­
venous injection of the biMAb ОС/TR was compared with the parental anti-
tumour MAb MOv18 (chapter 7) 
Finally, in order to obtain more insight in the in vivo behaviour of anti-tumour χ 
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anti-CD3 b i M A b s , the t o x i c i t y , p h a r m a c o k i n e t i c s , b i o d i s t r i b u t i o n and biological 
e f fects of i n t r a v e n o u s l y a d m i n i s t e r e d b i M A b ОС/TR F(ab') 2 w e r e s t u d i e d in 
pat ients s u s p e c t e d of hav ing ovar ian cancer (chapter 8) . 
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labelled OV-TL 3 Fab' in patients suspected of 
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S Ρ Strijk, Ρ Kenemans, F H M Corstens 
Nucí Med Commun 1992, 13 885-893 
Abstract 
Fab' fragments of the monoclonal antibody OV-TL 3, that recognizes an ovarian 
carcinoma-associated antigen (OA3), were labelled with 9 9 mTc using D-glucarate 
as a ligand. Twenty patients suspected of having primary or recurrent ovarian 
cancer received intravenously 1 mg of the Fab' labelled with 740 MBq 9 9 mTc. 
Both planar and single photon emission computed tomographic (SPECT) scinti­
graphy were performed up to 30 hour (h) after intravenous infusion. In 19 out 
of 20 patients surgical and histopathological evaluations were performed 
between two and six days post infusion. Imaging results were compared with 
X-ray computed tomography (CT), ultrasonography (US) and CA 125 serum 
level. 
Blood clearance was fast with median х г ß of 9.5 h. Thirty-seven per cent of 
the injected dose (% ID) was excreted in the urine within the first 24 h, 
whereas 7% ID was excreted in the 24 h faeces. In one patient with an OA3 
negative ovarian carcinoma, radioimmunoscmtigraphy (RIS) did not visualize the 
tumour. In two other patients a benign ovarian cyst was found, also showing no 
elevated uptake. In 13 out of 17 patients ovarian cancer lesions were detected 
with RIS, whereas CT and US detected lesions in, respectively, 15 and 12 
patients. Of 36 surgically defined tumour deposits larger than 1 cm in diameter, 
53% were detected and localised with RIS, whereas CT and US detected 6 1 % 
and 40%, respectively. Radioimmunoscmtigraphy with 99mTc - OV-TL 3 Fab' is 
less distressing for the patients but the overall imaging performance is not 
improved when compared with 111ln - OV-TL 3 F(ab')2. 
42 
chapter 2 
Introduction 
In a previous study, using F(ab')2 fragments of the monoclonal antibody (MAb) 
OV-TL 3 labelled with indium-111 in patients suspected of having ovarian 
cancer, radioimmunoscmtigraphy (RIS) detected and localized 6 7 % of all tumour 
deposits larger than 1 cm in diameter (1) To obtain these results imaging up to 
72 h post infusion (ρ ι ) was necessary, an interval that is too long for everyday 
clinical practice Apart from a transient skin rash in two patients, no immediate 
or delayed adverse reactions were seen in that study Human anti mouse 
antibody (HAMA) responses after the injection of the F(ab')2 fragment were 
measured in 2 0 % of the patients (2) 
Fab' fragments potentially have several advantages over F(ab')2 fragments Fab' 
fragments have better accessibility to the tumour due to their smaller size, are 
cleared from the blood more rapidly (3) and are expected to be less immuno­
genic However, these advantages may all be balanced by a possibly decreased 
absolute uptake in the tumour and a reduced residence time of the Fab' as 
compared to the F(ab')2 fragment 
1 1 1 ln is not the ideal nuclide for RIS the photon energy is too high for imaging 
with general all purpose gamma-cameras and the radiation burden per mCi 
administered is not particularly low From the physical point of view technetium 
99m has much better characteristics for RIS, due to its shorter half life of 6 h, 
single photon energy of 140 keV and lack of beta radiation In addition, 9 9 mTc is 
relatively inexpensive and readily available in almost all nuclear medicine 
departments 
Several methods have been used to label MAbs with 99nnTc Mostly, chelating 
agents are being used to link the radionuclide to the MAb (4) However, 
methods to label MAbs directly with 9 9 mTc have also been developed (5,6,7) 
Steigman et al (8) suggested a possible role of sulphydryl groups in the direct 
binding of 9 9 mTc to proteins This hypothesis was further substantiated by Paik 
et al (9) Pak et al (10) developed a stable 'instant kit' direct 9 9 mTc labelling 
technique using D-glucarate as a transfer ligand Using this technique, our group 
demonstrated more favourable biodistribution in an animal model with 9 9 mTc 
labelled OV-TL 3 Fab' than with the 1 1 1 ln labelled Fab' fragment (11). 
Because of the potential advantages of Fab' over F(ab')2 fragments, as 
mentioned above, and of 9 9 mTc over i n l n , a patient study was undertaken to 
determine the feasibility of imaging ovarian carcinoma with the MAb fragment 
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OV-TL 3 Fab', using a novel and direct 9 9 mTc labelling technique (10). 
Patients & methods 
Monoclonal antibody 
OV-TL 3, a murine MAb of the IgG, subclass, was generated using a cell 
suspension prepared from an endometrioid ovarian carcinoma (12) Immuno 
histochemical studies have shown that OV TL 3 reacts with more than 9 0 % of 
human ovarian carcinomas of various histological types (12,13) Cross reactivity 
was found with several other adenocarcinomas and a number of normal tissues 
(14) Furthermore, the antigen recognized by OV-TL 3 could not be detected in 
patient's blood (15) 
Preparation of Fab ' fragments 
F(ab')2 fragments of OV-TL 3 were prepared by direct pepsin digestion of the 
IgG The crude F(ab')2 was purified by cation exchange chromatography on S-
Sepharose Fast Flow The F(ab')2 was pooled, concentrated and dialysed into 
phosphate buffered saline (PBS) The OV-TL 3 F(ab')2 was reduced to Fab' by 
dithiothreitol (DTT) reduction Briefly, the F(ab')2 solution in PBS was adjusted 
to 100 mM Tris, pH 8 0 and 2 mM EDTA DTT (1 mM) was added and after a 1 
h incubation period at 37 °C, the sample was desalted on a Sephadex G-25 
column equilibrated in 50 mM sodium phosphate, 100 mM NaCI, 1 mM EDTA, 
pH 6 4 The Fab' was pooled, concentrated and 0.22 μττ\ filtered 
Radiolabelling 
The OV-TL 3 Fab' antibody fragments were labelled with 9 9 mTc in a procedure 
using D glucarate as the transfer ligand (10) Briefly, 1 ml of the 9 9 mTc sodium 
pertechnetate was added to a lyophihzed vial containing 12 5 mg mono-
potassium D-glucarate, 150 μg stannous chloride and 16 8 mg sodium 
bicarbonate. The resulting solution was allowed to stand for 1 mm at room 
temperature The antibody fragment (2.0 mg/mL in 50 mM sodium phosphate, 
100 mM NaCI, 1 mM EDTA, pH 6 5) was incubated with an equal volume of 
9 9 mTc D-glucarate at room temperature for 1 h 
Labelling efficiency and stability testing 
In all patients, prior to administration of the radiolabelled antibody preparation, 
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instant thin layer chromatography (ITLC) was used to determine the labelling 
efficiency For this purpose, Gelman ITLC-SG strips were used with 100 mM 
acetate (pH 6 0) solution as solvent 
In case the labelling efficiency was less than 9 5 % the labelled antibody was 
purified on a packed column (Pharmacia PD10) ITLC was repeated to 
determine the final labelling efficiency 
The 99mTc-labelled OV-TL 3 Fab' fragments were incubated at 37 °C in either 
human plasma or PBS for 24 h At several times aliquotes were assayed for the 
percentage of the Fab'-associated radioactivity using paper chromatography in a 
acetonitnle water system, followed by quantification of the free and bound 
radioactivity 
Immunoreactivity 
Binding properties of the OV-TL 3 antibody and its F(ab')2 and Fab' fragments 
were tested with an indirect radioimmunoassay. OVCAR-3 ovarian carcinoma 
cells bearing the OA3 antigen (16) were plated at 2 0 - 2 5 x10 5 cells per well 
in 96 well microtitre plates. Dilutions of the MAb and its fragments (F(ab')2 and 
Fab') in 0.3% gelatin PBS were added (100 IU per well) and incubated for 2 h 
at room temperature Plates were washed twice and 12SI goat anti mouse F(ab')2 
(100 μ\, 250000 cpm, 5-15 μΟ/μς) was added to each well Cells were 
incubated for 1.5 h at room temperature, washed twice and counted on a 
gamma counter Relative affinity constants for unlabelled OV-TL 3 and its 
fragments were calculated 
Patients and study design 
Patients suspected of having primary or recurrent ovarian cancer and scheduled 
to undergo surgery were entered in the study Patients had to be over the age 
of 40 years. All patients with known allergy to murine antigens, an allergic 
diathesis, a life-threatening infection or diagnosis of a second malignancy were 
excluded from the study After explanation of the study protocol, patients gave 
verbal and written consent All patients were evaluated at study entry by 
medical history and physical examination. An electrocardiogram, chest 
radiograph and CA 125 serum level (IRMA, Abbot, Chicago, USA) were 
obtained as part of the pre-antibody injection evaluation. All studies were 
conducted with the approval of the Human Research Review Committee of the 
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University Hospital Nijmegen, The Netherlands. 
In all patients, X-ray computed tomography (CT) and ultrasonography (US) of 
the abdomen and pelvis were performed prior to intravenous (i.v.) administration 
of the radioimmunoconjugate. With a third generation CT scanner (Somatom 3, 
Siemens Inc., Hoffman Estates, II, USA) slices of 8 mm thickness at 8 mm inter­
vals were imaged from the level of the diaphragm to the perineum with the aid 
of oral and rectal contrast agents. All CT scans were evaluated and reported by 
one radiologist, who was unaware of immunoscintigraphic or surgical results 
US was performed by a gynaecologist as a routine pre-operative evaluation 
using a transabdominal sector scanner (DRF 100, Diasonics, Les Ulis, France). 
Results were reported without any knowledge of immunoscintigraphic, radio­
graphic, or surgical results. 
Patients received 1 mg of OV-TL 3 Fab' fragments labelled with 740 MBq 9 9 mTc 
by ι ν infusion in a cephalic vein A skin test was not performed before the 
injection. The antibody preparation was diluted in 5 ml saline and infused over a 
5 minutes period of time, followed by an infusion of 10 ml saline No thyroid-
blocking agent was used in this study. Vital signs were measured frequently up 
to 2 h after the antibody infusion. 
Blood samples were taken at 1, 4, 10 and 30 mm and at 1, 2, 3, 5, 8 and 24 h 
p.ι.. 9 9 mTc activity in the samples was measured using a well-type counter. From 
these results individual half-lives of disappearance from the blood were 
calculated using non-linear least squares regression analysis. Furthermore, blood 
samples were taken prior to, and 3 and 6 weeks after, antibody infusion in order 
to evaluate antibody-induced HAMA development. 
Planar images of chest, abdomen and pelvic regions in both anterior and 
posterior views of the patients were obtained at approximately 1, 4, and 20 h 
ρ ι with a maximum of 2000000 counts (cts) or a preset time of 5 minutes. 
Images were obtained with a single-headed gamma camera (Type Orbiter, 
Siemens Inc., Hoffman Estates, II, USA), equipped with a parallel hole low 
energy general purpose collimator. All planar views were recorded using the 140 
keV gamma ray peak of 9 9 mTc with a symmetric 15% window Typical 5 
minutes planar images had 1000000 to 2000000 cts at 4 h and 200000 to 
800000 cts at 20 h p.ι.. Results were obtained without the use of image 
subtraction techniques. 
To reduce bladder activity, patients were asked to void prior to imaging of the 
pelvis. Furthermore, as part of the presurgical standard preparation, all patients 
were subjected to a thorough bowel lavage procedure before the final images 
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Table 1 Characteristics of 20 patients suspected of having ovarian cancer 
Pt Age FIGO Histological Diff. CA 125* 
nr (yr) stage tumour type grade (U/ml) 
01 
02 
03 
04 
05 
06 
07 
08 
09 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
76 
74 
65 
54 
66 
75 
46 
70 
58 
50 
45 
69 
55 
36 
67 
58 
51 
48 
55 
lllc 
lllc 
l c * * * 
l e · " * 
lllc 
lllc 
lb 
lllc 
la 
IV 
lllc 
-
lllc 
lc 
H e · · · 
-
l l l c * · · 
IV 
Serous 
Endometrioid 
Adenocarcinoma 
Mixed epithelial 
Serous 
Malignant Brenner 
Endometrioid 
Serous 
Mucinous 
Mixed epithelial 
Endometrioid 
Mucinous, borderline 
Mixed Mullenan 
Mucinous 
Serous 
Benign ovarian cyst 
Malignant lymphoma 
Serous 
Serous 
III 
III 
III 
II 
III 
III 
II 
II 
III 
II 
III 
II 
II 
III 
II 
4 4 0 
2 2 0 0 
3500 
230 
240 
120 
2 3 0 0 
17000 
61 
12000 
2 2 0 0 
21 
1400 
238 
93 
< 7 
5 4 0 0 
840 
2 4 0 0 
• cut off value for serum CA 125 35 U/ml 
** tumour recurrence 
were recorded These images after intestinal lavage were taken approximately 
26 h p.ι. and consisted of planar images of anterior abdomen and pelvis Typical 
count rates for these final images were between 350000 and 900000 cts for 
which more than 10 mm recording time was needed 
A SPECT study was performed at 21 h p.ι. using the same gamma camera as 
for planar imaging The same peak energy and window settings were used The 
360° orbit consisted of 64 projections at an acquisition time of 40 s/angle, 
recorded in a 128 χ 128 format Typical frames had 20000 to 50000 cts. 
Prior to surgical evaluation, planar scans and SPECT slices were interpreted by 
two nuclear medicine physicians unaware of CT and US results. Images were 
interpreted as positive when areas of localized increased uptake were 
consistently seen on all images recorded over time. 
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Tissue uptake measurements 
In 19 out of 20 patients extensive surgery was performed between 2 and 6 
days (mean. 47 h; median. 44 h) after i.v. infusion of the antibody preparation. 
In one patient surgery was performed after 4 months, because four courses of 
chemotherapy were administered during that timespan. At surgery, tumour 
status was carefully mapped Total amount of ascites was measured and 
samples were taken for 9 9 mTc activity measurements. In one patient an ascites 
sample was also taken early during the study, at 3 h ρ ι All suspected tissues 
found at surgery were either removed in their entirety or biopsies were taken In 
selected patients tissue samples of liver, muscle, skin, and normal omentum 
were obtained. All tissues obtained at operation were weighed and measured for 
9 9 mTc activity using a well-type counter 9 9 mTc uptake in tissues was expressed 
as percentage of the injected dose per kilogram tissue (% ID/kg) Mean values 
± standard deviation (SD) are presented 
Results 
Labelling efficiency and stability of the radioimmunoconjugate 
Purification was performed in five cases in which initial labelling resulted in a 
labelling efficiency varying from 50 to 8 9 % . Mean labelling efficiency of the 
final product was 9 8 . 1 % (range 94.9% - 99.9%). Stability tests of the " " r e ­
labelled OV-TL 3 Fab' in human plasma at 37 °C showed that 7 2 % of the 
radioactivity was associated with the Fab' after 24 h. 
Immunoreactivity 
On OVCAR-3 cells the relative affinity constants by indirect radioimmunoassay 
were calculated to be 9.1 x10 e M 1 for the whole IgG, 1.6 x10 9 M" for the 
F(ab')2 and 3 5 x10 8 M ì for the Fab' fragment. 
Toxicity 
The procedure was well tolerated by all patients and could be completed within 
30 h. No signs of clinical toxicity were observed after the infusion with 740 
MBq 99mTc - OV-TL 3 Fab' (1 mg) in any of the patients studied. Up to 24 h ρ ι. 
no significant changes in haematology or blood chemistry parameters were 
noted 
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Blood clearance and excretion from the body 
Clearance of 99mTc from the blood could be described by a bi-exponential model 
with median half-life values of 0.6 h (range: 0.2 - 1.2 h) for the first phase and 
9.5 h (range: 5.3 - 14.0 h) for the second phase. Blood activity decreased to 
approximately 75% within the first 5 h. Mean excretion of the radiolabel in the 
urine as measured in nine randomly selected patients was 37 ± 12% ID in 24 
h, whereas excretion in faeces, measured in three patients, was 7 ± 3% ID 
during the same period. 
Table 2. Determination of cancer-positive patients with radioimmuno-scintigraphy 
using OV-TL 3 Fab' compared to three diagnostic modalities. 
Immuno- Ultra- X-ray CT CA 125 
scintigraphy sound* scan serum assay 
Sensitivity 13/17(76%) 12/16(75%) 15/17(88%) 17/17(100%) 
* in one patient no ultrasound was performed 
CT = computed tomography 
Imaging results 
Twenty patients suspected for primary (n = 16) or recurrent (n = 4) ovarian 
carcinoma were studied. Some patient characteristics are listed in Table 1. The 
mean age of the patients was 62 years (range: 36-76 years). 
In one patient at operation a rare malignant Brenner tumour of the ovaries was 
found. This tumour, negative for RIS, was excluded from further evaluation 
because of the lack of OA3 antigen expression. Two other patients with a 
benign ovarian cyst were also excluded. The cysts showed no elevated uptake 
of the radiotracer. 
High 99mTc uptake was seen in liver and spleen throughout the whole study. 
Kidneys were visualized as early as 10 min p.i. (posterior image) and intensity 
increased with time. Most bone structures were visualized from 1 h onwards. 
The thyroid was not visualized in any of the patients. Bowel uptake was seen in 
most of the patients from 4 h onwards, disappearing completely after thourough 
total bowel lavage. Representative images of studies in two patients are shown 
in Figs. 1 and 2. 
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16 
24 
Anterior planar pelvic images 1,16 and 24 h p.i. of a 46-year-old patient, 
suspected for ovarian carcinoma with a palpable mass in the pelvis and 
lower abdomen. On all images activity in the kidneys and the bladder is 
clearly visible. The bone structures were visualized from 1 h onwards. The 
cyst-like structures seen on the 1 h image showed localized uptake from 
16 h onwards. At surgery a large carcinoma was found. 
1 
Figure 2. Anterior planar pelvic images 1, 4, 20 and 28 h p.i. of a 50-year-old 
patient, suspected for ovarian carcinoma with a palpable tumour in the 
pelvis and ascites. On the 1 h image the bloodpool is clearly visible. From 1 
h onwards localized uptake is seen in the left pelvis, not disappearing after 
thorough bowel lavage (28 h image). At surgery a mixed epithelial 
cystadenocarcinoma was found. 
Table 3. Detection and localization of OA3 antigen positive tumour deposits larger 
than 1 cm in diameter found at surgery (n = 36; 20 abdominal + 16 
pelvic localizations). 
Patient 
number 
01 
02 
03 
04 
05 
07 
08 
09 
10 
11 
12 
13 
14 
15 
17 
18 
19 
Total 
Number of 
tumour sites 
(abd/pelv) 
3 / 1 
2 / 1 
2 / 1 
3 / 0 
1 / 1 
0 / 1 
1 / 1 
0 / 1 
1 / 2 
1 / 1 
0 / 1 
1 / 1 
0 / 1 
1 / 0 
2 / 1 
0 / 1 
2 / 1 
2 0 / 1 6 
36 
Detected by 
US 
(abd/pelv) 
0 / 1 
0 / 1 
0 / 1 
0 / 0 
0 / 1 
0 / 1 
0 / 1 
0 / 1 
0 / 2 
0 / 1 
# 
0 / 1 
0 / 1 
0 / 0 
1 / 1 
0 / 0 
0 / 0 
1 / 13 
(5% / 87%) 
14 
(40%) 
CT 
(abd/pelv) 
0 / 1 
0 / 1 
0 / 0 
1 / 0 
1 / 1 
0 / 1 
1 / 1 
0 / 1 
0 / 2 
0 / 1 
0 / 1 
1 / 1 
0 / 1 
1 / 0 
2 / 1 
0 / 0 
2 / 0 
9 / 13 
(45% /81%) 
22 
(61%) 
IS 
(abd/pelv) 
2 / 0 
1 / 0 
0 / 0 
2 / 0 
0 / 0 
0 / 1 
1 / 0 
0 / 1 
0 / 2 
1 / 1 
0 / 0 
1 / 1 
0 / 0 
1 / 0 
0 / 1 
0 / 1 
1 / 1 
1 0 / 9 
(50% /56%) 
19 
(53%) 
US = ultrasonography; CT = X-ray computed tomography; IS = immunoscintigraphy 
abd = abdominal tumour localization; pelv = pelvic tumour localization 
* in this patient no ultrasound was performed 
RIS results were evaluated in two different ways: overall sensitivity for the 
disease and sensitivity for distinct lesions larger than 1 cm in diameter as found 
at surgery. The sensitivity for the detection of ovarian cancer positive patients 
was compared with that of three other diagnostic modalities: US, CT and CA 
125 (Table 2). In the population of 17 patients sensitivity was similar for RIS, 
CT and US (75 to 88%). 
In the group of 17 patients, 36 intra-abdominal tumour deposits (> 1 cm) were 
found at surgery. Overall, RIS detected and localized 53% of these surgically 
documented tumour sites (Table 3). CT visualized 6 1 % of the lesions whereas 
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US visualized 40%. Tumour detection with RIS was found to be complementary 
to CT. Both techniques together were able to detect and localize 8 1 % of all 
tumour deposits. In a further analysis lesions were divided into two categories 
according to their localization: abdominal and pelvic (Table 3). Detection of 
abdominal lesions seemed to be better with IS. On the other hand, detection of 
pelvic lesions seemed to be better with CT as well as with US. In six patients 
tumour localizations could be visualized as early as 4 h p.i.. However, the most 
informative images were obtained at approximately 20 h p.i.. Scans performed 
later than 24 h p.i. were generally less adequate due to low count rate. 
However, the latter scans were performed. after extensive bowel lavage, 
providing the opportunity to discriminate between activity in the bowel and 
uptake in localizations suspected of tumour. 
Tissue uptake 
Highest mean tissue uptake was found in liver tissue, being 9.0 ± 4 . 9 % ID/kg 
(n = 6). Mean tumour uptake for all 36 tumour sites found at operation was 1.6 
± 0.7% ID/kg, whereas uptake in primary tumours (n = 13) was 1.9 ± 0.9% 
ID/kg. Uptake in background tissues such as muscle and skin was 0.6 ± 0.5% 
ID/kg (n = 13) and 0.4 ± 0.5% ID/kg (n = 14), respectively, resulting in a 
tumour to muscle ratio of approximately 5. In nine patients ascites was obtained 
at operation. Mean uptake in these specimens was 0.7 ± 0 .2% ID/L (n = 9). In 
one patient accumulation of activity in ascites was measured during RIS. " T c 
activity increased from 0.2% ID/L at 3 hour to 0.7% ID/L at 44 h p.i.. 
Discussion 
This study demonstrates the clinical feasibility of "Tc- labe l led OV-TL 3 Fab' in 
patients with ovarian cancer. In this patient population no adverse reactions 
were observed. 
A number of considerations, both theoretical and practical, makes a " " T e -
labelled MAb Fab' fragment an interesting candidate for the detection and 
localization of cancer. 
A novel 99nTc 'instant kit' direct labelling procedure (10) resulted in a stable 
product with high labelling efficiency. Using this technique, Pak et al. (17) 
demonstrated high stability upon challenge with DTPA, EDTA or low acidic pH 
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for several "Tc- labe l led MAb Fab' fragments. Furthermore, no loss of 
immunoreactivity was observed for the labelled fragments evaluated using an 
affinity chromatography technique. 
The main advantage of this new "Tc- labe l led Fab', compared with the 111 ln-
labelled F(ab')2 preparation used previously (1), is the short time required to 
make a diagnosis. With the F(ab')2 preparation it took at least 72 h to obtain a 
result, whereas with this 99nTc - Fab' the study can be completed within 30 h. 
In 46% (6/13) of the patients the 4 h images were excellent. Obviously, the 
time gained is of great importance for everyday clinical practice. 
On a patient basis, the sensitivity of RIS for the detection of ovarian cancer in 
this series of patients was 76%, being in the same range as with CT and US. 
However, positive identification with RIS could be given more credence than 
identification with other imaging techniques such as CT and US because the 
latter techniques lack tumour specificity. It is highly important to note that in 
the two patients with benign cysts and in the one patient with a Brenner tumour 
not expressing the antigen recognized by OV-TL 3 Fab', the study was 
negative Numbers are too small to present calculations on specificity for 
tumour detection. Of 36 tumour deposits larger than 1 cm in diameter found at 
operation, 53% was detected and localized with RIS while CT and US detected 
6 1 % and 4 0 % of these deposits, respectively. 
Using the 99mTc-labelled Fab' fragments of the MAb 9.2.27 Eary et al. (18) 
detected 70% of known metastatic melanoma sites. Compared with our study 
the higher detection rate probably results from the superficial cutaneous location 
of many of these tumour sites. Comparison of our results using a 99mTc - Fab' 
fragment with that obtained by others using 99mTc - IgG (19) seems not relevant 
since the dynamic distribution of both preparations are too different. 
Blood clearance with 99mTc - OV-TL 3 Fab' was rapid with median half-life 
values of 0.6 and 9.5 h. Clearance was in the same range as obtained by 
Goldenberg et al. (20) with the 99mTc-labelled anti-CEA Fab' fragment (median 
half-life values of 0.7 and 13.2 h). Blood clearance was faster than with the 
i n ln-labelled F(ab')2 preparation of OV-TL 3 (mean half-life values· 6.1 and 17.9 
h) used previously (21). Because of the relatively short physical half-life of 
99mTc, fast blood and background clearance are of critical importance to get 
sufficient contrast between the signal in the tumour and the noise in the 
background within 24 h (22). However, fast clearance may also reduce the 
opportunity of the radioimmunoconjugate to localize in tumour tissue possibly 
resulting in low tumour uptake. 
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" T c - OV TL 3 Fab' is cleared from the body mainly through the kidneys 
approximately 4 0 % of the activity is excreted into the urine within 24 h. Using 
a 99rnTc-labelled anti-melanoma Fab', Eary et al (18) reported similar results 
55% excretion in urine in 20 h Besides excretion through the kidneys when 
using 9 9 mTc - Fab', a large portion of the activity is also trapped in the kidneys 
Quantitative measurements, using the region of interest technique (ROD, 
demonstrated continuous accumulation of 9 9 mTc in the kidneys throughout the 
study 
Absolute tumour uptake with 99mTc-labelled OV-TL 3 Fab' at the time of surgery 
was less than with the 111ln-labelled OV-TL 3 F(ab')2 (21) Mean primary tumour 
uptake was 1 9 ± 0 9% ID/kg for the 9 9 mTc - Fab' at 2-6 days ρ ι , compared to 
3 9 ± 1 0% ID/kg for the 1 1 1 ln - F(ab')2 at 5-7 days ρ ι Tissue distribution of 
the 9 9 mTc antibody fragment resulted in mean tumour to muscle ratios of only 
5 1, whereas ratios of 13 0 were obtained with the 1 1 1 ln labelled F(ab')2 In 
spite of this rather low absolute and low relative tumour uptake obtained with 
99mTc-labelled OV-TL 3 Fab', 5 3 % of all tumour deposits could be visualized 
Affinity of the OV-TL 3 Fab' fragment for the corresponding antigen is lower 
than that of the original intact IgG or its F(ab')2 fragment (22). Low affinity 
together with fast blood clearance may lead to lower specific tumour uptake 
On the other hand, low affinity could also lead to a more homogeneous 
distribution within tumour tissue (23) Low specific tumour uptake results in a 
relative increase of the nonantigen-specific contribution to the uptake The 
question remains, when using low affinity MAb Fab' fragments, as to whether 
tumour uptake is mainly the result of specific MAb mediated mechanisms rather 
than non-tumour specific mechanisms (24) Kalevi et al (25) were able to 
visualize soft-tissue sarcomas in 18 out of 19 patients using an 111ln-labelled 
non tumor specific anti-myosin Fab' while the corresponding antigen could not 
be demonstrated In an animal model we definitely found specific tumour uptake 
with the radioimmunoconjugate used in the current study (11) In patients 
however, it still remains unclear to what extend tumour uptake results from 
specific antibody-antigen interaction 
As with 111ln-labelled F(ab')2, the uptake of 9 9 mTc in the liver was high This high 
uptake (mean tumour to liver ratio 0 3) made the detection of liver metastases 
as hot spots impossible When using 111ln-labelled immunoconjugates high liver 
uptake is thought to be the result of an n 1 l n related mechanism High liver 
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uptake in the current study is not in agreement with the findings of other 
groups using similar 99mTc labelled MAb Fab' fragments (18, 26), suggesting 
that in the current study liver uptake may also be the result of an antibody 
mediated mechanism rather than a role of the radionuclide only Furthermore, 
with regard to the high liver uptake, a possible role of the new labelling 
technique should also be considered 
Besides aspecific localization in liver and kidneys, 99mTc OV-TL 3 Fab' had a 
propensity to localize in spleen, bone marrow or bone and bowel Various 
degrees of activity in the intestines were visually identified in the majority of the 
patients Uptake in faeces was higher than with the 1 ^In-labelled F(ab')2 and 
was most probably, at least in part, the result of hepatobiliary clearance of 
99mTc from the liver Accumulation of activity in ascites was seen during the 
study as was observed with the n i ln-labelled F(ab')2 preparation Measurements 
in one patient indicated accumulation with time However, uptake in ascites did 
not disturb image interpretation in any of the patients 
The results obtained in this study indicate that safe and rapid detection of 
approximately half of the ovarian cancer tumour sites can be obtained with 
99mTc labelled OV-TL 3 Fab' 99mTc performs fairly well as a radionuclide for 
immunotargeting with OV TL 3 However, the Fab' fragment is cleared from the 
body too fast and its affinity for the antigen may be too low, resulting in rather 
low tumour uptake However, reappraisal of F(ab')2 fragments labelled with 
either 99mTc or 123l may provide better results within the same space of time 
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Humoral anti - OV-TL 3 response after i.ν. 
administration of radiolabelled Fab' or F(ab')2 
fragments in ovarian cancer patients 
J.G. Tibben, C.M.G. Thomas, L.F.A.G. Massuger, M.F.G. Segers, C.P.T. Schijf, 
F.H.M. Corstens, O.C. Boerman, 
Nucí Med Comm 1995, 16: 853-859 
Abstract 
The human anti-mouse antibody (HAMA) response was determined in serum of 
patients suspected of having ovarian cancer who underwent radioimmunoscinti-
graphy with either 9 9 mTc - OV-TL 3 Fab' (n=20) or 1 1 1 ln - DTPA - OV-TL 3 
F(ab')2 (n = 73) Blood samples were collected prior to and at several time points 
post ι ν injection The detection of HAMA was performed with an m-house 
OV-TL 3 F(ab')2-based sandwich-type IRMA 
The homologous IRMA demonstrated that 8 out of 20 (40%) patients had 
developed HAMA responses after injection of Fab' fragments and that 14 out of 
73 (19%) patients had developed HAMA-responses after F(ab')2 administration 
The subclass of the measured HAMA was analyzed in a limited number of 
samples, showing IgG, IgM as well as mixed responses The kinetics of the 
HAMA responses varied greatly Our study showed the relevance of the 
sampling time and frequency HAMA responses can be easily underestimated in 
case of a lower sampling frequency. 
The homologous IRMA described in this study efficiently quantified the OV-TL 
3-specific HAMA responses With additional assays the subclass of the HAMA 
could be further analyzed Remarkably, the fraction of HAMA-responders after 
injection of OV TL 3 Fab' fragments was in the same range as the proportion of 
HAMA-responders after F(ab')2 administration. 
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Introduction 
The development of human anti-mouse antibodies (HAMA) is considered an 
important disadvantage of the application of murine monoclonal antibodies 
(MAb) for clinical purposes. The presence of HAMA may lead to enhanced blood 
clearance, increased hepatic and splenic uptake and a reduction of tumour 
uptake upon repeated injection of the antibody ( 1 , 2) 
In a previous study we have assessed the diagnostic accuracy of immunoscinti 
graphy with 1 l 1 l n - DTPA - OV-TL 3 F(ab')2 m ovarian cancer patients (3) 
Subsequently, we have attempted to improve the radioimmunoscmtigraphic 
detection of ovarian carcinomas by using 9 9 mTc labelled Fab' fragments of OV 
TL 3 (4). Fab' fragments were used because of their potential advantages over 
whole IgG and F(ab')2 fragments: more rapid penetration of tumour tissue and 
more rapid blood clearance which may lead to enhanced tumour/background 
ratios (5) In addition, Fab' fragments were expected to be less immunogenic ( 1 , 
6). 
The present study describes the occurrence of HAMA in ovarian cancer patients 
after a single intravenous injection of 1 mg of 9 9 mTc OV TL 3 Fab' or 1 1 l l n -
DTPA - OV-TL 3 F(ab')2 as determined with a homologous sandwich-type 
immunoradiometric assay (IRMA) and further characterized by a heterologous 
IRMA and affinity chromatography procedures 
Patients & methods 
Patients 
Serum specimens were obtained from 93 patients suspected of having ovarian 
cancer who underwent radioimmunoscintigraphy with either 9 9 mTc OV-TL 3 
Fab' (n = 20) or n i l n - DTPA - OV TL 3 F(ab')2 (n = 73). Blood samples were 
collected prior to i.v. injection and at several time points post injection (p.ι ). 
The blood specimens were centrifuged for 10 mm at 2000xg at room tempera­
ture and the serum samples were stored at -35 °C until analysis. 
HAMA assay 
The detection of HAMA in the serum specimen was performed with an m-house 
sandwich-type IRMA based on DTPA-conjugated F(ab')2 fragments of the MAb 
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OV-TL 3 The capture site of the IRMA was prepared by absorbing the purified 
OV-TL 3 F(ab')2 - DTPA (Centocor Europe B.V., Leiden, The Netherlands) to 
polystyrene microtitration wells (Eflab Oy, Helsinki, Finland) as described 
previously (7) The signal site was based on 125l-labelled OV-TL 3 F(ab')2-DTPA 
using the chloramme-T method (8). Specific activities of 222 χ 109 Bq per gram 
(ι e , 6 //Ci///g) were obtained after desalting of the radiolabeled preparation on 
a PD-10 column (Pharmacia, Uppsala, Sweden) and subsequent further purifica­
tion on a Sephacryl S-300 column (1.6 cm χ 66 cm). 
The immunoassay procedure comprised the following steps 100 μ\ of undiluted 
serum sample, or the calibration standard as well as a positive and negative 
control serum sample were pipetted into the coated microtitration wells, 
together with 100 μΐ appropriately diluted 12Sl-labelled signal antibody (1500 Bq 
per well) and incubated overnight at room temperature The reaction mixture 
was aspirated and the wells were washed five times with washing buffer (50 
mM phosphate buffer, 154 mmol NaCI and 7.5 mmol of NaN3 per liter, pH 7 4) 
using a 12-channel washer (Wallac Oy, Turku, Finland). The radioactivity of the 
individual wells was counted for 5 minutes in a gamma counter (1260 Multi-
gamma II, Wallac Oy, Turku, Finland) and the results were calculated with a 
commercially available data management program (Multicalc, Wallac Oy, Turku, 
Finland) 
The assay was calibrated using a serum specimen that gave a strongly positive 
response Serial dilutions of this particular sample served as calibration stan­
dards in each run of the assay. We defined the 32-fold dilution of the sample to 
contain 1 arbitrary HAMA unit per liter (arb unit/L). 
HAMA nature 
The subclass of the HAMA response was further characterized by processing 
selected serum specimens containing (apparent) HAMA in a semi-quantitative 
heterologous assay. This assay applies the OV-TL 3 F(ab')2 - coated micro­
titration wells of the m-house IRMA described above as the capture site and 1 2 S I -
labelled rabbit - anti-human IgG (H + L)(Pierce, Rockford, II, USA) at the signal 
site To determine whether a specimen reacted positively or negatively in this 
semi-quantitative heterologous assay, the cut-off level of this assay was defined 
as the mean response plus three times the standard deviation (SD) of a series of 
HAMA negative serum samples (n = 21) 
As an additional method to determine the subclass of detected HAMA (IgG 
and/or IgM) in selected samples with high HAMA concentrations we performed 
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affinity chromatography as described previously (9) prior to assaying the 
subsequently isolated IgG and IgM fractions in the homologous HAMA IRMA. 
Briefly, the chromatography procedure comprised two steps: (a) Isolation of IgG-
type HAMA by absorption to a HiTrap Protein G column (1 mL; Pharmacia, 
Uppsala, Sweden), and (b) isolation of IgM-type HAMA on a goat-anti human 
IgM coupled HiTrap NHS-activated column (1 mL, Pharmacia, Uppsala, 
Sweden). 
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Figure 1 Composite standard curve ( ·) calibrated from the results of 5 successive 
immunoradiometric assays for HAMA, carried out in duplicate and the 
precision profiles (o), the within assay curve variation for the standard 
points of the assay 
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Results 
The standard curve and the precision profile of the HAMA-IRMA are shown in 
Figure 1. The dose-response curve shown represents the mean of 5 assay runs, 
each with duplicate determinations of serum standards. The total coefficient of 
intra-assay variations (CVs) for the response as counts bound of standard dose 
over maximum (i.e., undiluted standard) dose for each standard ranges from 0 
to 12%, indicating that reproducibility and precision of the standard curves are 
satisfactory. The detection limit of the assay, defined as the mean response + 
2xSD of a series of HAMA negative serum samples (n = 86), was 0.6 arb. 
unit/L The assay results of the p.i. serum specimens were considered signifi­
cantly positive if these were above the cut-off set at 0.6 arb. unit/L. 
Response against the OV-TL 3 Fab'immunoconjugate 
The HAMA concentrations of the patients sera prior to and post injection of OV-
TL 3 Fab' are depicted in Table 1. Eight patients (ι е., 8 out of 20; 40%) 
demonstrated p.i. HAMA concentrations above the clinical cut-off level of 0.6 
arb. unit/L. This group was designated HAMA-responders. The eight HAMA-
responders demonstrated HAMA starting one (n = 2), two (n = 3), three (n = 1), 
five (n = 1 ) or six (n = 1 ) weeks p.i. (Figure 2A). The maximum values during the 
follow-up of individual patients varied between 0.7 and 10 arb. unit/L. 
Only one patient had significantly increased HAMA serum concentrations prior 
to injection of the Fab' fragment. This patient with apparent pre-existent HAMA 
demonstrated HAMA concentrations of 13 and 15 arb. unit/L at different days 
pre-injection. The HAMA level still was 12 arb. unit/L one week p.i. From 2 to 
22 weeks p.i. HAMA levels appeared to decrease from 6.3 to 3.7 arb. unit/L, 
with a minimum concentration of 3.4 arb. unit/L. At 52 weeks p.i. the concen­
tration had increased again to 8.6 arb. unit/L. 
The remaining 11 patients (i.e., 11 out of 20; 55%) were HAMA-nonrespond-
ers, because none of these patients demonstrated positive test results at any 
time points during the study. 
In the group of HAMA-responders the heterologous IRMA indicated that the 
induced antibodies in patients 8 and 11 were IgG responses, whereas in 
patients 2, 6 and 13 this assay showed negative results, which might imply 
that these responses were IgM in nature. In addition, the affinity chromatogra 
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Table 1. The human anti-munne antibody responses expressed as arb. unit/L of 20 
patients injected with 1 mg of 99mTc - OV-TL 3 Fab'. 
HAMA-responders (8 patients): 
patient HAMA responses3 ь pre-injection and at post injection weeks 
number pre- 1 2 3 4 - 6 7 - 1 2 1 3 - 5 2 > 52 
¡nj. 
2 
6 
8 
9 
11 
12 
13 
20 
< 
< 
< 
< 
< 
< 
< 
< 
3 . 5 N 0 . 9 
< 
< 
< 
0.8 
0.7 
< 
7 
I P 
7 
4 
0.8 
< 
3 . 0 
3 . 6 
4 .8 
< 
4 . 3 N 
0 . 7 
1 0 P 
< 
1 . 0 N 
1 . 9 
9 . 2 
< 
< 
1 . 5 
5.7 
< 
1 . 6 
1 . 3 
apparent pre-existent HAMA (1 patient): 
patient HAMA responses рг -injection and at post injection weeks 
number pre- 1 2 3 4 - 6 7 - 1 2 1 3 - 5 2 
inj. 
10 1 5 N 1 2 N 6 . 3 3.4 
> 5 2 
3 . 7 8 . 6 N 
< = less than 0.6 arb. unit/L; 
response in heterologous assay: N = negative, У = positive 
phy procedure confirmed the IgG nature of the HAMA response in the 5 weeks 
p.ι. serum sample of patient 1 1 . In the patient with apparent pre-existent HAMA 
(nr 10) the heterologous assay as well as the affinity chromatography procedure 
showed negative results both in the case of pre-injection serum samples as well 
as p.i. specimen, suggesting that the reacting analyte was neither human IgG 
nor IgM. 
Response against the OV-TL 3 F(ab')2 immunoconjugate 
The serum HAMA concentrations of the patients who received 1 1 1 ln - DTPA -
OV-TL 3 F(ab')2 are shown in Table 2. Fourteen patients (i.e., 14 out of 73; 
19%) demonstrated p.i. HAMA concentrations above the cut-off level and were 
designated HAMA-responders. These patients demonstrated HAMA starting 
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Table 2 The human anti-murine antibody responses expressed as arb. unit/L of 73 
patients injected with 1 mg of 111ln - DTPA - OV-TL 3 F(ab')2. 
HAMA-responders (14 patients): 
patient HAMA responses" ь pre-injection and at post injection weeks 
number pre-inj. 1-3 4 - 6 7 - 1 2 1 3 - 5 2 
8 
2 0 
2 1 
2 4 
2 5 
3 0 
3 1 
4 4 
4 9 
5 1 
52 
54 
6 2 
7 1 
a p p a r e n t ore-
< 
< 
< 
< 
< 
< 
< 
< 
< 
< 
< 
< 
< 
•existent 
0 . 8 
2 . 0 
1 . 2 
3 . 2 P 
2 . 1 
< 
1 3 
1 8 
1 . 5 
< 
18 
< 
1 . 0 
3 . 8 
2 . 6 P 
2 . 6 N 
1 . 5 
1 . 6 
0 . 9 
1 . 7 
HAMA (6 pat ients) · 
1 7 
1 . 8 
2 . 3 
8 . 4 
3 2 P 
0 . 8 
< 
patient HAMA responses pre-injection and at post injection weeks 
number pre-inj 1-3 4 - 6 7 - 1 2 13 
2 
7 
2 9 
4 8 
6 3 
7 0 
2 . 6N 
3 . 7 N 
2 5N 
2 . 6 P 
1 . 1 
1 . 5 N 
1 . 9 N 
2 . 2 
3 . 0 
1 . 9 N 
2 . 5 N 
3 . 4 N 
4 . 8 P 
5 . 8 P 
52 
1 . 9 
1 . 5 N 
1 . 8 
a ) < = less than 0.6 arb unit/L; 
b ) response in heterologous assay N = negative, Ρ = positive, 
three (n = 8), four (n = 1) or six (n = 5) weeks p.i. (Figure 2B). The maximum 
values during follow-up of individual patients varied between 0.8 and 32 arb. 
unit/L. All patients except one patient (nr 44) remained HAMA-positive until the 
end of the sampling period. In one patient (nr 21) HAMA development was 
remarkably slow and continued to increase until a maximum concentration of 32 
arb. unit/L at 16 weeks p.i.. 
Six patients showed elevated HAMA concentrations (1.1 to 3.7 arb. unit/L) prior 
to injection of the F(ab')2 fragments (apparent pre-existent HAMA). 
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The majority of the patients (i.e , 53 out of 73; 73%) participating in this study 
were HAMA-nonresponders 
The IgG nature of the HAMA response was assessed with the heterologous 
IRMA m the serum specimens of patients 2 1 , 25 and 30, while in a sample of 
patient 31 this assay showed a negative result, suggesting that this may be an 
IgM HAMA response The affinity chromatography procedure demonstrated IgG 
as well as IgM in the serum specimens of patients 2 1 , 5 1 , and 71 
In the group of apparent pre-existent HAMA patients the heterologous IRMA 
revealed negative results (nr 2, 7, and 70). The affinity chromatography pro­
cedure confirmed that the measured analyte in the serum specimen of patient 7 
was not of IgG nature This procedure was not sensitive enough to either 
confirm or rule out the presence of an IgM HAMA response in this patient In 
patient 29 the initially negative result of the heterologous IRMA in the pre 
injection serum sample is followed by a positive test result at 4 weeks ρ ι , 
suggesting that pre injection a non-IgG HAMA was measured, whereas ρ ι an 
anti OV TL 3 IgG had developed. The affinity chromatography procedure 
confirmed the IgG nature in the 4 weeks ρ ι serum sample In patient 48 the 
pre-injection serum sample as well as the 6 weeks ρ ι serum sample showed 
positive test results in the heterologous IRMA, indicating the presence of pre 
existent IgG HAMA 
Discussion 
We have studied the development of HAMA responses after injection of 9 9 mTc -
OV-TL 3 Fab' or 1 l 1 l n - DTPA - OV-TL 3 F(ab')2 in 20 and 73 ovarian cancer 
patients, respectively HAMA quantification of the serum specimens was based 
on an m-house homologous sandwich-type IRMA system using OV-TL 3 F(ab')2 
Assays described to measure the HAMA response are radioimmunoassays (10, 
11), enzyme-linked immunosorbent assays (12), high performance liquid 
chromatography procedures ( 1 , 13, 14), immunofluorometric assays (7, 15), 
double-antigen assays (16, 17) and agglutination tests (18) The HAMA Survey 
Group divided the available assay systems into three categories- a) bridging 
assays using the same antibody for the capture and the signal site, b) indirect 
assays using a mouse MAb for the capture site and a species-specific antibody 
for the detection step and c) direct assays measuring antigen-HAMA immune 
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complexes (19, 20). Comparing the results of the various assay systems is 
complicated due to the differences in their analytical performance. The various 
assay systems differ in units used to report HAMA, definition of cut-off 
between negative and positive results, and materials used as standards and/or 
controls (19, 20) Obviously, there is a need to standardize HAMA assays. 
In our in-house double determinant HAMA assay we used the OV-TL 3 F(ab')2 
fragment both at the capture as well as at the signalling site (bridging assay) A 
homologous sandwich-type assay system seems to be most suited to detect 
antibody-specific HAMA responses (7, 20), although the Ig subclass of the 
HAMA itself should additionally be established 
The reproducibility and precision of the standard curves of the applied quantitat­
ive HAMA assay were satisfactory, indicating the reliability of this method to 
measure the HAMA responses brought about by either the monovalent or 
bivalent OV-TL 3 fragments. 
The proportion of patients who developed HAMA responses after injection of 
Fab' fragments (8/20, 40%) was in the same range as the proportion of HAMA-
responders after F(ab')2 administration (14/73, 19%)(Fisher's Exact Test, 
p > 0 . 0 5 ) . Other studies have suggested that the number of patients that would 
develop HAMA would be smaller after administration of Fab' fragments as 
compared to F(ab')2 fragments or whole IgG ( 1 , 2 1 , 22). Several studies 
reported no or only minor responses after i.v administration of Fab' fragments 
(22, 23, 24, 25). In serum samples obtained before and at 2 to 8 weeks after 
i v injection of "'In-labelled antimyosin Fab' no HAMA development was 
demonstrated in more than 500 patients (22). Differences in assay charac­
teristics may explain the lower incidence of HAMA observed in these studies. 
Homologous sandwich assays are assumed to be more sensitive for detection of 
HAMA responses. Secondly, the present study shows the relevance of the 
sampling time and frequency During the OV-TL 3 Fab' study the sampling 
started as soon as 1 week p.i.. Five patients who participated in this study 
became HAMA positive in the first two weeks p.i., while in one patient the 
HAMA levels declined below the cut-off already at three weeks ρ ι.. HAMA 
responses may have been underestimated due to the lower sampling frequency 
(22, 24, 25). 
In contrast to other anti-tumour antibodies, the OV-TL 3 MAb may be relatively 
more immunogenic, irrespective of its molecular form. The two radioimmuno-
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conjugates, " T c - OV-TL 3 Fab' versus 1 1Ίπ - DTPA - OV-TL 3 F(ab')2, used in 
our studies have different in vivo characteristics. The blood clearance of the 
F(ab')2 'S slower as compared to that of the Fab' fragment. One might expect 
that this may cause the F(ab')2 fragments to be more immunogenic The F(ab')2 
fragments were labelled with n i l n via the DTPA-chelator, while the OV-TL 3 
Fab' fragments were directly labelled with 9 9 mTc. The presence of the additional 
linker molecule in the F(ab')2 conjugate may also have induced an immune 
response (26). 
With the use of a heterologous IRMA and an affinity chromatography procedure 
the immunoglobulin subclass of the measured HAMA was further characterized 
in a limited number of samples. Most p.i. HAMA responses were IgG 
responses, and, although not tested, some of the negative results of the 
heterologous IRMA were most likely IgM HAMA responses In the group of 
HAMA responders of the F(ab')2 study some mixed IgG and IgM responses were 
detected. 
In the particular patient in the Fab' study with apparent pre-existent HAMA the 
heterologous IRMA as well as the affinity chromatography procedure showed 
negative results in all samples, suggesting that the detected HAMA were neither 
IgG nor IgM. The medical history of this patient revealed that she had suffered 
from rheumatoid arthritis complaints. The apparent HAMA may be the result of 
rheumatoid factors. However, it has been reported that rheumatoid factors 
interfere in HAMA assays by reacting with the Fc-portion of the antibodies used 
in these assays (27, 28). Since our in-house assay was based on OV-TL 3 
F(ab')2 such an interaction could not have occurred 
In one patient with apparent pre existent HAMA in the F(ab')2 study the initial 
negative result of the heterologous assay in the pre-mjection serum sample was 
followed by a positive test result in the serum sample obtained 4 weeks ρ ι , 
indicating that pre-mjection a non IgG HAMA is measured whereas ρ ι an anti-
OV-TL 3 IgG has developed. In another patient of the F(ab')2 study the pre-
injection serum sample as well as the 6 weeks ρ ι. sample showed positive test 
results in the heterologous IRMA, indicating the presence of a pre-existing IgG 
HAMA. Thompson et al demonstrated anti-mouse activity in approximately 
10% of 1008 healthy blood donors (29) Boscato and Stuart described the 
presence of antibody-binding substances in 30-40 % of 668 serum samples of 
laboratory personnel and blood donors (30, 31). Similarly, the presence of 
heterophils antibodies has been demonstrated in the serum samples from 3 0 % 
of gynaecologie cancer patients and healthy controls with the use of a murine 
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antibody based IFMA (15). 
In this study serum samples were collected during one year ρ ι , allowing the 
analysis of the kinetics of the HAMA réponses Six out of 8 HAMA-responders 
of the Fab' study and 8 out of 14 HAMA-responders of the F(ab')2 study 
demonstrated HAMA within three weeks ρ ι., indicating a quick HAMA response 
developed in these patients In three patients of the Fab' study the HAMA levels 
declined below the cut-off within 13 weeks p.ι . In the F(ab')2 study all patients 
except one remained HAMA-positive until the end of the sampling period, 
indicating that long lasting HAMA responses were elicited. In one of these 
"F(ab')2 patients" the development of HAMA was remarkably slow and con 
tinued to increase to a maximum concentration of 32 arb unit/L at 16 weeks 
p.ι These data indicate that short as well as long-lasting HAMA responses 
were induced after ι v. administration of both 9 9 mTc - OV-TL 3 Fab' and i n l n -
DTPA - OV-TL 3 F(ab')2 in ovarian cancer patients 
In summary, the m-house OV-TL 3 F(ab')2-based homologous sandwich-type 
IRMA described in this study efficiently quantified the OV-TL 3 specific HAMA 
responses With an additional heterologous assay and affinity chromatography 
the Ig subclass of the HAMA could be further characterized. Remarkably, the 
fraction of HAMA-responders after injection of OV-TL 3 Fab' fragments was in 
the same range as the proportion of HAMA-responders after F(ab')2 administra­
tion 
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Decreased kidney uptake of technetium-99m-labelled 
Fab' fragments in ovarian carcinoma bearing nude 
mice using a cleavable chelator 
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Abstract 
A new 99mTc labelling method using a cleavable chelator, RP-1, was developed. 
In this study Balb/c mice with ovarian carcinoma xenografts received various 
Fab' fragments labelled with " T c either directly or via RP-1. Kidney uptake 
was significantly lower for the RP-1 linked conjugates. Tumour uptake showed 
no significant differences between RP-1 conjugates and directly labelled 
preparations. 
In conclusion, with the use of the cleavable linker RP-1, kidney uptake can be 
reduced significantly resulting in a lower radiation dose to the kidneys. 
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Introduction 
Radiolabeled monoclonal antibodies (MAbs) against tumour-associated antigens 
can be used for targeting radionuclides to tumours (1) During the last decade 
efforts were made to optimize the technology For radioimmunodetection. Fab' 
fragments are considered as alternative formulation to whole IgG The use of 
Fab' fragments has several advantages when compared to intact MAb Smaller 
fragments have a faster blood clearance, are less immunogenic, and provide 
better penetration in tumour tissue (2, 3, 4) Rapid tumour uptake and fast 
reduction of background activity implies tumour visualisation within 24 hours (h) 
after injection (5, 6, 7) In this situation, technetium 99m with its superb 
characteristics as a radionuclide for imaging, can be used despite its relatively 
short (6 h) half life 
In clinical studies using 99mTc labelled Fab' fragments, high kidney uptake is 
observed (6, 8), resulting in a high radiation dose to the kidneys and hampering 
detection of tumour deposits near the kidneys In recent years, the use of 
cleavable linkers for labelling i n l n to Mabs was described in order to reduce 
physiologic retention in normal organs such as liver, spleen and kidney (9, 10) 
Similarly, a cleavable chelator for 99mTc, RP-1, was developed to reduce kidney 
uptake (11) An ester-linkage is included in this afunctional chelating agent (RP-
1), such that upon cleavage of this ester-linkage, the radiolabel is complexed in 
the N3S core of triglycine (Figure 1) This complex is stable in vivo and is rapidly 
excreted through the kidneys The present study was performed to compare the 
biodistribution of directly labelled and RP 1 linked 99mTc-labelled Fab' fragments 
of MAbs directed against ovarian carcinomas in ovarian carcinoma bearing nude 
mice 
Materials & methods 
Xenograft 
The ovarian carcinoma cell line NIH OVCAR 3 (12) was used The tumour model 
was established by subcutaneous injection of 3x107 NIH OVCAR-3 cells 
Tumours were resected aseptically, and pieces of 2-3 mm diameter were serially 
transplanted subcutaneously in the left flank of female athymic Balb/c mice 
under ether anaesthesia Six to eight weeks after transplantation when tumours 
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measured circa 1 cm in diameter, mice were used for biodistribution studies. 
Monoclonal antibodies 
The following monoclonal antibodies of the IgG, subclass were used in these 
studies: (1) OV-TL 3 (13), recently shown to recognize a 30 kDa ovarian 
carcinoma-associated antigen (14), (2) OC125 (15), directed against the ovarian 
carcinoma-associated antigen expressed on a high molecular weight 
glycoprotein ( > 2 0 0 kDa)(16), (3) chimeric MOv18 (17), recently shown to be 
directed against a 38 kDa folate-binding protein (18) and (4) 323/A3, directed 
against a 30-40 kDa panadenocarcmoma-associated antigen (19). R11D10, an 
antimyosin MAb (20) was used as a non-specific control antibody in these 
studies. All antibodies were supplied by Centocor B.V., Leiden, The 
Netherlands. 
Preparation of the Fab' fragments 
Antibodies were purified by Protein-Α affinity chromatography. F(ab')2 
fragments were prepared by pepsin digestion of the Protein-Α purified IgG (21) 
The crude F(ab')2 fragments were subsequently purified by cation exchange 
chromatography on S Sepharose Fast Flow F(ab')2 fragments (5-10 mg/mL) 
were reduced with dithiothreitol (10 mM). The antibody fragment solution was 
desalted by Sephadex G-25 chromatography with phosphate buffer; high 
performance liquid chromatography (HPLC) analysis on a Protein Pak 125 
column (Waters, Milford, MA, USA) indicated complete reduction. 
Direct labelling of the Fab' fragments with 99mTc 
The Fab' fragments of OV-TL 3 and 323/A3 were directly labelled with 9 9 mTc as 
described previously (22). Briefly, 1 mL of 9 9 mTc-sodium pertechnetate (40 mCi) 
was added to a lyophilized vial containing 12.5 mg of monopotassium D-
glucarate, 100 pg of stannous chloride and 16.8 mg of sodium bicarbonate. The 
solution was incubated for 1 mm at room temperature. Then the Fab' fragments 
at 2.0 mg/mL in 50 mM sodiumphosphate, 100 mM NaCI, 1 mM EDTA, pH 6.5 
was mixed with an equal volume of [99mTc]-D-glucarate and incubated at room 
temperature for 1 h. 
Preparation of the Fab'- RP-1 chelator conjugates 
The Fab' fragments of OV TL 3, 323/A3, OC125, MOv18, and R11D10 were 
labelled with 9 9 mTc through the use of the cleavable chelator, RP-1 (Figure 1). 
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Synthesis of this chelator has been described by Weber et al. (11). RP-1 was 
conjugated to the Fab' fragments of the five monoclonal antibodies as described 
(11) Briefly, 25 μΐ of RP-1 in DMF (4%) was mixed with 1.0 mL of Fab' 
solution (4 mg/mL in phosphate buffer). Following 1.5 h of incubation at room 
temperature, excess reagent was removed by gel filtration on Sephadex G-25 
The number of chelates per antibody is dependent on the number of available 
SH-groups. Per Fab' fragment 1-4 SH-groups are available for association with a 
chelator molecule 
99mTc labelling of the Fab'- RP-1 chelator conjugates 
One mL 9 9 mTc-sodium pertechnetate solution (40 mCi) was added to a vial 
containing potassium D-glucarate (12 mg) and stannous chloride (100/vg) in 0 2 
M bicarbonate solution. After standing at room temperature for 15 mm the 
solution was mixed with an equal volume of Fab' fragments and incubated for 1 
h at room temperature. 
O ^ ^ N H HN 
CO,H 
Figure 1 Structural formula of the bifunctional chelator RP-1 
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Quality control 
Prior to antibody injection the labelling efficiency was determined by instant thin 
layer chromatography (ITLC), using 0.2 M acetate buffer (pH 6.0) as solvent. 
The immunoreactive fraction (IRF) was assessed by titration of a fixed amount 
of labelled antibody (20000 cpm) with increasing numbers of OVCAR-3 or HeLa 
cells (О.бхЮ6 - 10x10е) in 0.5 mL binding buffer (RPMI medium, 0.5% BSA, 50 
mM HEPES). After 4 h of incubation at 4°C, cells were centrifuged (5 min, 
800g) in an Eppendorf microcentrifuge. The supernatant was aspirated and the 
pellet was counted in a well-type gamma-counter. Data were plotted as 
described by Lindmo et al. (23) and the IRF was calculated from the y-axis 
abscissa. 
Biodistribution experiments 
First, Balb/c mice with subcutaneous human ovarian carcinoma xenografts were 
injected via the tail vein with Fab' fragments of OV-TL 3 or 323/A3 (200 
¿/L/mouse; 10 pg) labelled with 99mTc (120 - 170 /УСІ) either directly or via RP-1. 
Subsequently, the biodistribution of Fab' fragments of four MAbs directed 
against antigens present on ovarian adenocarcinomas (OV-TL 3, 323/A3, 
MOv18, OC125) and a non-specific control antibody (R11D10) labelled with 
9 9 mTc via the RP-1 chelator (10 μg•, 120 - 170 μ0\; 200 /vL/mouse) was 
compared in this mouse model. 
At 1, 4, 8, and 24 h post injection (p.i.) at least three mice per data point were 
bled under ether anaesthesia. After cervical dislocation mice were dissected. 
The amount of activity in tumour and normal tissues (blood, liver, spleen, 
kidney, intestine, heart, lung, muscle, femur) was determined in a well-type 
counter, using an injection standard to correct for physical decay. Uptake was 
expressed as percentage of the injected dose per gram of tissue (%ID/g). Urine 
and faeces were collected and counted per three mice. 
The experiments were carried out in compliance with the Dutch regulations 
relating to the conduction of animal experiments. 
Statistical analysis 
To determine whether differences in tissue uptake at the various time points 
were statistically different the ANOVA test was used. 
The area under the curve (AUC) corrected for physical decay of 9 9 mTc was used 
as an estimation of the radiation burden to the kidneys. The AUC was 
calculated from the %ID/g tissue throughout the study time (0 - 24 h p.i.). It 
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was assumed that at timepoint zero the uptake was 0%ID/g. 
In order to evaluate the imaging properties of the preparations, tumour/kidney 
ratios were calculated. Differences between ratios as well as AUCs were tested 
with the Student's t-test. 
In all tests used, significance was assumed at a p-value of 0.05. The Bonferoni 
correction was used to correct for multiple testing. 
Results 
Quality control 
ITLC of the immunoconjugates, labelled with 9 9 mTc directly as well as via RP-1, 
indicated that more than 95% of the radioactivity was protein bound. The 
immunoreactive fraction varied between 55 and 7 2 % for each of the 
radioimmunoconjugates used in this study (Table 1). 
Table 1 Immunoreactive fraction of Fab' fragments labelled with 99mTc either 
directly or via RP-1 determined by maximum binding to OVCAR-3 or HeLa 
cells 
Immunoreactive fraction (%) 
72 
67 
55 
58 
65 
Biodistribution experiments 
Firstly, the biodistribution of Fab' fragments of tumour specific MAbs OV-TL 3 
and 323/A3 labelled with 9 9 mTc either directly or via RP-1 was studied. Of all 
organs, highest uptake was observed in the kidneys, varying from 80.4 ± 
4 5%ID/g to 27.0 ± 3.7%ID/g (Figure 2). Using RP-1, kidney uptake of OV-TL 
3 and 323/A3 at 24 h p.ι. was only 2 2 % and 16%, respectively, of the uptake 
of the directly labelled preparations. Kidney uptake was significantly lower for 
the RP-1 conjugates at all time points. Although an absolute decrease of kidney 
Immunoconjugate 
99mTc - OV-TL 3 
99mTc - RP-1 - OV-TL 3 
99mTc - 323/A3 
99mTc - RP-1 - 323/A3 
9 9 m Tc- RP-1 -Μ0ν1θ 
9 9 m Tc- RP-1 -0C125 
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uptake of approximately 10%ID was observed, this difference could not be 
demonstrated in the measurements of the radiolabel excretion in urine and 
faeces. At 24 h p.i., cumulative excretion in urine and faeces was in the same 
range for all four preparations, ranging from 70 to 9 5 % ID. Tumour uptake did 
not show significant differences for any of the immunoconjugates, and varied 
between 2.1 ± 0.3%ID/g for RP-1-linked OV-TL 3 and 3.7 ± 1.0%ID/g for 
directly labelled 323/A3 (Figure 3). 
Biodistribution data for the other organs are presented in Table 2a-g. Splenic 
uptake was influen~ed by the labelling method used: the uptake of RP-1-linked 
conjugates was significantly lower compared with directly labelled preparations. 
Differences in uptake in the other organs were not statistically significant. 
Subsequently, a study was performed comparing RP-1-linked 9 9 mTc - Fab' 
fragments of OV-TL 3, 323/A3, MOv18, OC125 with the non-specific control 
R11D10. Tumour uptake is presented in Figure 4. Highest uptake of 3.2 ± 
1.6%ID/g was obtained by 323/A3, lowest uptake of 1.3 ± 0.4%ID/g was 
obtained by R11D10. For all antibodies the kidneys showed the highest uptake. 
Kidney uptake ranged from 52 6 ± 7.3%ID/g after injection of MOv18 to 27 0 
± 3.7%ID/g seen with 323/A3 (Figure 5) These values indicated that besides 
the labelling method antibody characteristics also affect the biodistribution. At 
24 h p.ι., 77%ID of R11D10 was excreted in urine and faeces. Excretion of the 
anti-tumour MAbs was in the same range and varied from 76 to 95%ID. From 4 
h ρ ι. onwards liver uptake of OV-TL 3, MOv18 and OC125 was significantly 
lower compared with the non-specific control (Table 2a-g). The same MAbs 
showed a significantly lower spleen uptake from 4 h p.ι. onwards. Distribution 
data for the other organs did not show consistent differences. 
Estimation of the radiation dose 
The estimated radiation dose to the kidneys, expressed as the AUC corrected 
for physical decay of 9 9 mTc is presented in Table 3. The estimated radiation 
doses for the RP-1 linked conjugates of OV-TL 3 and 323/A3 were significantly 
lower compared with the directly labelled preparations. 
When comparing all RP-1-linked immunoconjugates, the estimated radiation 
doses for the tumour-associated MAbs were significantly lower compared with 
the non-specific control MAb R11 D10. 
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Figure 2. Kidney uptake of Fab' fragments of OV-TL 3 (circle symbols) and 323/A3 
(square symbols) labelled with 9 9 m Tc either directly (filled symbols) or via 
RP-1 (open symbols) 
time post injection (h) 
Figure 3. Tumour uptake of Fab' fragments of OV-TL 3 (circle symbols) and 
323/A3 (square symbols) labelled with " T c either directly (filled 
symbols) or via RP-1 (open symbols). 
Table 2a. Tissue distribution of directly labelled " T c - OV-TL 3 Fab' in ovarian 
carcinoma bearing nude mice (%ID/g, mean ± SD, η = 3). 
Organ 
Kidney 
Tumour 
Blood 
Liver 
Spleen 
Intestine 
Heart 
Lung 
Muscle 
Bone 
Time post injection 
1 
69.3 ± 8.8 
1.6 ± 0.4 
11.1 ± 0.8 
2.7 ± 0.1 
2.5 ± 0.2 
1.5 ± 0.3 
2.5 ± 0.4 
3.8 ± 0.3 
0.6 ± 0.2 
1.5 ± 0.3 
(h) 
4 
49.5 ± 5.2 
3.6 ± 2.8 
4.8 ± 0.4 
1.9 ± 0.2 
1.6 ± 0.2 
2.1 ± 0.2 
1.7 ± 0.1 
2.3 ± 0.4 
0.3 ± 0.04 
0.9 ± 0.2 
8 
41.5 ± 7.2 
2.2 ± 0.2 
2.0 ± 1.4 
1.8 ± 0.3 
1.3 ± 0.2 
2.1 ± 0.6 
1.0 ± 0.1 
1.4 ± 0.2 
0.3 ± 0.02 
0.7 ± 0.08 
24 
18.2 ± 5.6 
2.7 ± 0.9 
0.4 ± 0.1 
0.8 ± 0.2 
0.7 ± 0.2 
0.4 ± 0.3 
0.3 ± 0.03 
0.6 ± 0.2 
0.1 ± 0.01 
0.2 ± 0.06 
Table 2b. Tissue distribution of RP-1-linked 9 9 m Tc - OV-TL 3 Fab' in ovarian carcinoma 
bearing nude mice (%ID/g, mean ± SD, η = 3). 
Organ 
Kidney 
Tumour 
Blood 
Liver 
Spleen 
Intestine 
Heart 
Lung 
Muscle 
Bone 
Time post inj 
1 
49.3 ± 4.8 
2.1 ± 0.5 
10.0 ± 0.8 
2.1 ± 0.3 
1.7 ± 0.2 
1.8 ± 0.2 
2.9 ± 0.1 
3.4 ± 0.3 
0.6 ± 0.2 
1.1 ± 0.2 
ection (h) 
4 
18.0 ± 1.1 
2.1 ± 0.4 
1.9 ± 0.2 
0.8 ± 0.2 
0.4 ± 0.06 
3.5 ± 0.8 
0.7 ± 0.1 
1.1 ± 0 . 1 
0.4 ± 0.02 
0.4 ± 0.03 
8 
14.9 ± 1.3 
2.1 ± 0.3 
0.9 ± 0.09 
0.7 ± 0.3 
0.3 ± 0.03 
3.3 ± 1.7 
0.3 ± 0.02 
0.8 ± 0.2 
0.2 ± 0.04 
0.3 ± 0.04 
24 
4.0 
1.6 
0.2 
0.1 
0.08 
0.2 
0.05 
0.2 
0.03 
0.05 
± 0.2 
± 0.5 
± 0.01 
± 0.01 
± 0.01 
± 0.03 
± 0.01 
± 0.08 
± 0.01 
± 0.01 
Table 2c. Tissue distribution of directly labelled 9 9 mTc - 323/A3 Fab' in ovarian 
carcinoma bearing nude mice (%ID/g, mean ± SD, η = 3). 
Organ 
Kidney 
Tumour 
Blood 
Liver 
Spleen 
Intestine 
Heart 
Lung 
Muscle 
Bone 
Time post injection 
1 
80.4 ± 4.5 
2.1 ± 0.8 
14.6 ± 1.8 
4.2 ± 0.5 
2.6 ± 0.07 
2.7 ± 0.05 
3.8 ± 0.9 
4.6 ± 0.5 
1.2 ± 0.5 
2.3 ± 0.4 
(h) 
4 
56.9 ± 4.2 
3.7 ± 1.0 
5.3 ± 1.2 
3.0 ± 0.4 
1.4 ± 0.2 
3.8 ± 0.4 
1.5 ± 0.3 
2.5 ± 0.2 
2.3 ± 1.6 
2.7 ± 0.8 
8 
52.4 ± 
3.6 ± 
2.0 ± 
1.9 ± 
1.0 ± 
2.0 ± 
0.8 ± 
1.2 ± 
0.3 ± 
0.6 ± 
13.1 
1.6 
0.3 
0.4 
0.1 
1.1 
0.2 
0.3 
0.1 
0.2 
24 
23.2 ± 2.9 
2.0 ± 0.4 
0.3 ± 0.03 
0.8 ± 0.02 
0.5 ± 0.08 
0.7 ± 0.2 
0.2 + 0.03 
0.3 ± 0.02 
0.1 ± 0.02 
0.2 ± 0.02 
Table 2d. Tissue distribution of RP-1 -linked 9 9 m Tc - 323/A3 Fab' in ovarian carcinoma 
bearing nude mice (%ID/g, mean ± SD, η = 3). 
Organ 
Kidney 
Tumour 
Blood 
Liver 
Spleen 
Intestine 
Heart 
Lung 
Muscle 
Bone 
Time post injection 
1 
27.0 ± 3.7 
2.6 ± 0.8 
16.0 ± 1.1 
3.7 ± 0.08 
2.7 ± 0.05 
3.1 ± 0.4 
4.0 ± 0.2 
5.5 ± 0.8 
1.3 ± 0.5 
2.3 ± 0.4 
(h) 
4 
13.4 ± 0.4 
3.2 ± 1.6 
5.8 ± 0.6 
2.2 ± 0.4 
1.0 ± 0.09 
5.2 ± 0.3 
1.6 ± 0.1 
2.8 ± 0.5 
0.8 ± 0.1 
1.3 ± 0.5 
8 
9.4 ± 1.6 
3.0 ± 0.9 
2.5 ± 0.09 
1.3 ± 0.3 
0.5 ± 0.08 
3.5 ± 0.8 
0.7 ± 0.1 
2.2 ± 1.2 
0.4 ± 0.07 
0.6 ± 0.2 
24 
3.8 
3.0 
0.4 
0.4 
0.2 
0.7 
0.1 
0.3 
0.08 
0.1 
± 0.3 
± 0.4 
± 0.09 
± 0.06 
± 0.06 
± 0.05 
± 0.02 
± 0.09 
± 0.06 
± 0.05 
Table 2e. Tissue distribution of RP-1-linked " T c - OC125 Fab' in ovarian carcinoma 
bearing nude mice (%ID/g, mean ± SD, η = 3). 
Organ 
Kidney 
Tumour 
Blood 
Liver 
Spleen 
Intestine 
Heart 
Lung 
Muscle 
Bone 
Time post injection (h) 
1 
28.4 ± 5.4 
1.7 ± 0.2 
13.3 ± 1.5 
2.5 ± 0.4 
2.1 ± 0.3 
3.4 ± 0.7 
3.5 ± 0.7 
4.3 ± 0.7 
1.0 ± 0.7 
2.0 ± 1.3 
4 
10.8 ± 1.9 
2.5 ± 0.7 
3.6 ± 0.5 
1.2 ± 0.1 
0.6 ± 0.04 
4.1 ± 0.4 
1.1 ± 0.1 
2.1 ± 0.6 
0.6 ± 0.07 
0.5 ± 0.1 
8 
5.1 ± 0.4 
2.3 ± 0.2 
1.4 ± 0.06 
0.6 ± 0.04 
0.3 ± 0.01 
4.0 ± 0.5 
0.4 ± 0.02 
0.9 ± 0.3 
0.2 ± 0.06 
0.2 ± 0.04 
2 4 
1.7 ± 0.7 
1.4 ± 0.3 
0.3 ± 0.1 
0.2 ± 0.05 
0.09 ± 0.03 
0.4 ± 0.2 
0.08 ± 0.02 
0.3 ± 0.02 
0.03 ± 0.02 
0.07 ± 0.02 
Table 2f. Tissue distribution of RP-1-linked 9 9 m Tc - MOv18 Fab' in ovarian carcinoma 
bearing nude mice (%ID/g, mean ± SD, η = 3). 
Organ 
Kidney 
Tumour 
Blood 
Liver 
Spleen 
Intestine 
Heart 
Lung 
Muscle 
Bone 
Time post injection 
1 
52.6 ± 7.3 
1.5 ± 0.4 
7.8 ± 1.7 
2.1 ± 0.3 
1.4 ± 0.2 
3.4 ± 0.3 
2.3 ± 0.2 
3.0 ± 0.2 
0.9 ± 0.4 
0.9 ± 0.06 
(h) 
4 
23.2 ± 5.7 
1.9 ± 0.7 
1.6 ± 0.3 
0.7 ± 0.02 
0.4 ± 0.06 
2.7 ± 1.0 
0.5 ± 0.05 
0.8 ± 0.1 
0.5 ± 0.3 
0.4 ± 0.09 
15.0 ± 0.5 
1.0 ± 0.2 
0.8 ± 0.07 
0.5 ± 0.1 
0.2 ± 0.04 
1.8 ± 0.7 
0.2 ± 0.03 
0.5 ± 0.05 
0.1 ± 0.04 
0.2 ± 0.01 
24 
7.7 ± 2.6 
1.0 ± 0.4 
0.3 ± 0.07 
0.2 ± 0.07 
0.1 ± 0.02 
0.5 ± 0.08 
0.1 ± 0.03 
0.2 ± 0.04 
0.04 ± 0.02 
0.1 ± 0.02 
Table 2g. Tissue distribution of RP-1-linked 99mTc - R11D10 Fab' in ovarian carcinoma 
bearing nude mice (%ID/g, mean ± SD, η = 3). 
Organ 
Kidney 
Tumour 
Blood 
Liver 
Spleen 
Intestine 
Heart 
Lung 
Muscle 
Bone 
Time post injection (h) 
1 
45.3 ± 2.5 
1.3 ± 0.6 
9.0 ± 1.1 
3.3 ± 0.3 
2 0 ± 0.07 
2.6 ± 0.4 
2.2 ± 0.1 
2.8 ± 1.0 
0.6 ± 0.2 
1.1 ± 0.4 
4 
34.0 ± 3.2 
1.3 ± 0.4 
2.6 ± 0.6 
1.9 ± 0.07 
1.0 ± 0.08 
2.2 ± 0.5 
0.8 ± 0.1 
1.3 ± 0.1 
0.3 ± 0.05 
0.6 ± 0.2 
8 
27.7 ± 3.7 
1.0 ± 0.2 
1.5 ± 0.2 
2.0 ± 0.4 
1.0 ± 0.1 
1.9 ± 0.7 
0.5 ± 0.05 
1.1 ± 0.3 
0.5 ± 0.5 
0.4 ± 0.05 
24 
17.0 ± 2.6 
1.2 ± 0.7 
0.5 ± 0.2 
1.6 ± 0.6 
1.0 ± 0.4 
0.7 ± 0.4 
0.3 ± 0.1 
0.5 ± 0.2 
0.2 ± 0.2 
0.3 ± 0.08 
Table 3. The estimated radiation dose to the kidneys, expressed as the area under 
the curve (AUC) corrected for physical decay of 99mTc for directly labelled 
or RP-1-linked 99mTc - Fab' fragments in ovarian carcinoma bearing nude 
mice (%ID/g χ h p.ι.; mean ± SD). 
Immunoconjugate 
9 9 m Tc -
9 9 m T c . 
9 9 m T c . 
9 9 m T c • 
" " T c • 
9 9 m T c . 
9 9 m Tc -
OV-TL 3 
-RP-1 - OV-TL 3 
• 323/A3 
RP-1 - 323/A3 
RP-1 - MOv18 
- RP-1 - OC125 
RP-1 - R11D10 
AUC for kidney 
406.5 ± 20.1 
188.7 ± 6.0 
4 8 8 . 4 ± 31.0 
116.7 ± 5.2 
95.6 ± 6.2 
208.3 ± 10.5 
274.3 ± 9.8 
Tumour-to-tissue ratios 
The tumour-to-kidney ratios for the RP-1-linked conjugates were significantly 
higher when compared with the directly labelled preparations. At 24 h p.i. the 
tumour-to-kidney ratios were 0.18 ± 0.07 and 0.09 ± 0.01 for directly labelled 
OV-TL 3 and 323/A3, respectively, and 0.41 ± 0.13 and 0.81 ± 0.13 for RP-1 
linked OV-TL 3 and 323/A3, respectively. 
In the comparative study, the highest tumour-to-kidney ratio of 0.89 ± 0.4 was 
obtained 24 h after injection of OC125. Similar ratios were observed after 
injection of OV-TL 3 and 323/A3 (0.41 ± 0.13 and 0.81 ± 0.13, respectively). 
time post injection (h) 
Figure 4. Tumour uptake of Fab' fragments (o = OV-TL 3; · = 323/A3; 
MOv1 8; D = OC1 25; Δ = R11D10) labelled with 99mTc via RP-1 
σι 
Q 
Q. 
о 
time post injection (h) 
Figure 5. Kidney uptake of Fab' fragments (o = OV-TL 3; · = 323/A3; 
MOv18; D = OC125; Δ = R11D10) labelled with 99mTc via RP-1 
The tumour-to-kidney ratio of 0.14 ± 0.02 obtained by MOv18 was somewhat 
lower, but was still significantly higher than the ratio of 0.07 ± 0.03 obtained 
by the non-specific control R11D10. The highest tumour-to-muscle ratios of 64 
± 30 (%ID/g / %ID/g) were obtained at 24 h p.ι. with OV-TL 3 The ratios of 
the tumour-associated MAbs were all higher compared with the non-specific 
control MAb R11D10. 
Discussion 
With 99mTc-labelled Fab' fragments successful tumour detection in patients has 
been described (5, 6, 7, 8). Because of its physical characteristics, its low costs 
and its availability 9 9 mTc is a superb radionuclide for diagnostic purposes. Fab' 
fragments are chosen because these smaller fragments have a faster blood 
clearance, are less immunogenic, and can penetrate better in tumour tissue 
when compared with intact IgG and F(ab')2 fragments (4). Goldenberg et al (6) 
administered 99mTc-labelled anti-CEA Fab' fragments to patients with various 
cancers and demonstrated successful imaging of tumour lesions within 24 h ρ ι 
However, high kidney uptake was observed thus posing problems in the 
detection of tumour deposits in the vicinity of the kidneys We encountered 
similar problems following administration of 99mTc-labelled OV-TL 3 Fab' in 
patients with ovarian carcinoma (8). In this study, quantitative measurements 
with the gamma camera showed with time increasing retention of 9 9 mTc in the 
kidneys up to 30 h p.ι As an explanation for this phenomenom, Granowska et 
al. (24) suggested reabsorption in the proximal tubules and deposition of 9 9 mTc 
in the kidneys as a result of the development of a 9 9 mTc peptide at meta-
bolization of 99mTc-labelled immunoconjugates. 
The use of cleavable linkers for labelling n i l n to MAbs in order to lower liver 
uptake has been described earlier. In a study comparing five different cleavable 
linkers. Meares et al. showed that introduction of an ester-linkage in the afunc­
tional chelating agent most effectively lowered liver uptake (9, 25). Paik et al. 
(10) introduced a diester linkage between an anti melanoma antibody and a 
DTPA-chelate The diester preparation cleared faster from the blood and uptake 
in normal tissues such as liver, spleen, and kidney appeared decreased when 
compared to a peptide linkage. The same approach was chosen by Weber et al. 
(11) with the development of an ester-linked afunctional chelator (RP-1) using 
the N3S core of mercaptoacetyl-tnglycine. In an animal study in normal mice 
they demonstrated that the ester linked conjugate showed an increased 
88 
chapter 4 
clearance from the kidney compared to the directly labelled preparation. The 
results suggested that the ester linkage is hydrolysed in the kidneys to produce 
a 9 9 mTc-(mercapto)tnglycine which is rapidly excreted 
In the present study we investigated this novel chelator in an experimental 
animal model to assure that the linkage is not only stable in serum but also in 
the tumour. 
Kidney uptake was significantly lower for the RP-1-linked conjugates throughout 
the study, indicating metabolization in the kidneys of the immunoconjugate into 
readily excreted complexes. The results indicate that the kidney uptake can be 
reduced when Fab' fragments are labelled via RP-1. 
The blood clearance of the immunoconjugates was not significantly different, 
indicating that the conjugates labelled via RP-1 were probably stable in serum. 
Most importantly, no significant differences in tumour uptake were found for 
both labelling methods, suggesting that hydrolysis of the ester-linkage does not 
occur in the tumour or in serum. Of the normal tissues, the uptake in spleen 
was significantly lower for the immunoconjugates labelled via RP-1 compared to 
the directly labelled preparations, suggesting that hydrolysis of the ester-linkage 
may also occur in the spleen. Thus, labelling via the RP-1 chelator resulted in 
lower kidney uptake whereas uptake in tumour and other normal tissues was 
not significantly affected. 
In our animal model, a substantial decrease of the radiation dose to the kidneys 
could be achieved using the RP-1 chelator. Using the AUC corrected for physical 
decay of 9 9 mTc as an estimation for the radiation burden, a reduction of 50-
75% was achieved with the use of the RP-1 labelling method in this mouse 
model. 
Throughout the study the tumour-to-kidney ratios were significantly higher for 
the immunoconjugates labelled via RP-1. However, even at 24 h p.ι. these ratios 
were lower than 1.0. So, it seems unlikely that the reduction in kidney uptake 
will be sufficient to improve the detection of tumour deposits near the kidneys 
in clinical studies. 
At 24 h p.ι. tumour-to-background ratios ranging from 28 to 64 were obtained 
for the RP-1-linked tumour-associated MAbs indicating that imaging with these 
radioimmunoconjugates is feasible. 
In conclusion, the introduction of an ester-linkage in the afunctional chelator 
can significantly reduce the uptake of the kidneys, while tumour uptake is not 
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a f f e c t e d Based on our results in th is exper imental m o d e l it is e x p e c t e d that the 
use of the RP-1 l inker can reduce the radiat ion dose to the k idneys in cl inical 
r a d i o i m m u n o d e t e c t i o n studies H o w e v e r , w h e t h e r this r e d u c t i o n wi l l 
s ign i f icant ly i m p r o v e the d e t e c t i o n of t u m o u r deposi ts near the k idneys in 
cl inical r a d i o i m m u n o s c i n t i g r a p h i c studies remains to be i n v e s t i g a t e d 
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Effect of the route of administration on the 
biodistribution of radioiodinated OV-TL 3 F(ab')2 
in experimental ovarian cancer 
J.G. Tibben, L.F.A.G. Massuger, O.C. Boerman, G.F. Borm, R.A.M.J. Ciaessens, 
F.H.M. Corstens 
Eur J Nucl Med 1994, 21:1183-11 90 
Abstract 
The effect of the route of administration on the distribution of radioiodmated 
OV-TL 3 F(ab')2 was studied in Balb/c female mice with intraperitoneal (ι p.) or 
subcutaneous (s.c.) ovarian carcinoma xenografts. In the ι p. tumour model in 
which both ascites and solid tumour deposits were present, ι p. administration 
resulted in a lower estimated radiation dose to blood as compared with intra­
venous (ι ν ) administration. In this model normalization to equal estimated 
radiation doses to blood for both routes of administration, indicated that a twice 
as high estimated radiation dose can be guided to solid i.p. tumour deposits 
following ι ρ administration. Evacuation of ascitic tumour cells prior to 
monoclonal antibody (MAb) injection further increased the estimated radiation 
dose to solid i.p tumour deposits following i.p. delivery. Following simultaneous 
ι ν and i.p. injection of the MAb, tissue uptake showed no relevant differences 
in the s с tumour model. Overall, the i.p. route of administration was found to 
be the best choice for therapeutic delivery of 1 3 1 l-labelled MAbs. 
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Introduction 
The targeting properties and clinical potential of the monoclonal antibody (MAb) 
OV-TL 3 were established in radioimmunoscintigraphic (RIS) studies. The 
diagnostic accuracy of n i l n - OV-TL 3 F(ab')2 and 9 9 mTc - OV-TL 3 Fab' in 
ovarian carcinoma patients was 94 and 7 6 % , respectively ( 1 , 2). Based on 
these findings, OV-TL 3 seems a suitable candidate for radioimmunotherapy 
(RIT). 
For therapeutic purposes radiolabeled MAbs can be administered systemically 
as well as locoregionally By intravenous (ι v.) administration all disseminated 
tumour localizations can be reached (3, 4) Locoregional administration may be 
favourable in the treatment of diseases which are known to spread locally. In 
patients with ovarian carcinoma so far the intraperitoneal (i.p ) route of adminis 
tration has to date been used for RIT (5, 6, 7). However, comparative data on 
the effect of the mode of delivery on the actual tumour uptake and the reduc­
tion of the radiation dose to the dose limiting organs are rather scarce. 
In a previous study on the biodistribution of radiolabeled intact OV-TL 3 and it's 
F(ab')2 fragments, highest tumour to non-tumour ratio's were obtained with the 
radioiodinated F(ab')2 fragments (8) Animal RIT studies have shown that radio-
lodinated F(ab')2 fragments have greater therapeutic potential than intact 
antibodies (9, 10). These data suggest that F(ab')2 fragments are the most 
suitable form of the antibody for RIS and RIT. 
Biodistribution studies after simultaneous i.v. and ι p. administration of radio­
iodinated MAb OV-TL 3 F(ab')2 were performed in both a s.c tumour model and 
an ι ρ tumour model These biodistribution data were used to evaluate the 
effect of the route of administration on the radiation dose to various organs 
Materials & methods 
Subcutaneous ovarian carcinoma model 
The s с. tumour model was established in nude mice by s с. injection of 3x10 7 
NIH OVCAR-3 cells (11) Tumours were serially transplanted subcutaneously at 
the left lumbar region of female Balb/c nude mice. Eight weeks after transplan­
tation mice were used for biodistribution studies. 
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Intraperitoneal ovarian carcinoma model 
The ι.ρ tumour model was established by ι p. injection of 1x10 7 NIH:0VCAR-3 
cells (1 ml) in female Balb/c nude mice In vivo passage of the ascitic cells was 
performed to continue the model. Two weeks after tumour induction, mice were 
used for biodistribution studies. More than 95% of the mice injected i.p. 
developed disease within 2 weeks. Intraperitoneal disease consisted of ascites 
and solid tumour implants. 
Monoclonal antibody 
The MAb OV-TL 3 is directed against a 30 kDa protein with multiple trans­
membrane regions, present on most ovarian carcinomas (12, 13) The produc­
tion and purification of F(ab')2 fragments of this MAb have been described 
previously (8) 
Radiolabelling and quality control 
F(ab')2 fragments of OV-TL 3 were labelled with 1 2 5 l or 1 3 1 l using the lodogen 
method (14) with minor modifications as described previously (8). 
Immunoreactivity of the preparations was assessed by incubation of a fixed 
amount of labelled antibody (10000 cpm) with increasing numbers of OVCAR-3 
ovarian carcinoma cells (0 6x10 e - 10x10e) in 0.5 ml binding buffer (RPMI 
medium, 0 5% BSA, 50 mM HEPES). After 4 h of incubation at 4°C, the 
radioactivity in the pellet was counted in a well-type gamma counter A dupli­
cate of the lowest cell concentration was incubated in the presence of excess 
unlabelled antibody to correct for non-specific binding Data were plotted as 
described by Lindmo et al. (15) and the immunoreactive fraction was calculated 
from the y-axis abscissa. 
Biodistribution studies 
Subcutaneous tumour model 
Female nude mice with s.c. ovarian carcinoma received 1 3 1 l - ÜV-TL 3 F(ab')2 
(10 / У С І / 1 0 pg; 0.2 ml/animal) via the tail vein, immediately followed by i.p. 
injection of 1 2 5 l - OV-TL 3 F(ab')2 (10 //Ci/10 /;g; 2 ml/animal) A least four mice 
were used per data point. The mice were bled under ether anaesthesia at 4, 24, 
72 and 168 h post injection (p i . ) . After cervical dislocation, mice were dis­
sected. The i.p. fluid was collected. Blood, liver, spleen, kidneys, intestine, 
heart, lung, muscle, bone (femur) and tumour were removed Solid tissues were 
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washed and blotted dry Tissues were weighed and radioactivity was measured 
in a well-type gamma-counter (LKB-Wallac, Finland). Tissue uptake was 
expressed as percentage of the injected dose per gram tissue (% ID/g). The 
uptake in i.p washing was expressed as percentage of the injected dose (% ID). 
Intraperitoneal tumour model 
Female nude mice with i.p ovarian carcinoma received 1 3 1 l - OV-TL 3 F(ab')2 (10 
μ Ο / Ю pg, 0.2 ml/animal) through the tail vein, followed by ι ρ injection of 1 2 5 l -
OV-TL 3 F(ab')2 ПО / У С І / 1 0 pg; 1 ml/animal). A minimum of four mice was used 
per data point. The biodistribution of the radioimmunoconjugates was assessed 
as described above. The uptake in ascitic cells was expressed as % ID 
Modified intraperitoneal tumour model 
Two weeks after induction of i.p. ovarian carcinoma in female nude mice, the 
bulk of the ascites was evacuated by washing the intraperitoneal cavity with 
normal saline (37° C, 3x5 ml) via a needle inserted through the abdominal wall 
The following day, mice received l 3 1 l - OV-TL 3 F(ab')2 (10 дСі/10 pg, 0 2 
ml/animal) through the tail vein, followed by i.p. adminstration of 1 2 5 l - OV-TL 3 
F(ab')2 (10 / У С І / 1 0 pg; 1 ml/animal). Identical procedures as described above 
were carried out. 
Dosimetry 
The radiation dose of relevant tissues was estimated using the area under the 
curve (AUC) of the uptake (h χ % ID/g) corrected for the physical decay of 1 3 1 l 
The AUC was estimated over the period from 0 to 168 h p.ι using the trap 
ezoidal method 
As it was not possible to measure the uptake in the red marrow accurately, we 
assumed blood to be the representative of this dose-limiting organ. In order to 
compare results at the maximal tolerated doses (or any pair of doses leading to 
an equal radiation dose to blood) for each organ and each route of administra 
tion the relative AUC was calculated according to the formula: 
relative AUC = AUC for organ χ 100% 
AUC for blood 
Thus, all AUC's were expressed as a fraction of the radiation dose to blood. 
We choose not to calculate the absolute radiation doses expressed as mGy per 
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organ according to the Medical Internal Radiation Dose committee (MIRD) 
methodology (16, 17) since this method introduces inaccuracies whereas only 
relative radiation doses are essential for these studies. 
Statistical analysis 
Results are presented as mean ± standard deviation. Differences between the 
AUC's after i.v. and i.p. administration were evaluated with Student's t-test. 
Significance was assumed at a p-value < 0.05. 
Results 
Radiolabelling and quality control 
ITLC analysis of the radioiodinated preparations showed that more than 95% of 
the iodine-labels was protein bound after purification. The immunoreactive 
fraction was 60 ± 10% for the 126l-labelled preparations and 64 ± 6% for the 
"'-labelled OV-TL 3 F(ab')2 fragments. 
Biodistribution studies 
Subcutaneous tumour model 
As soon as 4 h p.i. blood levels were similar after i.v. and i.p. administration in 
the s.c. tumour model (Figure 1). Throughout the study the uptake in other 
organs such as liver, spleen, kidney, etc. did not show significant differences 
according to the route of administration (Table 1). Following i.v. as well as i.p. 
administration, radiolabel levels in all normal tissues showed a continuous 
decrease over time. However, after both i.v. and i.p. administration localization 
of the radioimmunoconjugates in the tumour increased over time up to 24 h p.i. 
to 11.0 ± 1.4 %ID/g and 12.0 ± 1.3 %ID/g, respectively (mean tumour 
weight: 0.12 g; range 0.03 - 0.23 g) (Figure 1). At all time points s.c. tumour 
uptake was in the same range for both routes of administration. At 4 h p.i. the 
amount of the radiolabel in the peritoneal washings was higher after i.p. 
administration (18.6 %ID) compared to i.v. injection (1.2 %ID). From 24 h 
onwards no relevant differences were observed (Table 1). 
The AUC's for blood after i.v. and i.p. administration were similar (p>0.05) . 
When the AUC's for all tissues were related to equal estimated radiation doses 
(i.e. equal AUC's) to blood, the AUC's for s.c. tumour and for normal tissues 
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after ι ρ administration were equivalent with the AUCs after ι v. administration 
(p>0.05) (Table 2). 
Intraperitoneal tumour model 
The blood levels in mice with i.p. tumours are presented in Figure 2. At 4 h ρ ι 
the blood level was higher after i.v. injection. From 24 h onwards no differences 
were seen. At 4 h ρ ι. uptake in other normal organs was also higher after ι v. 
administration (Table 3). During the first 24 h p.ι uptake in i.p. tumour deposits 
(mean weight 0.21 g, range 0.01 - 0 58 g) was significantly higher after i.v. 
injection Highest uptake in the i.p. solid tumour of 7.9 ± 1 6 %ID/g after i.v 
injection and 2 1 ± 0.7 %ID/g after i.p. administration was found at 4 h p.ι 
(Figure 2). From 72 h p.ι onwards i.p. tumour uptake was in the same range for 
both routes of administration. A substantial amount of the injected dose was 
associated with the ascitic cells after both i.v and ι ρ injection After ι ρ 
administration initially 72 ± 3 7 %ID was bound to the ascitic cells (Table 2) 
After i.v injection 17.3 ± 2.4 % ID was bound to the ascitic cells at 24 h ρ ι 
Throughout the study ascitic cell-associated radioactivity was markedly higher 
for the i.p route of administration than for i.v. injection. 
The AUC for blood after ι p. administration was 6.7 times smaller than after ι ν 
injection ( p < 0 05). Assuming that the radiation dose to the blood is the 
representative for the radiation dose to the dose-limiting organ (red marrow), the 
administered activity given i.p could be 6.7 times larger compared with i.v. 
route of administration. The relative AUCs for normal tissues after ι ν adminis 
tration were 2 to 5 times smaller than after ι ρ administration (p<0.05)(Table 
4). The relative AUC for ι p. solid tumour after i.p. delivery was 2 times larger 
as compared to i.v administration ( p < 0 . 0 5 ) . 
Modified intraperitoneal tumour model 
In the ι ρ tumour model the major fraction of the ι ρ injected MAb dose was 
associated with the ascitic cells. In order to evaluate whether this massive 
binding to the ascitic tumour cells would fundamentally alter the biodistribution 
of the radioimmunoconjugates, the peritoneal cavity was flushed intensively 
before administration of the radioimmunoconjugates. After washing of the 
peritoneal cavity the amount of ascitic cells was reduced 3- to 40-fold After 
evacuation of the ascites the lowest amount of ascitic cells was less than 107 
99 
О 01 
24 48 72 96 120 144 16Θ 192 
time post injection (h) 
Figure 1. Blood levels (circle symbols) and tumour uptake (square symbols) of 
radioiodinated OV-TL F(ab')2 after intravenous (open symbols) and intra­
peritoneal (filled symbols) administration in mice subcutaneously bearing 
ovarian carcinoma. (For standard deviations see Table 1) 
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Figure 2. Blood levels (circle symbols) and tumour uptake (square symbols) of 
radioiodinated OV-TL F(ab')2 after intravenous (open symbols) and 
intraperitoneal (filled symbols) administration in mice intraperitoneal^ 
bearing ovarian carcinoma. (For standard deviations see Table 3) 
Table 1a. Tissue distribution of intravenously administered , 3 1l-OV-TL 3 F(ab')2 
in nude mice subcutaneously bearing ovarian carcinoma (% ID/g, 
mean ± SD, η = 4 ) . 
Organ 
Blood 
Muscle 
Liver 
Bowel 
Kidney 
Tumour 
Washing* 
Time post injection (h) 
4 
16.7 ± 0.5 
1.4 ± 0.2 
3.5 ± 0.4 
1.6 ± 0.1 
9.2 ± 0.8 
5.4 ± 1.3 
1.2 ± 0.2 
24 
3.0 ± 0.5 
0.5 ± 0.2 
0.Θ ± 0.1 
0.7 ± 0.3 
1.6 ± 0.3 
11.0 ± 1.4 
0.4 ± 0.2 
72 
0.1 ± 0.02 
0.03 ± 0.01 
0.06 ± 0 01 
0.03 ± 0.01 
0.09 ± 0.01 
4.8 ± 0.8 
0.08 ± 0.04 
168 
0.02 ± 0 01 
0.01 ± 0 01 
0.03 ± 0.01 
0.01 ± 0.01 
0.02 ± 0.01 
2 6 ± 0 . 7 
0.01 ± 0.03 
% ID 
Table 1b. Tissue distribution of intraperitoneal^ administered ,25l-OV-TL 3 
F(ab')2 'η nude mice subcutaneously bearing ovarian carcinoma (% 
ID/g, mean ± SD, η = 4). 
Organ 
Blood 
Muscle 
Liver 
Bowel 
Kidney 
Tumour 
Washing* 
Time post injection (h) 
4 24 
14.2 ± 3.4 5.1 ± 1.0 
1.5 ± 0.6 0.8 ± 0.4 
3.0 ± 0.8 1.3 ± 0.2 
1.4 ± 0.2 1.1 ± 0.5 
8.3 ± 1.6 2.7 ± 0.7 
2.9 ± 1.2 12.0 ± 1 3 
18.6 ± 16.8 0.5 ± 0.1 
72 
0.2 ± 0 02 
0.04 ± 0.01 
0.09 ± 0.01 
0.04 ± 0.01 
0.2 ± 0.01 
5 9 ± 1 . 1 
0.08 ± 0.04 
168 
0.02 ± 0.01 
0.01 ± 0.01 
0.03 ± 0 01 
0.02 ± 0 01 
0.03 ± 0.01 
2.4 ± 1.1 
0 06 ± 0.04 
% ID 
Table 2. The relative normalized estimated radiation dose to the organs 
expressed as the relative normalized area under the curve (AUC) for 
intravenously and intraperitoneal^ administered radioiodinated OV-TL 
3 F(ab')2 m mice subcutaneously bearing ovarian carcinoma. 
Organ 
Blood 
Muscle 
Liver 
Bowel 
Kidney 
Tumour 
Relative 
I.V. 
100 
12 
23 
15 
54 
276 
normalized AUC (%) 
i.p. 
100 
16 
25 
18 
57 
269 
i.v./ι.p.* 
1.3 ± 0 3 
1.1 ± 0.2 
1 2 ± 0.3 
1.1 ± 0.2 
1 0 ± 0.1 
estimate ± SE 
Table За. Tissue distribution of intravenously administered 131l-OV-TL 3 F(ab')2 
in nude mice intraperitoneal^ bearing ovarian carcinoma (% ID/g, 
mean ± SD, η = 4 ) . 
Organ 
Blood 
Muscle 
Liver 
Bowel 
Kidney 
Tumour 
Ascites* 
Time post injection (h) 
4 24 
12.7 ± 1.4 0.3 ± 0.1 
1.3 ± 0.6 0.1 ± 0.02 
2.5 ± 0.3 0.2 ± 0.04 
1.5 ± 0.1 0.3 ± 0.03 
7.0 ± 1.7 0.3 ± 0.03 
7.1 ± 1.6 5.9 ± 1.1 
4.1 ± 2.7 17.3 ± 2.4 
72 
0.1 
0.04 
0.06 
0.05 
0.1 
1.9 
8.8 
± 0.01 
± 0.01 
± 0.02 
± 0.02 
± 0.05 
± 0.6 
± 5.6 
168 
0.03 ± 0.02 
0.01 ± 0.00 
0.03 ± 0.01 
0.01 ± 0.00 
0.03 ± 0.01 
0.4 ± 0.3 
1.3 ± 0.8 
% ID 
Table 3b Tissue distribution of intraperitoneal^ administered 125l-OV-TL 3 
F(ab')2 in nude mice intrapentoneally bearing ovarian carcinoma (% 
ID/g, mean ± SD, η = 4 ) . 
Organ 
Blood 
Muscle 
Liver 
Bowel 
Kidney 
Tumour 
Ascites* 
Time post injection (h) 
4 24 
0.2 ± 0.03 0.3 ± 0.01 
0.2 ± 0.1 0.1 ± 0.01 
0.1 ± 0.02 0.1 ± 0.01 
0.3 ± 0.07 0.3 ± 0.01 
0.7 ± 0.2 0.5 ± 0.07 
2.1 ± 0.7 1.2 ± 0.5 
72.0 ± 3.7 62.5 ± 3.8 
72 
0.2 
0.09 
0.09 
0.1 
0.3 
1.2 
32.1 
± 0.07 
± 0.04 
± 0.02 
± 0.06 
± 0 2 
± 1.1 
± 5.7 
168 
0.05 ± 0.02 
0.02 ± 0.00 
0.04 ± 0.00 
0.03 ± 0.01 
0.07 ± 0.03 
0.7 ± 0.5 
5.0 ± 0.9 
% ID 
Table 4. The relative normalized estimated radiation dose to the organs 
expressed as the relative normalized area under the curve (AUC) for 
intravenously and intraperitoneal^ administered radioiodinated OV-TL 
3 F(ab')2 m mice intraperitoneal^ bearing ovarian carcinoma. 
Organ Relative 
i.V. 
Blood 100 
Muscle 14 
Liver 25 
Bowel 21 
Kidney 59 
Tumour 286 
* estimate ± SE 
normalized AUC (%) 
ι.p. 
100 
56 
52 
100 
196 
696 
I.V./¡.p.* 
4.0 ± 0.7 
2.0 ± 0.2 
4.8 ± 0.6 
3.4 ± 0.6 
2.4 ± 0.7 
chapter 5 
30 ι 1 
0 24 48 72 96 120 144 168 192 
time post injection (h) 
Figure 3. Blood levels (circle symbols) and tumour uptake (square symbols) of 
radioiodinated OV-TL F(ab')2 after intravenous (open symbols) and intra­
peritoneal (filled symbols) administration in mice intraperitoneally bearing 
ovarian carcinoma following to evacuation of ascites. (For standard devi­
ations see Table 5) 
cells (4 h p.i.). However, up to 109 ascitic cells were found in the peritoneal 
cavity at 168 h p.i. After i.p. administration 20 %ID to 35 %ID was still bound 
to the remaining ascitic cells, whereas following i.v. injection 3 %ID was 
associated with these cells (Table 5). 
During the first 24 h p.i. the blood concentration was lower after i.p. adminis­
tration as compared to i.v. injection (Figure 3). As compared with the i.p. 
tumour model with ascites, the blood levels after i.p. injection were higher at 4 
and 24 h p.i. Following i.v. administration the blood concentration increased 
only at 24 h p.i. as compared with the i.p. model with ascites. At 4 h p.i. 
uptake in the other normal tissues was lower following i.p. administration than 
following i.v. administration (Table 5). From 24 h onwards uptake was in the 
same range for both routes of administration. After evacuation of the ascites, 
uptake in the normal organs was higher at 4 and 24 h p.i. as compared to the 
i.p. model with ascites. After evacuation of ascites, highest uptake in solid 
103 
Table 5a. Tissue distribution of intravenously administered ,31l-OV-TL 3 F(ab')2 
in nude mice intraperitoneal^ bearing ovarian carcinoma following 
evacuation of ascites (% ID/g, mean ± SD, η = 5). 
Organ 
Blood 
Muscle 
Liver 
Bowel 
Kidney 
Tumour 
Ascites* 
Time post inject 
4 
10.7 ± 1.0 
0.8 ± 0.2 
2.0 ± 0.2 
1.7 ± 0.4 
5.5 ± 0.7 
10.5 ± 1.7 
2.8 ± 1.5 
ion (h) 
2 4 
1.3 ± 0.3 
0.2 ± 0.02 
0.3 ± 0.06 
0.2 ± 0.04 
0.8 ± 0.2 
9.3 ± 2.8 
3.0 ± 2.1 
72 
0.04 ± 0.01 
0.01 ± 0.01 
0.03 ± 0.01 
0.02 ± 0.01 
0.09 ± 0.02 
2.0 ± 1.2 
2.2 ± 0.4 
168 
0.01 
0.01 
0.01 
0.01 
0.02 
0.2 
0 3 
± 0.00 
± 0.00 
± 0.00 
± 0.00 
± 0.00 
± 0.07 
± 0.1 
% ID 
Table 5b. Tissue distribution of intraperitoneal^ administered 125l-OV-TL 3 
F(ab')2 in nude mice intrapentoneally bearing ovarian carcinoma 
following to evacuation of ascites (% ID/g, mean ± SD, η = 5). 
Organ 
Blood 
Muscle 
Liver 
Bowel 
Kidney 
Tumour 
Ascites* 
Time post inject 
4 
3.4 ± 
0.4 ± 
0.7 ± 
0.9 ± 
3.1 ± 
21.0 ± 
33.6 ± 
2.9 
0.2 
0.5 
0.5 
1.6 
21.0 
16.1 
ion (h) 
24 
0.7 ± 
0.2 ± 
0.2 ± 
0.2 ± 
0.7 ± 
11.3 ± 
23.1 ± 
0.6 
0.01 
0.1 
0.05 
0.2 
8.5 
19.1 
72 
0.07 ± 0.02 
0.02 ± 0.01 
0.05 ± 0.00 
0.06 ± 0.02 
0.2 ± 0.02 
2.1 ± 1.8 
17.4 ± 3.7 
168 
0.01 
0.01 
0.02 
0.01 
0.04 
0.6 
2.8 
± 0.00 
± 0.00 
± 0.00 
± 0.00 
± 0.01 
± 0.2 
± 1.1 
% ID 
Table 6. The relative normalized estimated radiation dose to the organs 
expressed as the rel normalized area under the curve (AUC) for intra­
venously and intrapentoneally administered radioiodinated OV-TL 3 
F(ab')2 in mice intrapentoneally bearing ovarian carcinoma following 
evacuation of ascites. 
Organ Norm 
I.V. 
Blood 100 
Muscle 10 
Liver 21 
Bowel 16 
Kidney 55 
Tumour 337 
* estimate ± SE 
ahzed AUC (%) 
ι.p. 
100 
19 
28 
28 
101 
1142 
i.v./i.p.* 
1.9 ± 0.5 
1.4 ± 0.4 
1.8 ± 0.5 
1.9 ± 0.5 
3.4 ± 1.1 
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tumour deposits (mean weight 0.16 g, range 0.02 - 0.37 g) was observed at 4 
h p.ι for both i.v. and i.p. injection (Figure 3). Tumour uptake after i.p. adminis­
tration markedly increased to 21.0 ± 21.0 %ID/g In mice with only a small 
amount of remaining ascitic tumour cells ( < 107 cells) i.p injection even 
resulted in tumour uptake as high as 43.5 ± 7.8 %ID/g at 4 h p.ι. (η = 2) and 
18.2 ± 4.6 %ID/g at 24 h p.ι. (n = 3) Obviously, in these mice the amount of 
the radioimmunoconjugate bound to ascitic cells was lower as compared with 
the other mice 
In the modified ι p. model, the AUC for blood after ι ρ injection was 2 5 times 
smaller than after i.v. injection (p<0.05) The relative AUCs for normal tissues 
after i.p. administration were approximately 2 times larger than those following 
ι v. delivery (p>0.05)(Table 6). The relative AUC for solid ι p. tumour after ι ρ 
administration was 3 times larger than after ι ν injection (ρ < 0.05). 
As compared to the i.p. tumour model with ascites, the AUCs for blood were 
equivalent. Thus, the estimated radiation dose to blood is not substantially 
altered by evacuation of ascites prior to MAb administration In contrast, the 
estimated radiation doses to tumour were higher after evacuation of ascites. 
The highest radiation dose to tumour was obtained after i.p. administration 
Discussion 
In the s.c. tumour model blood and normal tissue uptake were similar after i.v. 
and ι p. administration of OV-TL 3 F(ab')2 These results indicate that the ι ρ 
administered MAb rapidly appeared in the systemic circulation. Furthermore, 
there was no difference in s.c. tumour uptake of OV-TL 3 F(ab')2 after ι ν and 
i.p. injection. Thus, in the s.c tumour model no advantage was achieved with 
ι p. or i.v. administration of the MAb for either organs at risk or tumour 
deposits. 
In the i.p. tumour model blood levels of the MAb were higher following ι v. 
injection at 4 h p.ι. After 24 h the concentration in the blood was equal for both 
routes of delivery. The uptake in i.p. solid tumour deposits was higher after i.v 
injection when compared to i.p. administration. Mosely et al found similar blood 
data for OC125 F(ab')2 in an i.p. ovarian carcinoma mouse model, although in 
their study the initial uptake of OV-TL 3 F(ab')2 after i.p. injection was some­
what higher (18). In contrast, Mosely et al. found higher tumour uptake follow-
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mg ι.p. delivery of OV-TL 3 F(ab')2. In their study the advantage for the i.p. 
delivery route, may be the result of the extremely low tumour uptake after i.v. 
injection - less than 3 %ID/g. Studies on locoregional and systemic administra­
tion of whole IgG reported higher absolute tumour uptake as compared to 
F(ab')2 fragments. After i.v. and i.p. administration of 7D3 IgG to mesothelioma-
bearing mice, i.p. solid tumour uptake showed no advantage for either route of 
administration (19). Administration of AUA1 MAb to colon carcinoma-bearing 
mice showed an initial advantage for i.p. delivery, although this beneficial effect 
was lost by 24 h p.ι. (20). 
As compared with the s с. tumour model, the uptake in blood and in normal 
tissues following i.v. injection (24 h p.ι.) and i.p. administration (especially at 4 
and 24 h p.ι.) was much lower in the i.p. tumour model. Since in the i.p. tumour 
model almost 2 0 % of the i.v. administered dose and approximately 70 % of the 
i.p. administered dose was bound to ascitic cells, the amount of MAb available 
for distribution throughout the rest of the body was markedly reduced. As 
compared with the s.c. tumour model, tumour uptake was lower both after i.v. 
and i.p. administration in the i.p. tumour model. Binding to ascitic cells of the 
larger part of the injected MAb dose substantially reduced the solid tumour 
uptake as observed in other animal studies (21). 
To enhance the fraction of the injected dose available for biodistribution, the i.p. 
tumour model was modified. In mice with i.p. tumour the bulk of the ascitic 
cells was evacuated prior to ι v. and i.p. injection of the radioimmunoconjugate. 
In this model a substantially lower fraction of the injected dose was bound to 
ascitic cells. Consequently, uptake in blood, normal organs and solid i.p. tumour 
increased during the first 24 h p.ι. for both routes of administration as com­
pared with the i.p. tumour model with ascites. In the modified i.p. tumour 
model, uptake in blood and normal organs was lower during the first 24 h after 
i.p. administration than after i.v. injection. The uptake in solid i.p. tumour 
deposits was higher after i.p. administration during 24 h p.ι as compared with 
i.v. administration. Thus, the i.v./i.p. ratio for tumour uptake had reversed. In 
the i.p. model with ascites maximum tumour uptake following i.v. and i.p. 
administration was 7.9%ID/g and 2.1 %ID/g, respectively, whereas after 
evacuation of the ascites tumour uptake reached 10.5%ID/g and 21.0 %ID/g 
for i.v. and i.p. injection, respectively. This advantage was especially observed 
in mice with few ascitic cells ( < 107) after washing. In these mice solid i.p. 
tumour uptake up to 4 3 . 5 % ID/g at 4 h p.ι. and 18.2% ID/g at 24 h p.ι. was 
found after i.p. injection, whereas after i.v. administration 12% ID/g tumour 
106 
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uptake was obtained. 
These data indicate that in the i.p. model tumour uptake was influenced by the 
presence of and binding to ascitic cells, resulting in higher tumour uptake after 
ι ν injection. Evacuation of ascites prior to administration of the MAb substan­
tially increased tumour uptake. Both direct binding as well as systemic supply to 
the ι p. solid tumour deposits of the i.p. administered MAb may have contrib­
uted to the high level of uptake. In contrast. Ward & Wallace found similar 
uptake in i.p solid tumour and s.c. tumour and suggested that the lack of 
benefit of i.p. administration for ι p. tumour uptake indicates that tumour uptake 
is dependent on systemic supply of MAb (22). However, autoradiography of ι p. 
tumours from mesothelioma-beanng mice, showed that after i.p administration 
of 7D3 IgG the antibody mainly localized at the periphery of the tumour, 
whereas following i.v. injection the MAb predominantly localized in the inter-
stitium and no radioactivity was seen at the periphery (19). In our experiments, 
the ι v. administration resulted in 12 %ID/g uptake in solid i.p. tumour deposits, 
whereas after ι ρ administration tumour uptake up to 43 %ID/g was found 
These results suggest a more continuous supply from the peritoneal cavity to 
the systemic circulation resulting in a much higher tumour uptake However, 
since the blood levels remain lower after i.p. administration it seems more likely 
that the additional 31 %ID/g resulted from ι p. uptake in solid tumour deposits 
of the ι p. injected dose. 
In the s с. model the uptake in tumour was shown to be dependent on systemic 
supply of the MAb: no differences in uptake were observed for the systemic 
and the locoregional route of delivery. Antibody clearance from the peritoneal 
cavity is thought to be mainly achieved by trans-diaphragmatic lymphatic 
absorption (23). This implies that in the s.c. tumour model the passage of the 
diaphragm and the lymphatics by ι ρ injected F(ab')2 fragments seems hardly a 
barrier for entering the systemic circulation. 
To evaluate the effect of the route of administration on the administered activity 
that can be guided to the tumour and the organs at risk, the biodistribution data 
were used for a dosimetric analysis. 
In the s с. tumour model, no significant differences were found between i.v 
and i.p injection with regard to the AUCs of blood, normal tissues and tumour. 
These data indicate that for distant metastases either route of administration 
can be used 
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In the ι.p. tumour model with ascites the AUC for blood was significantly 
smaller after i.p. injection than after ι v. administration Equalization of the AUC 
for blood for both routes of delivery indicated that the amount of i.p adminis­
tered activity can be 6 7 times larger as compared with the ι ν route of 
administration ( p < 0 . 0 5 ) . This advantage for the i.p route of administration was 
mainly a result of the differences in blood levels during the first 24 h ρ ι. Wahl 
et al used the AUC to estimate the advantage of regional delivery of the MAb 
5G6 4 in mice with ι ρ ovarian tumours and also observed that the ι ρ delivery 
advantage had largely disappeared from 24 h p.ι. onwards (24). In our experi 
ments, the relative AUC for tumour was twice as high after i.p. administration 
as compared to ι ν injection. According to these calculations, the locoregional 
route of administration is advantageous in the i.p tumour model. 
Evacuation of the bulk of ascitic cells prior to MAb administration slightly 
altered the ratios Equal AUCs for blood can be obtained when the amount of 
ι ρ administered activity is two times larger than the ι ν administered activity. 
The advantage of i.p delivery for blood decreased somewhat as a result of the 
higher blood levels after evacuation of ascites. The AUC for solid tumour 
showed more relevant changes. In the ι ρ model with ascites the relative AUCs 
for tumour after ι ν and ι ρ administration were 2 8 6 % and 6 9 6 % , respectively, 
whereas after evacuation of ascites the AUCs increased to 3 3 7 % and 1142% 
after i.v and i.p injection, respectively. The amount of i.p. administered activity 
can be three times larger as compared with the i.v. administered activity 
In conclusion, in the i.p tumour model used, the ι ρ route of administration is 
favoured for therapeutic delivery of radiolabeled MAbs. Evacuation of ascitic 
tumour cells prior to MAb administration further increases the estimated 
radiation dose to solid intraperitoneal tumour deposits following intraperitoneal 
delivery 
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Intraperitoneal administration of chimeric monoclonal 
antibody MOv18 IgG in ovarian carcinoma patients: 
pharmacokinetics, biodistribution and dosimetry 
J.G. Tibben, W.C.A.M. Buijs, O.C. Boerman, L.F.A.G. Massuger, E.B. Koenders, 
С.P.T. Schijf, C.F.M. Molthoff, F.H.M. Corstens 
Abstract 
To assess the potential of intraperitoneal (i.p.) MAb-based radioimmunotherapy 
we studied the toxicity, pharmacokinetics, biodistribution, and dosimetry 
associated with the i.p. administration of chimeric MOv18 IgG (cM0v18) in 
patients suspected of having ovarian carcinoma. 
So far, eleven patients received 150 MBq 131l - cMOv18 IgG i.p. with protein 
doses escalating from 1 5 to 80 mg. 
No side effects were observed at any protein dose level. Activity in the blood 
could be described by a bi-exponential curve with a mean doubling time of 6.9 
± 3.2 h and a mean half-life of 1 60 ± 45 h for the elimination phase. Cumulat-
ive excretion in the urine amounted to 20 ± 10 %ID in 120 h. Scintigraphic 
images showed accumulation in ovarian cancer tumours, while all other tissues 
showed with time decreasing activity levels post infusion. Tumour uptake as 
determined in ovarian cancer tissue biopsies ranged from 3.4 to 12.3 %ID/kg. 
Dosimetric analysis data indicated that 1.7 to 9.5 mGy/MBq can be guided to 
small tumour deposits. Myelosuppression will be dose-limiting: at a total dose of 
7400 MBq, the radiation dose to the marrow was estimated to be 2.4 - 3.1 Gy, 
while in literature 2 Gy is considered to be the maximum tolerated dose. The 
estimated radiation doses for organs in the abdomen such as liver, spleen and 
kidney will probably be tolerated without any toxicity. 
Our results indicate that 131l - cMOv18 IgG may offer therapeutic perspectives in 
patients with minimal disease ovarian cancer. Dosimetric analysis indicated that 
therapeutic doses to the tumour can be achieved in patients with relatively high 
tumour uptake. 
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Introduction 
Radioimmunoscintigraphy (RIS) studies have demonstrated preferential tumour 
localization of radiolabeled anti-tumour monoclonal antibodies (MAbs) in vivo 
Several studies have focused on guiding therapeutic doses of radioactivity to 
tumours with anti-tumour MAbs ( 1 , 2, 3). 
Ovarian carcinoma is mostly confined to the peritoneal cavity. In the far majority 
of ovarian cancer radioimmunotherapy (RIT) studies, the intraperitoneal (i.p.) 
route of administration was used. Several studies in ovarian carcinoma patients 
have indicated that therapeutic responses can be achieved in patients with small 
tumour deposits after i.p. administration of MAbs labelled with 1 3 1 l , 90Y or 186Re 
up to doses of 7400 MBq (200 mCi), 900 MBq (25 mCi) and 6600 MBq (180 
mCi), respectively ( 1 , 2, 3). I.p. administration of radiolabeled MAbs may 
reduce the toxicity to the dose-limiting organs such as bone marrow, allowing 
higher doses to be administered (4, 5, 6). We were able to show in mice with 
ovarian cancer xenografts that ι p. administration resulted in a higher radiation 
dose to solid tumour deposits compared with intravenous (i.v.) injection (7). 
Sofar, no consensus has been achieved with regard to the use of intact or frag­
mented MAbs for radioimmunotherapy (RIT) in humans Comparative studies in 
animal models have shown a greater therapeutic potential for F(ab')2 as com­
pared with intact antibodies (8, 9). In patients only few comparative studies 
have been conducted. In patients with head and neck cancer simultaneous i.v. 
administration of E48 IgG and F(ab')2 resulted in higher tumour uptake for IgG 
as compared with the F(ab')2, whereas mean tumour to non-tumour ratios did 
not show significant differences (10). Buist et al reported higher tumour uptake 
for IgG as compared with F(ab')2 fragments in ovarian cancer patients after 
simultaneous i.v injection of both radiolabeled chimeric M o v i 8 (cMOv18) IgG 
and its fragments (11). However, the tumour to normal tissue ratios were 
similar (11) These results in cancer patients suggested that intact MAb may be 
as suitable for RIT as F(ab')2 fragments. 
Human anti-mouse antibody (HAMA) development is considered a disadvantage 
of the in vivo application of murine MAbs. HAMA may interfere with tumour 
targeting at repeated injection due to complex formation, resulting in increased 
blood clearance, altered biodistribution and reduced tumour uptake (12, 13, 14). 
The use of chimeric MAbs may reduce the incidence of HAMA. Indeed, Buist et 
al. have reported that immune responses could not be detected in serum 
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samples of ovarian cancer patients after i.v. administration of cMOv18 IgG and 
its fragments (15). However, other investigators have demonstrated that 
chimeric antibodies may still elicit a humoral immune response (14, 16, 17). 
The present study aimed to investigate the toxicity, pharmacokinetics, biodistn-
bution, and dosimetry associated with the i.p. administration of an escalating 
protein dose of radioiodinated cMOv18 IgG in ovarian cancer patients. The MAb 
has been used successfully for RIS of ovarian tumours. RIS with 131l-labelled 
murine M 0 v 1 8 in ovarian cancer patients to detect tumour had an overall 
sensitivity of 8 4 % (4). The aim of the current antibody dose escalation study 
was to assess the safety of infusion of higher protein doses. Such doses will be 
necessary to achieve acceptable specific activities in a radioimmunotherapeutic 
setting. 
Patients & methods 
Monoclonal antibody 
The MOv18 MAb is a murine antibody of the IgG, immunoglobulin subclass, 
recognizing a 38 kDa folate binding protein expressed on the majority of ovarian 
carcinomas as well as on adenocarcinomas of the fallopian tube, endometrium 
and cervix (18, 19, 20, 21). Expression on normal tissues was restricted to the 
epithelium of renal tubules, fallopian tube, lung, thyroid, and choroid plexus 
(22). The chimeric M 0 v 1 8 IgG was produced by fusion of the variable regions 
of the murine M 0 v 1 8 with human IgG, constant regions (Dr. L.R. Coney, 
Centocor Inc., Malvern, PA, USA). Sterile vials with purified, pyrogen-free 
cM0v18 IgG (1 mg/mL) were provided by Centocor Europe, Leiden, The Nether­
lands. 
Radiolabelling & quality control 
c M 0 v 1 8 IgG was labelled with 1 3 1 l according to the lodogen method (23). All 
solutions and labware were used sterile and pyrogen-free. Briefly, cM0v18 IgG 
(1 mL) with 100 μΐ 0.5 M sodium phosphate (pH 7.2) was added to an lodogen 
coated tube (25 μg/^\ mL). Following ten minutes incubation with 1 3 1 l (370 MBq; 
50 /il - 1 mL; Medgenix, Fleurus, Belgium) the reaction mixture was applied on a 
Sephadex G-25 column and eluted with PBS. The fractions containing the 
labelled antibody were pooled. Instant thin layer chromatography (ITLC) was 
used to determine the presence of free 1 3 1 l in the preparations. Immunoreactivity 
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of each preparation was assessed on HeLa (human cervix carcinoma) cells as 
described previously (7) In selected patients the stability and immunoreactivity 
of the radioimmunoconjugate in blood was determined up to 144 hours post 
injection (h ρ ι ) 
Patients 
All patients entered in the study were suspected of having ovarian cancer and 
were scheduled to undergo explorative laparotomy Patients had to be over the 
age of 18 years and had to have a life expectancy of at least 3 months All 
patients with previous exposure to murine MAbs, known allergy for rodents, 
allergic diathesis, life threatening infection, organ failure, evidence of recent 
myocardial infarction or diagnosis of a second malignancy were excluded The 
study was conducted with the approval of the Internal Review Board of the 
University Hospital Nijmegen, The Netherlands Written informed consent was 
obtained from each individual patient prior to study entry. 
Table 1 Patient characteristics 
Patient 
number 
01 
02 
03 
04 
05 
06 
07 
08 
09 
10 
11 
MAb 
(mg) 
15 
15 
15 
30 
30 
30 
50 
50 
5 0 
80 
8 0 
Age 
(yr) 
64 
4 6 
68 
37 
18 
41 
51 
54 
45 
78 
66 
FIGO 
stage 
na 
Ilia 
Ic 
na 
na 
na 
na 
na 
lllc 
lie 
na 
Histology 
Serous 
cystadenoma 
Malignant mixed 
Mullenan tumour 
Corpus carcinoma 
Benign teratoma 
Non-Hodgkin 
lymphoma 
Serous cystadenoma 
Myoma 
Inclusion cyst 
Serous 
cystadenocarcinoma 
Endometrioid 
adenocarcinoma 
Sigmoid 
adenocarcinoma 
Diff 
grade 
na 
III 
II 
na 
na 
na 
na 
na 
III 
III 
II 
RI 
-
+ 
-
-
-
-
-
-
+ 
+ 
+ 
na = not applicable, - = negative, + = positive 
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Study design 
Prior to the antibody injection a medical history of each patient was taken and a 
physical examination was performed. An electrocardiogram, a chest radiograph, 
ultrasound of the pelvis and X-ray computed tomography (CT) or magnetic 
resonance imaging (MRI) of the abdomen (optional) were obtained. 
A weighted protein dose escalation was intended, starting at a 15 mg protein 
dose Three patients were planned to receive the same dosage If no toxicity 
was observed, the study was to be continued at the next higher dose level until 
a maximum of 100 mg 
Access to the i.p. cavity was obtained by insertion of a Verres needle under 
local anaesthesia Patients received an i.p infusion of approximately 1.5 L of 
normal saline (37 °C) followed by a single ι p. infusion of 150 MBq (4 mCi) 
1 3 1 l - cM0v18 IgG The radioimmunoconjugate was diluted in 50 mL of saline 
and infused during 5 minutes The thyroid was blocked with 100 mg potassium 
iodide two times a day and potassium Perchlorate 200 mg four times a day 
orally starting 4 h before the infusion and continued for 2 weeks. Vital signs 
were measured frequently up to 8 h p.ι. and at several time points during 7 
days after infusion. 
Blood samples were collected just prior to the antibody administration and at 
various timepoints until surgery. Radioactivity in the blood as a percentage of 
the injected dose (% ID/g) was determined. The half-life of disappearance from 
the blood was calculated using non-linear least square regression analysis. 
Planar images of the total body in both anterior and posterior view of the 
patients were obtained at five different time points Images were obtained with 
a dual-headed gamma camera (Type MultiSpect2, Siemens Inc., Hoffman 
Estates, II, USA) equipped with a high energy collimator. The images were 
recorded on an ICON computer system (Siemens Inc., Hoffman Estates, II, 
USA). Planar views were recorded using the 364 keV gamma ray peak of 1 3 1 l 
with a symmetric 15% window and with a preset scan speed of 4 cm/mm. To 
reduce bladder activity patients were asked to void prior to imaging. 
Surgery was performed at 1 week ρ ι in all patients. The tumour status was 
carefully mapped. Ascites and peritoneal washings were collected Suspected 
tissues were either removed or biopsied. If feasible, tissue samples of muscle, 
skin and normal omentum were obtained. All tissues removed at surgery were 
weighed and the amount of radioactivity of 1 3 1 l was measured using a well-type 
gamma counter. Tissue uptake was expressed as percentage of the injected 
dose per kilogram tissue (%ID/kg). 
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Dosimetric analysis 
The conjugated views counting technique was used to quantitate the activity 
uptake in some organs (24). Briefly, region of interest (ROI) measurements of 
whole body, thorax, abdomen, and extremities were drawn on anterior and 
posterior view images at all time points. The geometric mean of anterior and 
posterior images was calculated after correction for differences in attenuation 
between extremities and thorax versus the abdomen The differences in 
attenuation were determined with a 1 3 1 l transmission flood source The absolute 
retention of activity m a ROI was calculated via comparison with the total body 
scintigraphic recording directly after infusion 
During the first 24 h ρ ι the intra-abdominal organs were surrounded by 
activity During this time few radioactivity had entered the circulation The ROI 
of the abdominal organs - such as liver, spleen and kidney - created at those 
time points do not reflect radioactivity uptake, but rather represent the radioac 
tivity surrounding these organs. At later time points no accumulation of radio­
activity in the abdominal organs was observed. It is assumed that the radioac­
tivity in the abdominal organs represented blood perfusion only Therefore, 
activity in these organs was calculated based on the fractional blood volume as 
published in the ICRP 23 and 53 (25, 26). 
The radioactivity in the ROI of the abdomen was assumed to be partly the result 
of blood perfusion of the organs localized in this region. The fractional blood 
volume for these organs was estimated based on data published in the ICRP 23 
and 53 on anatomical values for reference man (25, 26) The retention of 
radioactivity in the peritoneal cavity was calculated to be "%ID in the ROI of the 
abdomen" minus "%ID in the blood of all organs in the ROI of the abdomen" 
and minus "%ID in the ROI of the tumour" 
The photon S-values for 1 3 1 l in the peritoneal cavity as calculated by Watson et 
al (27) were used to estimate the radiation doses resulting from the radioactivity 
in the intraperitoneal cavity. 
Radiation absorbed doses to the organs as a result of blood activity were calcu­
lated with the MIRDOSE3 program (M. Stabin, Oak Ridge Institute for Science 
and Education, Oak Ridge, Tennessee, USA) 
Statistical analysis 
Results are presented as mean ± standard deviation. 
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Results 
Radiolabelling & quality control 
The labelling efficiency of the radioiodination of the antibody was between 65 
and 8 0 % ITLC indicated that more than 9 5 % of the 1 3 1 l was protein-bound In 
selected patients blood samples were obtained post injection to determine the 
stability of the radioimmunoconjugate in the circulation, showing that > 9 5 % of 
the radioactivity was protein bound up to at least 122 h ρ ι 
The immunoreactive fraction of the radioimmunoconjugate was 60 ± 7% In 
selected patients the immunoreactivity of the radioimmunoconjugate in the 
circulation was determined up to 144 h p i , indicating that the immuno 
reactivity of the circulating activity during the study (58 ± 11%) was in the 
same order as the IRF of the preparation at the time of injection 
Toxicity 
The procedure of the ι ρ administration was well tolerated The volume of 
normal saline that could be infused in individual patients without causing 
inconvenient abdominal distension, varied strongly and seemed to correlate with 
the patient's stature and parity No clinical side effects were observed after ι ρ 
infusion No significant changes in haematologic or blood chemistry parameters 
were seen up to 1 week ρ ι 
Pharmacokinetics 
The concentration of radioactivity in blood expressed as a fraction (% ID/g) was 
not affected by the administered protein dose, therefore the data of all patients 
were pooled The mean blood activity curve is presented in Figure 1 The mean 
peak blood concentration was 10 ± 2 %ID/L and was reached between 48 and 
96 h ρ ι Radioactivity in the blood could be described by a bi exponential curve 
with a mean doubling time of 6 9 ± 3 2 and a mean half life of 160 ± 45 h for 
the elimination phase 
Gradually, the radioactivity appeared in the urine Maximum excretion was 
observed shortly after the maximum blood concentration had occurred A mean 
cumulative excretion of the radiolabel in the urine of 20 ± 10 %ID was found in 
the first 120 h ρ ι 
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time post injection (hr) 
Figure 1 Radioactivity in the blood after ι ρ infusion of n , l - cMOv18 IgG in patients 
suspected of having ovarian cancer (n = 11). 
Radioimmunoscin tigraph y 
So far, eleven patients entered the study Patient characteristics are summarized 
in Table 1 Three patients had an ovarian malignancy and three other patients 
were diagnosed to have a non-ovarian malignancy, whereas the remaining five 
patients had benign gynaecologie tumours 
In all patients the radioimmunoconjugate diffused throughout the peritoneal 
cavity after ι ρ infusion as was observed on the 1 h ρ ι images (Figure 2) At 1 
and 24 h the radioactivity was confined to the peritoneal cavity. At consecutive 
time points the images showed that the radioactivity appeared in the circulation 
On the images of the three patients with ovarian carcinoma the separate tumour 
lesions were visualized A typical example is shown in Figure 3 The presence of 
malignant tumour was surgically and histologically confirmed The benign 
tumours of five patients did not show elevated uptake In addition, no elevated 
uptake was seen in the patient with a endometrium carcinoma and the patient 
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Figure 2. Anterior planar image at 1 h p.i. showing the distribution of the radio-
immunoconjugate through the peritoneal cavity. 
Figure 3. Anterior planar image at 144 h p.i. of a patient with a serous adeno-
carcinoma of both ovaries showing elevated tumour uptake. 
with a non-Hodgkin lymphoma. In contrast, the patient with an adenocarcinoma 
of the sigmoid did show elevated tumour uptake. 
After the radioimmunoconjugate had reached its maximal blood level, no 
accumulation was seen in normal organs such as liver, kidneys, or bone 
marrow. 
Tissue uptake 
Uptake in malignant ovarian tumour deposits at 1 week ρ ι. ranged from 3 4 to 
12 3 %ID/kg, whereas uptake in benign tumour ranged from 0.5 to 1.8 %ID/kg 
Uptake in non ovarian malignancies varied from 0.1 to 2.1 %ID/kg. Mean 
uptake in muscle tissue was 1.4 ± 0.5 %ID/kg. The tumour-to-muscle ratios 
ranged from 3 to 8 for the patients with malignant ovarian tumours, whereas in 
the patients with benign tumours the mean ratios varied from 0.1 to 1.3 In the 
patients with a non-ovarian cancer the tumour-to-muscle ratios were 0.1 to 2.6. 
Dosimetry 
The retention in total body, abdomen and the peritoneal cavity based on the 
images were calculated for the first ten patients (Table 2a). Mean total body 
retention was 63 ± 9 % ID at 144 h p.ι according to the ROI-measurements. 
Based on the ROI measurements, retention in the peritoneal cavity was approxi­
mately 8 0 % of the activity in the total body at 1 h p.ι, whereas visually all 
activity was localized intracavitary. The calculated difference of 2 0 % between 
abdomen and total body is the result of scatter to the adjacent areas. Since the 
scatter is also included at the following images, the retention in the peritoneal 
cavity was set on 100 %ID at 1 h p.ι. for dosimetric calculation purposes Data 
of the following days were corrected analogously (Table 2b). 
For the 3 patients with ovarian carcinoma the radiation absorbed doses of 1 3 1 l to 
several organs of interest were estimated (Table 3) The total body biological 
half life ranged from 135 to 241 h in these three patients. Extrapolation of the 
presented data to an administered dose of 7400 MBq (200 rnCi), would result in 
an estimated absorbed radiation dose to the red marrow of 2.4 - 3.1 Gy. For the 
intestine, liver and kidney this dose would result in 5 8 - 6 4 Gy, 3.1 - 3 8 Gy, 
and 3.4 4.3 Gy, respectively. 
With ι p. administration of 150 MBq (4 mCi) the radiation doses that were 
guided to the large ovarian carcinoma tumour masses (weight: 80 - 1070 g) 
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Table 2a. Retention expressed as % of the total body activity directly after 
injection based on regions of interest measurements 
Time post 
in j . (h) 
1 
24 
48 
72 
96 
120 
144 
Num iber of 
patients 
10 
9 
7 
4 
3 
8 
7 
Retention (%) 
total body 
100 
91 ± 9 
87 ± 9 
83 ± 7 
88 ± 1 
71 ± 12 
63 ± 9 
. abdomen 
81 ± 2 
71 ± 8 
50 ± 10 
37 ± 5 
36 ± 2 
27 ± 4 
24 ± 3 
peritoneal cavity 
79 ± 3 
66 ± 11 
41 ± 12 
23 ± 5 
26 ± 3 
18 ± 5 
15 ± 4 
Table 2b. Retention expressed as % of the total body activity corrected for 
scatter 
peritoneal cavity 
Time post 
inj . (h) 
1 
24 
48 
72 
120 
144 
Number of 
patients 
3 
2 
2 
2 
3 
3 
Retention (%) 
abdomen 
100 
80 
51 
42 
31 
28 
r 
97 
72 
38 
28 
20 
18 
present in 3 patients ranged from 0.3 to 1.5 Gy. With a 7400 MBq (200 mCi) 
dose these tumours would have received a radiation dose varying from 1 5 to 76 
Gy. Assuming that only small volume disease (1 - 2 cm in diameter) will be 
present in a therapeutic setting and that tumour uptake will be the same as in 
the large tumours, estimated radiation absorbed doses varying from 12 to 71 
Gy would be guided to small deposits at a 7400 MBq (200 mCi) dose. 
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Table 3. Estimated absorbed radiation doses for i.p. administered 1Э1 l-labelled 
cMOvl 8 IgG in patients with ovarian carcinoma. 
Patient 2 
Organ 
Intestine, small 
Intestine, large 
Kidney 
Liver 
Red marrow 
Spleen 
Thyroid 
Patient 9 
Organ 
Intestine, small 
Intestine, large 
Kidney 
Liver 
Red marrow 
Spleen 
Thyroid 
Patient 10 
Organ 
Intestine, small 
Intestine, large 
Kidney 
Liver 
Red marrow 
Spleen 
Thyroid 
Total dose 
mGy/MBq 
8.7 χ 1 0 1 
5.6 χ 1 0 ' 
5 . 8 x 1 0 1 
5.2 χ 1 0 ' 
4.2 χ 1 0 1 
4 . 4 x 1 0 ' 
2 . 6 x 1 0 ' 
Total dose 
mGy/MBq 
7.Эх 1 0 ' 
5.2 χ 1 0 ' 
4.7 χ 1 0 ' 
4.2 χ 1 0 ' 
З . З х 1 0 ' 
3.4 χ 1 0 ' 
1.7 χ 1 0 ' 
Total dose 
mGy/MBq 
8.4 χ 1 0 ' 
5.Ox 1 0 ' 
5.5 χ 1 0 ' 
4 . 9 x 1 0 ' 
3 . 8 x 1 0 ' 
4.0 χ 1 0 ' 
2.1 χ 1 0 ' 
Total dose for 
148 MBq (mGy) 
129 
82 
86 
78 
62 
65 
38 
Total dose for 
148 MBq (mGy) 
116 
76 
7 0 
62 
50 
50 
26 
Total dose for 
148 MBq (mGy) 
124 
7 4 
82 
73 
56 
59 
31 
Contribution from 
activity m PC (%) 
53 
21 
53 
48 
32 
38 
2 
Contribution from 
activity in PC (%) 
54 
21 
60 
56 
37 
46 
2 
Contribution from 
activity in PC (%) 
59 
25 
60 
55 
37 
45 
2 
PC = peritoneal cavity 
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Discussion 
The present study was performed to investigate the therapeutic applicability of 
i.p. administration of the chimeric MAb MOv18 IgG labelled with 131l in patients 
suspected of having ovarian carcinoma. The toxicity, pharmacokinetics, bio-
distribution, and dosimetry associated with the locoregional administration of an 
escalating protein dose of this chimeric MAb were studied. 
With a protein dose escalating from 15 mg up to 80 mg, no adverse reactions 
were observed in the patients studied. With a protein dose of 80 mg achievable 
specific activities (150 MBq/mg) can be used in a future therapeutic setting. 
Planar images showed good distribution throughout the peritoneal cavity in all 
patients, despite previous surgery for other disease in some of the patients. 
The radioimmunoconjugate is slowly cleared from the peritoneal cavity and 
approximately 15% is still localized intraperitoneally at 144 h p.i. These findings 
are in concert with those from Crippa et al. who reported that 20 %ID was still 
present in the peritoneal cavity at 96 h p.i. after i.p. administration of murine 
MOv18 IgG (4). 
The i.p. administered radioimmunoconjugate entered the circulation gradually. 
The peak concentration in the blood was observed between 48 and 96 h p.i. 
After i.p. administration of 131l - labelled HMFG1 and AUA1 MAb the peak 
concentration in blood was observed at 40 h p.i. (28). The blood clearance of 
i.p. administered cM0v18 IgG was relatively slow with a mean elimination half-
life of 160 h, whereas Buist et al. reported a half-life of 70 h for the elimination 
phase after i.v. administration (11). These results are in accordance with the 
data presented by Crippa et al, who reported half-lives of murine MOv18 IgG of 
75 h after i.v. and of 147 - 274 h after i.p. administration (4). These data 
indicate that the chimerization of the MOv18 MAb did not alter its pharmaco-
kinetics significantly. Molthoff et al. also found that the in vivo behaviour of 
cMOv18 was comparable to that of its murine form (29). 
With the use of ITLC it was demonstrated that more than 90% of the radioac-
tivity in the circulation was protein-bound up to at least 5 days p.L, suggesting 
that possible dehalogenation resulted in rapid excretion of free iodine. In 
addition, no loss of immunoreactivity was observed when analyzing blood speci-
men in a Lindmo assay. 
Approximately 20 %ID of the radioactivity was excreted into the urine in 5 
days, a similar percentage as found by Buist et al after i.v. administration of 
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c M 0 v 1 8 IgG (11). These data suggest that the clearance from the body of the 
ι ρ administered radioimmunoconjugate is somewhat delayed 
After ι ρ infusion of cMOv18 IgG planar images of the three patients with 
ovarian carcinoma showed good delineation of the tumours once the radio­
immunoconjugate had entered the systemic circulation. Tissue uptake measure­
ments showed large variability in ovarian tumour uptake ranging from 3 4 to 
12 3 %ID/kg Buist et al. reported that six days after ι ν injection of 1 mg of 
cMOv18 IgG mean tumour uptake was 6 2 ± 5 0 %ID/kg, with mean tumour 
to background ratios of 6 7 ± 4 7 (11) These data indicate that there are no 
significant differences in tumour uptake for both routes of administration Ward 
& Wallace came to the same conclusion after comparing the distribution of 
radiolabelled HMFG2 IgG after ι ν and ι ρ administration in mice bearing human 
ovarian carcinoma xenografts (30) Although at present data of only three 
ovarian carcinoma patients were available, findings of previous animal and 
clinical studies reporting higher tumour uptake after ι ρ administration as 
compared to ι ν injection could not be confirmed (7, 30) Our clinical data 
suggest that tumour uptake takes place by virtue of systemic supply of the 
MAb, mainly due to vascularity and blood perfusion of tumour tissue Our data 
suggest that the advantage of locoregional administration will probably be 
limited to reduced uptake in normal tissues However, in case of RIT the 
relatively long retention in the peritoneal cavity may result in long lasting 
bathing in a radiolabeled MAb fluid of small tumour nodules on the peritoneal 
wall and on the intestine 
Extrapolating the dosimetry data of the current study, the radiation dose to 
small tumour deposits of 1 - 2 cm in diameter was estimated to be 12 to 71 Gy 
at a 7400 MBq (200 mCi) dose. These estimations were based on the assump­
tions that tumour uptake level and tumour residence time in small tumour 
deposits will be the same as in the large tumours present in the patients 
studied The limited number of 4 primary tumours in three patients does not 
allow to draw conclusions on the relationship between tumour size and tumour 
uptake. However, there are data in literature demonstrating an inverse relation 
between tumour size and tumour uptake (32, 33) In contrast, Buist et al could 
not demonstrate a correlation between tumour size and tumour uptake in 
ovarian carcinoma patients (11) Tumour uptake and, subsequently, the radi­
ation dose to the tumour seem to vary considerably between patients (32, 34) 
Based on the dosimetric analysis of the data obtained after ι ρ injection of 1 3 1 l -
labelled B72 3 IgG in ten patients with adenocarcinoma, Larson et al. recom 
126 
chapter 6 
mended to individually estimate the radiation dose on basis of a diagnostic dose 
in order to determine the efficacy of a therapeutic dose (34). Assuming that 
60 - 80 Gy would be required to obtain a therapeutic effect on tumours (34, 35, 
36), our findings suggest that with i.p. administration of 5550 - 7400 MBq 
(150 - 200 mCi) 131 l-labelled cM0v18 IgG anti-tumour effects may be induced. 
The radiation dose for bone marrow calculated in the present study is in general 
agreement with the estimations reported by others (28, 34). The estimated 
radiation dose to marrow after i.p. administration of cMOv18 IgG (0.33 - 0.42 
mGy/MBq) was lower than after ¡.v. administration of anti-CEA MAb NP-4 IgG 
(1.07 mGy/MBq) (32). Our results suggest that locoregional administration has 
the advantage of a reduced radiation absorbed dose to the bone marrow. For 
bone marrow 2 Gy is considered to be the maximum tolerated dose (34, 35). In 
case of a 7400 MBq dose the radiation dose to the marrow will amount to 2.4 -
3.1 Gy. Therefore, myelosuppression will probably remain the dose-limiting 
factor. 
The estimated radiation doses for abdominally situated organs such as liver, 
intestine and kidneys can probably be tolerated without any toxicity. 
In conclusion, the concept of targeting radiolabelled antibodies towards tumour 
cells after i.p. administration remains an attractive therapy concept for cancer 
patients. In potential, chimeric M0v18 IgG seems to offer therapeutic perspec-
tives particularly in patients with small tumour deposits. 
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Tumour targeting of the anti-ovarian carcinoma χ 
anti-CD3/TCR bispecific monoclonal antibody OC/TR 
and its parental MOv18 antibody in experimental 
ovarian cancer 
O.C. Boerman, J.G. Tibben, L.F.A.G. Massuger, R.A.M.J. Claessens, F.H.M. 
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Abstract 
The anti-tumour χ anti-T-cell bispecific monoclonal antibody (biMAb) ОС/TR is a 
biologically produced biMAb combining the anti ovarian carcinoma activity of 
the MOv18 MAb with anti-CD3/T-cell receptor (TCR) complex activity In this 
study, the in vitro binding characteristics of the ОС/TR biMAb and its tumour 
targeting potential in nude mice with Hela tumours was studied Scatchard 
analysis revealed that the affinity constant of the biMAb was 7-times lower 
than the affinity of the parental MOv18 antibody Uptake of the ОС/TR antibody 
in the Hela xenografts in nude mice was significantly higher than the tumour 
uptake of an irrelevant control antibody, indicating that the radioiodinated 
ОС/TR biMAb specifically localized in the tumour xenografts However, tumour 
uptake was significantly lower than the tumour uptake of the parental MOv18 
antibody This reduced tumour uptake most likely is a result of its reduced 
affinity We conclude that despite the loss of bivalent tumour cell binding, the 
biMAb ОС/TR can still specifically localize in tumours This indicates that the 
first prerequisite of an effective therapeutic approach using systemically applied 
biMAb can be met Whether the interaction with human T-cells will affect the 
tumour targeting potential of the biMAb in patients remains to be investigated 
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Introduction 
Redirecting effector cells of the immune system towards tumour cells with 
bispecific monoclonal antibodies (biMAbs) has been proposed as a new 
approach of cancer therapy (1,2) In this concept a biMAb reactive with a 
tumour cell on one hand and an effector cell on the other, is used to retarget 
the cytotoxic activity of the effector cell towards tumour cells T-cell lysis of a 
target cell is generally is restricted to major histocompatibility complex-associ 
ated (MHC) peptide recognition When a biMAb provides the physical linkage 
between a CD3/T-cell receptor (TCR) complex and a tumour cell, specific 
tumour cell lysis can occur (3,4) 
In most preclinical studies investigating the therapeutic potential of biMAbs, 
activated effector cells coated with biMAbs have been administered loco-
regionally (5-7) The first clinical studies have also focussed on locoregional 
infusion of redirected effector cells In a study in glioma patients biMAb coated 
cells were administered intracranially (8), while Bolhuis and coworkers (9) 
administered ex vivo expanded and activated autologous peripheral blood 
lymphocytes (PBLs) intraperitoneal^ (ι ρ ) in ovarian cancer patients However, 
only a minority of cancers can be treated locoregionally In addition, in vitro 
studies have shown that CD3/TCR complexes on preactivated PBLs that had 
earlier been engaged in target cell lysis are no longer able to lyse another cell 
Only biMAbs binding newly expressed CD3/TCR complexes were able to 
reengage the Τ cell in another lytic cycle (10) This observation indicates that 
the administration of precoated effector cells could only have limited efficacy 
Therefore, in vivo targeting of high doses of biMAbs to the tumour site in order 
to redirect the lytic activity of T-cells at the tumour site seems to be a more 
attractive approach However, tumour targeting of anti tumour χ anti-T cell 
biMAbs might be hampered by the loss of bivalent tumour cell binding, and/or 
the interaction of the biMAb with peripheral T-cells The present study investi­
gates the tumour targeting potential of an anti-tumour χ anti CD3 biMAb OC/TR 
in a nude mouse model 
The biMAb ОС/TR combines the anti-ovarian carcinoma activity of the MOv18 
MAb with anti-CD3/TCR complex activity (11) In patients with epithelial 
ovarian cancer radioiodmated MOv18 has been shown to specifically localize in 
ovarian carcinoma lesions (12,13). The biMAb ОС/TR was obtained after fusion 
of the M0v18-producing hybndoma cells with spleen cells from a BALB/c 
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mouse immunized with a human T-cell clone (11,14). In vitro studies indicated 
that this biMAb is able to induce efficient tumour cell lysis (11,14). In nude 
mice with i.p. growing NIH:OVCAR-3 ovarian carcinoma cells, tumour growth 
inhibition was achieved by treating the mice with IL-2 and activated PBL coated 
with ОС/TR F(ab')2 (7). In addition, a phase l/ll study in ovarian cancer patients 
treated with ОС/TR coated autologous PBL and IL-2 has shown some remark­
able responses (9). We planned to investigate the feasibility of a therapeutic 
approach based on the systemic administration of ОС/TR biMAb in ovarian 
cancer patients. Therefore, we studied the in vitro binding characteristics and 
the m vivo tumour targeting potential of intravenously (ι v.) administered OC/TR 
biMAb in a nude mouse model. 
Materials & methods 
Monoclonal antibodies 
The MOv18 antibody (IgG,) recognizes a 38 kDa cell surface glycoprotein 
(gp38) antigen expressed on most ovarian carcinomas (15) The gp38 antigen 
was identified as a folate binding protein (16-18). MOv18 is also reactive with 
adenocarcinomas of the fallopian tube, endometrium and cervix (19). 
The biMAb ОС/TR (IgG, χ IgG,) is produced by a tnoma cell line obtained after 
fusion of the MOv18 hybridoma with spleen cells from a BALB/c mouse 
immunized with a human T-cell clone (11,14). The biMAb was purified from 
tnoma culture supernatant on a MONO-S cation exchange column (Pharmacia, 
Woerden, The Netherlands) as described previously (14). Inherent to the 
biological biMAb production process an IgG with an intact anti-CD3 binding site 
and a heavy light chain pairing mismatch is produced. This 'anti-CD3 χ mis­
match biMAb' was also purified from the tnoma supernatant and used as a 
control antibody in the biodistribution studies. Both the ОС/TR antibody and the 
control antibody do not cross react with murine T-cells The antibody prepara­
tions were prepared and supplied by Centocor Europe B.V. (Leiden, The Nether­
lands) 
Cell lines 
The HeLa human cervix carcinoma cell line (MOv18-positive) and the Jurkat 
human acute T-cell leukemia cell line (CD3-positive) were obtained from the 
American Type Culture Collection. Cells were cultured in RPMI-1640 based 
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medium (Gibco, Paisley, UK) supplemented with 1 0 % fetal calf serum 
Radiolabelling and quality control 
The antibody preparations were labelled with 1 2 5 l or 1 3 1 l using the enzymobead 
method (BioRad, Richmond, CA), according to the manufacturer's instructions 
Briefly, 50 μg of IgG was mixed with 20 pi 0.5 M sodium phosphate (pH 7 2), 
50 μί. enzymobead suspension and 500 //Ci 1 2 5 l (Amersham International, UK) or 
l 3 1 l (Medgenix, Fleurus, Belgium). The reaction was initiated by adding D( + )glu-
cose to a final concentration of 0.3%. Following 15 minutes incubation the 
reaction mixture was applied on a Sephadex G-25 column (Pharmacia, Sweden) 
and eluted with PBS, 0 5% BSA. The fractions containing the labelled antibody 
were pooled and used for in vivo studies within 16 hours (h) The amount of 
free iodine in the preparations was determined by instant thin layer chromatog­
raphy (ITLC) 
The immunoreactivity against the ovarian carcinoma-associated antigen gp38 
(M0v18 reactivity) and/or against the CD3/TCR complex (anti-CD3/TCR 
reactivity) of the radioiodinated antibody preparations was determined on live 
HeLa cells or Jurkat cells, respectively. A fixed amount of labelled antibody 
(10000 cpm) was incubated with increasing numbers of cells (0 6x10 6 -
10x10e) in 0 5 mL binding buffer (RPMI medium, 0.5% BSA, 50 mM HEPES, 
0.05% NaN3). After 4 h of incubation at 4°C, the radioactivity in the pellet was 
counted in a well-type gamma counter A duplicate of the lowest cell concentra­
tion was incubated in the presence of excess unlabelled antibody to correct for 
nonspecific binding. The data were graphically analyzed in a modified Line-
weaver-Burke plot a double inverse plot derived from the conventional binding 
plot (specifically bound activity versus cell concentration). The immunoreactive 
fraction was calculated by linear extrapolation to the y-axis abscissa as 
described by Lindmo et al (20). 
In vitro binding assays 
The relative affinities of the unlabelled antibody preparations were compared in 
a homologous displacement assay A serial dilution of cold antibody (0 01 - 100 
//g/ml_) was incubated with HeLa cells (8 χ 10 s cells/vial) in the presence of a 
fixed amount of tracer antibody (15000 cpm) in binding buffer. After overnight 
incubation at 4 °C the cells were centrifuged (5 min, 2000g), the supernatant 
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was aspirated and the activity in the pellet was determined. The fraction of 
maximal bound tracer antibody (absence of cold competitor antibody) was 
plotted versus the concentration of cold antibody added. Relative affinity 
constants were calculated as the reciprocal concentration of unlabelled antibody 
required for 5 0 % displacement of the radiolabeled antibody (21). 
The affinities of the radioiodinated M 0 v 1 8 and ОС/TR preparations were 
compared in a Scatchard analysis (22). Briefly, live HeLa cells were washed 
once with cold binding buffer and incubated with serially diluted (10 - 10000 
pM) 125l-labelled antibody. Each vial was counted in the gamma counter to 
determine the total amount of activity added. For each antibody concentration 
the nonspecific binding was determined by incubating a duplicate sample in the 
presence of at least 500-fold excess of unlabelled antibody. After overnight 
incubation at 4 °C cells were centrifuged (5 min, 2000g), the supernatant was 
aspirated and the activity in the pellet was determined. The data were analysed 
by nonlinear weighted regression analysis. 
Table 1. In vitro binding characteristics of the antibody preparations 
Immunoreactive fraction (%) Affinity constant (M1) 
anti-дрЗ anti-CD3/TCR Displacement Scatchard 
MOv18lgG 61 3.0 x 1 0 e 20 χ 10s 
anti-CD3 IgG -- 81 
MOv18 χ anti-CD3 55 76 7.5 χ 107 2 9 χ 108 
anti-CD3 χ mismatch n.d. 69 
n.d. = not detectable 
Subcutaneous ovarian carcinoma model 
The subcutaneous (s.c.) tumour model was established in nude mice by s.c. 
injection of 1x10 7 HeLa cells. Tumours were resected aseptically, minced into 
small pieces of 2-3 mm diameter and serially transplanted subcutaneously at the 
left lumbar region of female BALB/c nude mice. Four to six weeks after trans­
plantation, when tumours measured approximately 5 mm in diameter, mice 
were used for biodistribution studies. 
Biodistribution studies 
Female nude mice with s.c. HeLa xenografts received 0.2 mL of a solution 
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containing both 1 2 5 l - MOv18 IgG (10 дСі/10 дд) and 1 3 Ί - control IgG (mis­
match χ anti-CD3) (10 /i/Ci/10 μφ via the tail vein. Another set of animals 
received a solution containing a mixture of both 1 2 5 l - ОС/TR IgG (10 //Ci/10 /yg) 
and 1 3 ' l - control IgG (anti-CD3 χ mismatch) (10 μ Ο / Ю /уд) via the tail vein. At 
least four mice were used per data point. The biodistribution of the radio-
lodinated antibodies was monitored during 14 days post injection (ρ ι.), enabling 
not only the comparison of tumour accumulation (0 - 3 days), but also of 
tumour retention (3-14 days ρ ι ) of the biMAb and its parental antibody The 
mice were bled under ether anaesthesia at 1, 3, 7 and 14 days p.i. After 
cervical dislocation mice were dissected Blood, liver, kidneys, intestine, muscle 
and tumour were removed Tissues were weighed and radioactivity was measu­
red in a well-type gamma-counter (LKB Wallac, Finland). A correction for scatter 
of 1 3 1 l in the 1 2 5 l channel was made. Tissue uptake was expressed as percentage 
of the injected dose per gram tissue (%ID/g) 
Statistical analysis 
Results are presented as mean ± standard deviation. Differences in tissue 
uptake of the three antibody preparations (MOv18, ОС/TR, control) were 
evaluated in a Student's t-test. 
Results 
Radiolabelling and quality control 
The labelling efficiency of the radioiodinations according to the enzymobead 
method was always between 60 and 8 0 % . ITLC analysis of the radioiodmated 
preparations showed that more than 9 5 % of the iodine-labels was protein-
bound after Sephadex G-25 gel filtration. The immunoreactive fractions of the 
radiolabeled preparations used in the biodistribution studies are presented in 
Table I The anti-tumour reactivity (55%) and the anti CD3 reactivity (76%) of 
the bispecific MAb ОС/TR were in the same range as the reactivity of the 
parental antibodies ( 6 1 % and 8 1 % , respectively). In addition, the control 
antibody (anti-CD3/TCR χ mismatch) revealed an immunoreactive fraction of 
6 9 % for the anti-CD3/TCR reactivity, combined with nondetectable anti-tumour 
reactivity, confirming its monospecific reactivity. 
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Figure 1. A. Homologous displacement assay for MOv18 (O) and OC/TR ( · ) . B. 
Scatchard plot of radioiodmated MOv18 (O) and OC/TR ( · ) binding to HeLa 
cells 
Table 2a. Tissue distribution of intravenously administered '2 5l - MOv18 IgG in 
nude mice wi th s.c. HeLa tumours (%ID/g, mean ± SD, η = 4 ) . 
Organ 
Blood 
Muscle 
Liver 
Intestine 
Kidney 
Tumour 
Time post injection 
1 
15.5 ± 2.6 
1.5 ± 0.2 
3.9 ± 1.0 
1.9 ± 0.2 
4.8 ± 0.9 
12.0 ± 1.8 
(days) 
3 
12.3 ± 1.4 
1.1 ± 0.1 
2.7 ± 0.5 
1.3 ± 0.2 
3.5 ± 0.2 
18.2 ± 2.9 
7 
10.3 ± 1.3 
0.9 ± 0.1 
2.6 ± 0.2 
1.1 ± 0.2 
3.0 ± 0.3 
18.0 ± 2.4 
14 
3 7 ± 1.4 
0.3 ± 0.1 
1.0 ± 0.4 
0.4 ± 0.1 
1.1 ± 0.4 
13.5 ± 0.8 
Table 2b. Tissue distribution of intravenously administered ' 2 5 l - ОС/TR IgG in 
nude mice with s.c. HeLa tumours (%ID/g, mean ± SD, n = 4). 
Organ 
Blood 
Muscle 
Liver 
Intestine 
Kidney 
Tumour 
Time post injection 
1 
13.9 ± 1.2 
2 2 ± 0.9 
4.7 ± 1.3 
2.4 ± 0.9 
5.1 ± 1.9 
14.1 ± 6.7 
(days) 
3 
12.8 ± 1.8 
1.4 ± 0.2 
3.6 ± 0.7 
1.7 ± 0.3 
3.7 ± 0.7 
13.4 ± 2.0 
7 
10.7 ± 2.3 
1.0 ± 0.2 
2.6 ± 0.7 
1.2 ± 0.2 
3.1 ± 0.8 
14.3 ± 1.6 
14 
4.9 ± 1.2 
0.5 ± 0 1 
1.1 ± 0.3 
0.5 ± 0 2 
1.4 ± 0.3 
8.1 ± 1.3 
Table 2c. Tissue distribution of intravenously administered 1 3 , l - anti-CD3 χ mis­
match IgG in nude mice with s.c. HeLa tomours (%ID/g, mean ± SD, 
n = 8). 
Organ 
Blood 
Muscle 
Liver 
Intestine 
Kidney 
Tumour 
Time post injection (days) 
1 
14.4 ± 2.8 
1.6 ± 0.2 
4.2 ± 1.0 
2.0 ± 0.5 
4.3 ± 0.8 
5 6 ± 1.1 
3 
12.3 ± 1.7 
1.2 ± 0.1 
3.2 ± 0.6 
1.6 ± 0.2 
3.8 ± 0.7 
5.5 ± 0.7 
7 
10.0 ± 2.2 
0.9 ± 0.2 
2.8 ± 0.6 
1.2 ± 0.2 
3.1 ± 0.6 
5.1 ± 1.3 
14 
5.9 ± 2.4 
0.6 ± 0.2 
1.7 ± 0.9 
0.7 ± 0.3 
1.8 ± 0 8 
3.3 ± 2.1 
In vitro binding assays 
The displacement of 125l-labelled M 0 v 1 8 binding to HeLa cells with cold M0v18 
is shown in Fig. 1A In this assay the unlabelled MOv18 antibody displays an 
apparent affinity of 3.0x10 8 M 1 . The apparant affinity of the biMAb ОС/TR in 
the same experiment is 4-times lower (7 5x10 7 M 1 ) . 
The Scatchard analysis of the tumour cell binding of both antibody preparations 
is depicted in Fig. 1B The affinity constant of the radioiodmated MOv18 
antibody was 2 04x10 9 M \ while the affinity of the ОС/TR biMAb was 7-
times lower: 2.86x10B M 1. This would indicate that the loss of bivalent antigen 
binding of the bispecific ОС/TR antibody causes a reduction of the affinity with 
a factor 7. The x-axis intercepts indicate that MOv18 could bind a maximum of 
5 3x10 e antigenic determinants on each Heia cell, while ОС/TR could bind 
4 5x10 6 determinants, confirming that both antibododies recognize the same 
epitope on the HeLa cells. 
Biodistribution studies 
The blood clearance data are presented in Figure 2B The blood clearance of the 
ОС/TR biMAb was similar to the clearance of the parental MOv18 antibody and 
the control antibody The elimination half-life (ТУгВ) of the three antibody 
preparations was 9 days. The label uptake of the normal tissues examined was 
lower than the blood level, but clearance of the radiolabel from these tissues 
followed the same pattern (Table 2) Both for MOv18 and ОС/TR the tumour 
uptake was higher than the blood level from three days p.i. onwards In con­
trast, for the control antibody (anti-CD3/TCR χ mismatch biMAb) tumour uptake 
was lower than the blood level at all time points Tumour uptake of MOv18 and 
ОС/TR plateaued between 3 and 7 days p i at 18 ± 3%ID/g and 14 ± 
2%ID/g, respectively (Fig 2A). At all time points, tumour uptake of both M 0 v 1 8 
as well as ОС/TR was significantly higher ( p < 0 05) than the tumour uptake of 
the control antibody, indicating that both antibody preparations showed 
specific, i.e. antigen-binding dependent, tumour localization In addition, MOv18 
tumour uptake was significantly higher than ОС/TR tumour uptake from 3 days 
ρ ι onwards ( p < 0 05) 
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intravenous administration in mice subcutaneously bearing ovarian 
carcinoma. 
Discussion 
The present study shows that the bispecific MOv18 χ anti-CD3/TCR MAb 
ОС/TR specifically localizes in human ovarian carcinoma xenografts in nude 
mice However, the tumour uptake of the ОС/TR biMAb was significantly lower 
than the tumour uptake of the parental MOv18 antibody This reduction in 
tumour uptake can not be ascribed to a more rapid blood clearance of the 
biMAb, since the blood clearance of both antibodies was identical Most likely, 
the reduced tumour uptake of the biMAb is a result of its reduced affinity 
Several studies in nude mouse models have demonstrated that antibody affinity 
is one of the important factors that determine tumour accumulation (23, 24) 
This relationship is elegantly demonstrated in the comparative biodistribution 
experiments of a series of six second generation anti-TAG72 antibodies in nude 
mice with LS174T xenografts (25) It is known that the affinity of a MAb as 
calculated from a Scatchard analysis is not only dependent on the antibody 
used, but also on other experimental conditions, e.g. antigen density on the 
target cell (26), assay volume (27), and ionic strength (28) Therefore, the 
absolute value of the affinity constant of an antibody has only limited value 
This could also explain the fact that the Ka for MOv18 as derived from our 
Scatchard analysis is significantly different from the Ka reported by Miotti et al 
(15) Their determination on OvCa432 cells under different assay conditions 
revealed a 10-times lower affinity constant (2 0x10 8 M ' ) . 
Still, our in results show that the ОС/TR biMAb has a relatively lower affinity 
than the MOv18 antibody. Our observation that the loss of bivalency causes a 
reduction in affinity by a factor 4-7 is in line with other reports comparing the 
affinity of monovalent and bivalent antibody preparations (29,30) Van Dijk et 
al. (29) studied the biodistribution of the anti-RCC χ anti-CD3 biMAb in RCC 
xenografted nude mice. Tumour uptake of the biMAb was not significantly 
different from the tumour uptake of the parental anti-RCC antibody. From their 
data it appeared that the tumour uptake of an anti-tumour antibody is more 
dependent on antibody size (i.e. the blood clearance rate) than antibody affinity 
However, in this study tumour uptake was monitored until 48 h p.ι , and 
possible differences in tumour retention between both antibody preparations 
could not be evaluated. 
In patients the biodistnbution of i.v. administered ОС/TR biMAb might be 
significantly altered by the interaction of the biMAb with T-cells. However, it is 
difficult to study this phenomenon with this biMAb in an animal model, not only 
because nude mice lack mature T-cells, but also because the ОС/TR biMAb 
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does not cross react with murine T-lymphocytes. It would be interesting to 
study the tumour uptake of an anti-T-cell χ anti-tumour biMAb in a syngeneic 
model. 
In conclusion, our data indicate that the biMAb ОС/TR can preferentially localize 
in MOv18-positive tumours. Its reduced affinity as compared to the parental 
MOv18 antibody most likely caused decreased tumour uptake. As indicated in 
the introduction, systemic administration of biMAbs may have some important 
advantages in trying to redirect endogenous T-cells towards a tumour. A clincial 
study to investigate the tumour targeting potential and the therapeutic efficacy 
of ОС/TR F(ab')2 in ovarian cancer patients has been initiated (31). 
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Cytokine release in an ovarian carcinoma patient 
following intravenous administration of bispecific 
antibody ОС/TR F(ab')2 
J.G. Tibben, O.C. Boerman, M. van Deuren, P.H.M, de Mulder, J.W.M, van der 
Meer, К.G.G. Keijser, R.A.M.J. Claessens, L.F.A.G. Massuger, F.H.M. Corstens 
J Natl Cancer Inst 1993, 85: 1003-1004 
Bispecific monoclonal antibodies (biMAbs), which are composed of an anti-
tumour and an anti-effector cell antibody and are thus able to retarget effector 
cells towards tumour cells, have been proposed as a new concept in cancer 
therapy (1). In vitro studies as well as animal experiments with biMAbs have 
demonstrated effective and selective tumour cell lysis (2) 
Limited clinical experience with this type of MAbs has been reported (3, 4) We 
began a phase-l trial in ovarian cancer patients to determine the safety and 
pharmacokinetics of the F(ab')2 fragments of the biMAb ОС/TR and its potential 
to localize in tumours after intravenous (ι ν ) administration The biMAb OC/TR 
combines the anti-tumour reactivity of the M 0 v 1 8 MAb with that of an anti-
human CD3 MAb (5) We observed unexpected toxic effects in the first patient 
enrolled in the study 
After giving written informed consent, this 71-year-old woman was given a 30-
minute ι ν infusion of 1 mg ОС/TR F(ab')2 labelled with 74 MBq (2 mCi) 1 2 3 l . 
Thirty minutes after the infusion, the patient began to experience the following 
symptoms chills and headache (from 30 minutes to 1 hour (h) after infusion), 
nausea, vomiting and diarrhoea (from 1 to 6 h after infusion); fever in combina­
tion with hypotension (from 8 to 16 h after infusion), and fatigue (from 16 to 
40 h after infusion) The patient received appropriate medical treatment for 
these symptoms At 48 h after infusion the patient's clinical condition was 
normalized 
Serum levels of tumour necrosis factor-alpha (TNF) and interferon gamma (IFN) 
peaked simultaneously 2 5 3 5 h after the infusion to levels six and 25 times 
pre-injection levels, respectively (Figure 1) Two-colour f low cytometry indicated 
that, immediately after the infusion, all peripheral CD3+ cells were coated with 
ОС/TR F(ab')2 Planar scintigraphic images showed high uptake in the spleen 
These findings indicated that ОС/TR F(ab')2 was associated with CD3+ positive 
cells in the circulation and in the spleen 
The observed symptoms suggest an acute release of cytokines on infusion of 
the biMAb ОС/TR F(ab')2 Several explanations may be applicable Endotoxin 
contamination during the labeling procedure of the radioimmunoconjugate could 
have caused the observed symptoms. Similar symptoms have been reported 
after intravenous administration of endotoxin (6) Subjects receiving endotoxin 
showed TNF peak levels after 90 minutes, whereas the IFN serum levels were 
not affected or were only slightly influenced. In contrast, a prompt increase in 
both TNF and IFN were reported after infusion of anti-CD3 MAb OKT3 (7) Our 
patient showed a simultaneous increase in TNF and IFN levels, suggesting T-cell 
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Tumour necrosis factor-alpha ( ·) and interferon-gamma (o) serum levels 
before and after infusion of F(ab')2 fragments of the biMAb ОС/TR in a 
71-year-old patient with ovarian carcinoma 
activation rather than endotoxin contamination 
In vitro studies indicate that intracellular clustering of the T-cell receptor 
complex is a prerequisite for effective T-cell activation with anti-CD3 MAbs (8). 
However, this T-cell receptor clustering requires either an intact Fc part of the 
anti-CD3 MAb or immobilization of the anti-CD3 MoAb (9). The anti-tumour 
MAb MOv18 has been shown to be unreactive with white blood cells and to 
have a very restricted reactivity with normal tissue (10). It was therefore 
assumed that F(ab')2 fragments of the biMAb ОС/TR cannot induce such 
clustering. 
In conclusion, our observations suggest that T-cell activation may also occur 
with a monovalent CD3-binding site in the absence of an Fc part when biMoAbs 
are administered systemically. 
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Abstract 
The bispecific monoclonal antibody (biMAb) ОС/TR combines the anti-ovarian 
cancer reactivity of the MOv18 monoclonal antibody (MAb) with the reactivity 
of an anti-CD3 MAb. Preclinical studies have indicated that this biMAb is able to 
redirect the cytolytic activity of T-cells towards tumour cells, resulting in 
efficient tumour cell lysis To assess the clinical potential of systemic biMAb-
based cancer therapy, we initiated a study in ovarian cancer patients 
Five patients suspected of ovarian cancer received 1 2 3 l - ОС/TR F(ab')2 intra 
venously (ι v.). Unexpectedly, the first patient developed side effects (grade III 
IV toxicity) starting 30 minutes post infusion (p.ι ) of 1 mg of ОС/TR F(ab')2. 
After approval of the Ethical Committee, the study was continued at lower dose 
levels (0.1 mg; 0.2 mg). However, at the 0.2 mg dose level similar side effects 
were observed 
Two colour FACS analysis indicated that all peripheral T-cells were coated with 
biMAb immediately following the infusion Scintigraphic images showed high 
uptake in spleen and bone marrow. The cytokines interleukin-2 and tumour 
necrosis factor-σ showed maximum serum concentrations 2 h p.ι. at the 1.0 
and 0.2 mg dose levels, respectively. Tumour uptake as determined in tissue 
biopsies ranged from 0.8 to 1.9%ID/kg, resulting in tumour-to-background 
ratios of 3 to 8. 
Our results indicate that at higher antibody dose levels ( > 0.1 mg) OC/TR 
F(ab')2 causes T-cell activation with acute release of cytokines. Only low doses 
(0 1 mg) biMAb can be administered safely Despite the interaction with T-cells, 
ОС/TR F(ab')2 preferentially localizes in tumours following i.v. administration, 
thus offering therapeutic perspectives 
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Introduction 
A decade ago redirecting effector cells towards tumour cells using bispecific 
monoclonal antibodies (biMAbs) has been proposed as a new concept for cancer 
therapy ( 1 , 2). In this approach biMAbs composed of an anti-tumour antibody 
on one hand and an anti-effector cell antibody on the other, are used to redirect 
the cytotoxic activity of effector cells towards tumour cells T-cell target 
recognition and cytolytic activity is restricted to major histocompatibility 
complex (MHC)-associated epitope presentation In vitro studies have indicated 
that МНС-restriction as well as epitope-specificity of T-cells can be circum­
vented with biMAbs With biMAbs physically linking a T-cell with a tumour cell, 
tumour cell lysis could be obtained using either tumour cell lines or freshly 
isolated tumour cells (3, 4). In several preclinical studies inhibition of tumour 
growth after locoregional administration of pre-activated human peripheral blood 
lymphocytes (PBL) retargeted with anti-tumour χ anti-CD3 biMAbs has been 
demonstrated (5, 6). 
Clinical experience with anti-tumour χ anti-CD3 biMAbs is limited and confined 
to locoregional administration of pre-activated PBL redirected with biMAbs (7, 8, 
9) The first results of these studies indicated that locoregional administration 
can induce local clinical responses. However, with locoregional administration 
growth of distant metastases was not controlled. 
It remains to be investigated whether this approach can also be applied 
systemically Intravenous (i.v.) administration of anti-tumour χ anti-CD3 biMAbs 
in mice with subcutaneous (s.c.) or intraperitoneal (i.p.) human colon carcinoma 
xenografts resulted in specific tumour localization (10, 11). Furthermore, in mice 
with s.c human Hodgkin lymphomas, i.v. administration of anti-tumour χ anti-T-
cell biMAb and pre-activated human PBL resulted in tumour cell lysis and cure 
(12). Moreover, in a syngeneic mouse model with i.p murine lymphoma long-
term survival and cure of the animals was demonstrated after a sole i.v 
injection of biMAb (13). 
In vitro studies have demonstrated that after one cytolytic cycle clustered 
CD3/T-cell receptor (TCR) complexes on the T-cell can no longer transduce the 
lytic signal. Repeated addition of biMAb is required for binding newly expressed 
CD3/TCR complexes to reengage the T-cell in another lytic cycle (14) This 
limitation of the cytolytic mechanism would indicate that administration of 
precoated T-cells is a poor strategy, even if the retargeted T-cells would find the 
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target cell in vivo Based on this, an approach in which the tumour cells are 
coated with biMAb seems preferable (15) In such an approach one would want 
to administer biMAbs systemically 
The present study aimed to investigate localization in tumour, biodistribution 
and toxicity associated with the systemic administration of the biMAb OC/TR 
F(ab')2 | n ovarian cancer patients 
Estimates on the toxicity related to ι ν administration of ОС/TR F(ab')2 were 
based on the following observations and considerations After repeated ι ρ 
infusions of redirected PBL, interleukin 2 (IL-2) and mg doses of ОС/TR F(ab')2. 
only mild toxicity was observed (9) Furthermore, F(ab')2 fragments of the 
biMAb were chosen to exclude other cytolytic mechanisms (antibody dependent 
cellular cytotoxicity, complement activation) than redirection of Τ cells A 
monovalent anti CD3 arm lacking an Fc part excludes crosslinking of CD3 TCR 
complex, therefore, no activation of lymphocytes was expected to occur (16, 
17) Based on these considerations no or at the most mild toxicity was expec­
ted after a single ι ν infusion of a low protein dose of ОС/TR F(ab')2 
To visualize and quantify the biodistribution the biMAb was radiolabeled 1 2 3 l 
was chosen as the most suitable radionuclide for this study because of its 
radiation characteristics and - compared to l 1 1 l n and 9 9 mTc - its minor tendency 
to non specificially accumulate in liver, spleen, kidney and bone marrow 
A weighted antibody dose escalation was proposed because it was assumed 
that the biMAb uptake in tumour in terms of protein amount per gram of tumour 
would increase when a higher protein dose would be administered 
Patients & methods 
Monoclonal antibody 
The biMAb ОС/TR ( ^ G ^ I g G ^ was obtained after fusion of the MOv18 
hybridoma with spleen cells from a Balb/c mouse immunized with a human T-
cell clone (18, 19) The MOv18 monoclonal antibody (MAb) is a murine anti­
body of the IgG! immunoglobulin subclass that recognizes a 38 kDa folate 
binding protein expressed on the majority of ovarian carcinomas as well as on 
adenocarcinomas of the fallopian tube, endometrium and cervix (20, 2 1 , 22, 
23) Using immunoblotting and Northern blot techniques reactivity with normal 
tissues was seen with ovarian, fallopian tube, kidney, lung, thyroid, and choroid 
plexus tissue (24) No reactivity with bone marrow and peripheral blood cells 
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was observed (20) The production and purification of the biMAb ОС/TR and its 
F(ab')2 fragments have been described previously (19). 
Radiolabelling & quality control 
F(ab')2 fragments of ОС/TR were labelled with approximately 185 MBq (5 mCi) 
of 1 2 3 l using the lodogen method (25). All solutions and labware were used 
sterile and pyrogen-free Briefly, the ОС/TR F(ab')2 with 50mM sodium phos­
phate (pH 7 2) was added to an lodogen coated tube (10/yg/100 μ\.) Following 
ten minutes incubation with 1 2 3 l (370 MBq, 25 μΐ, Medgenix, Fleurus, Belgium) 
the reaction mixture was applied on a Sephadex G-25 column and eluted with 
PBS The fractions containing the labelled antibody were pooled Instant thin 
layer chromatography (ITLC) was used to determine the presence of free 1 2 3 l in 
the preparations 
Immunoreactivity of the preparations was assessed both towards HeLa (human 
cervix carcinoma) cells and Jurkat (CD3-positive human acute Τ cell leukemia) 
cells as described previously (26) Data were plotted as described by Lindmo et 
al (27) and the immunoreactive fraction (IRF) was calculated from the y-axis 
abscissa 
Patients 
Patients enroled in the study (n = 5) were suspected of having ovarian cancer 
and were scheduled for surgery. Patients had to be over the age of 18 years 
and had to have a life expectancy of at least 3 months All patients with 
previous exposure to murine MAbs, known allergy for rodents, allergic diathesis, 
life-threatening infection, organ failure, evidence of recent myocardial infarction 
or diagnosis of a second malignancy were excluded Written informed consent 
was obtained prior to study entry. Patient characteristics are summarized in 
Table 1. All studies were conducted with the approval of the Internal Review 
Board of the University Hospital Nijmegen, The Netherlands 
Study design 
Prior to the antibody injection, patients were evaluated by medical history and 
physical examination An electrocardiogram, a chest radiograph, ultrasono­
graphy of the pelvis and X-ray computed tomography of the abdomen (optional) 
were obtained 
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Table 1. Patient characteristics and observations 
Patient biMAb Age FIGO Histology Side Cyto- RIS 
number dose (yr) stage effects kines 
+ + + + 01 
02 
03 
0 4 
05 
(mg) 
1.0 
0 1 
0 1 
0.1 
0 2 
71 
71 
4 9 
66 
56 
lile 
lile 
NA 
la 
NA 
Serous papillary 
cystadenocarcini 
Serous papillary 
adenocarcinoma 
Uterine myoma 
Endometrioid 
adenocarcinoma 
Serous cystaden + + 
NA = not applicable, - = negative; + = positive; + + = strongly positive 
A weighted protein dose escalation was intended, starting at a 1.0 mg protein 
dose. Three patients were planned to receive the same dosage. If no toxicity 
was observed, the study was to be continued at the next higher dose level. 
Endpoint of the study would be WHO-toxicity grade III or IV (28). 
Patients received a single i.v. infusion of 1 2 3 l - ОС/TR F(ab')2 The radioimmuno-
conjugate was diluted in 5 mL saline and infused over 30 minutes. In order to 
prevent thyroid radiation, patients were given 100 mg potassium iodide two 
times a day and potassium Perchlorate 200 mg four times a day orally starting 4 
h before the infusion and continued for 3 days. Vital signs were measured 
frequently up to 8 h post infusion (p.i.). 
Blood samples were collected just prior to the antibody administration and at 
various time intervals until surgery. Radioactivity in the blood as a percentage of 
the injected dose per gram of tissue (%ID/g) was determined. The half-life of 
disappearance from the blood was calculated using non-linear least square 
regression analysis 
Planar images of chest, abdomen and pelvic region in both anterior and posterior 
views were obtained at approximately 4, 24 and 48 h p.ι. with a preset time of 
5, 10, and 15 mm, respectively. Images were obtained with a single-headed 
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gamma camera (Type Orbiter, Siemens Ine , Hoffman Estates, II, USA) equipped 
with a medium energy collimator Planar views were recorded using the 1 59 
keV gamma ray peak of 1 2 3 l with a symmetric 15% window To reduce bladder 
activity patients were asked to void prior to imaging of the pelvic region 
The conjugate view counting technique was used to quantitate the activity 
uptake in some organs (29) Briefly, region of interest (ROI) measurements of 
these organs were performed on anterior and posterior view images at all time 
points After correction for background activity, the geometric mean of anterior 
and posterior images was calculated The absolute uptake in an organ was 
calculated via comparison with whole body counter measurements 
Surgery was performed at approximately 72 h ρ ι in all patients The tumour 
status was carefully mapped Ascites or peritoneal washings were collected 
Suspected tissues were either removed or biopsied If feasible, tissue samples 
of bone marrow, muscle, skin and normal omentum were obtained All tissues 
obtained at operation were weighed and the amount of radioactivity of 1 2 3 l was 
measured using a well type gamma counter 
FA CS analysis 
Two colour fluorescence assisted cell sorter (FACS) analysis was performed to 
study the binding of ОС/TR to white blood cells. Briefly, 100 μ ι samples of 
whole blood were incubated with anti-lgG^phycoerytrin (PE) (50 //L, 10 /yg/mL, 
Southern Biotechnology Associates) and/or with anti-CD3-fluorescecien isothio 
cynate (FITC) (15 μ ι , Becton & Dickinson, Etten-Leur, The Netherlands) Control 
samples were incubated with species and isotype-matched control antibodies 
(PE or FITC-labelled) After washing (200 μ ι HBSS, 0 5% BSA, 0 1 % NaN3) red 
blood cells were lysed with FACS-lysing solution (Becton & Dickinson, Etten 
Leur, The Netherlands) The fluorescence of the lymphocytes was analyzed on a 
Coulter Epics Elite f low cytometer (Coulter, Hialeah, Florida, USA) 
Cytokines 
Blood was collected in ethylene diamine tetra acetic acid (EDTA) tubes and 
immediately put on ice After centrifugaron at 4 °C, plasma was stored at -20 
°C until analysis Plasma levels of the cytokines IL-2, tumour necrosis factor а 
(TNF σ) and interferon-κ (IFN-p) were determined using commercial immuno 
radiometric assays (IRMAs) (IL-2 and IFN, Medgenix, Fleurus, Belgium) and an 
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in-house radioimmuno assay (TNF)(30). 
Humoral anti-OC/TR response 
Development of human anti-mouse antibodies (HAMA) was assessed using 
ОС/TR F(ab')2 m an in-house homologous sandwich-type IRMA. Briefly, OC/TR 
F(ab')2 coated polystyrene wells were incubated with patients sera. After 
washing, the bound HAMA were traced with 125l-labeled ОС/TR F(ab')2. 
Results 
Radiolabelling & quality contro/ 
The labeling efficiency of the radioiodination of the antibody was between 42 
and 78%. After gel filtration ITLC indicated that more than 9 5 % of the 1 2 3 l was 
protein bound The IRF was 40-52% for the anti-tumour arm of the biMAb and 
76 8 4 % for the anti CD3 arm of the antibody. 
Patients 
1.0 mg dose level. Thirty minutes after the ¡.v. infusion of 1 mg of 123l -
ОС/TR F(ab')2 the first patient experienced the following symptoms· chills and 
headache; nausea, vomiting, and diarrhoea; fever up to 40.0 °C in combination 
with hypotension; and fatigue. Symptomatic treatment consisted of admi­
nistration of plasma substitutes, metoclopramide and paracetamol. At 48 h p.ι. 
the patient's clinical condition was normalized. 
According to the study protocol the protein dose should be decreased in case 
toxicity grade III (nausea and vomiting) or IV (fever in combination with 
hypotension) occurred. However, toxicity occurred at the lowest dose level. It 
seemed of scientific interest to further investigate the objectives of the study 
and after approval of the Review Board the study was continued at lower dose 
levels, starting at 0.1 mg. 
0.1 mg dose level. Three patients were injected with 0.1 mg 1 2 3 l - OC/TR 
F(ab')2. One of these patients developed fever up to 39.0 °C from 8 to 10 h p.ι. 
No other side effects were observed. 
0.2 mg dose level. One patient received 0.2 mg. This patient developed 
almost identical symptoms as the first patient: chills and headache, nausea and 
vomiting, hypotension in combination with fever up to 39.1 °C. Again plasma 
substitutes and paracetamol were given to reduce these symptoms. At 24 h p.ι. 
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the patient's clinical condition was normalized. Grade IV toxicity (fever in 
combination with hypotension) again had occurred now at the 0.2 mg dose 
level. At this point the investigators decided to stop the study. 
0 12 24 36 48 
time post infusion (h) 
Figure 1. Blood clearance of 1J3I - ОС/TR F(ab')2 after i.v. administration in patients 
suspected of having ovarian cancer (n = 5) 
Pharmacokinetics 
Blood clearance data are presented in Figure 1. The blood concentrations in 
terms of %ID/g seemed not to be related to the administered antibody dose. 
Therefore, the data of all five patients were pooled. Clearance of ' 2 3 l from the 
blood could be described by a bi-exponential model with mean half-life values of 
1.0 ± 0.2 h (range: 0.7 - 1.2 h) for the distribution phase (ТУг α) and 18.1 ± 
6 7 h (range: 13.0 - 29.6 h) for the elimination phase [ТУг ß), which is in the 
normal range for a F(ab')2 fragment (32). Mean cumulative excretion of the 
radiolabel in the urine was 63 ± 15%ID in 24 h and 76 ± 16%ID in 48 h. 
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Figure 2. Anterior planar ¡mage of the pelvis at 24 h p.i. of a patient with a 
endometrioid adenocarcinoma of the left ovary showing elevated 
tumour uptake (arrow) in the solid part of the tumour whereas the 
cystic part remained photopenic ( + ). 
Figure 3. Anterior planar image of the thorax at 3 h p.i. showing high uptake in 
the lymphoid organs and the bone marrow containing structures. 
chapter 8b 
Organ 
Spleen 
Bone marrow 
Liver 
Kidney 
Thyroid 
Time post infusion (h) 
4 
15 2 + 3 8 
1 4 ± 0.5 
8 5 ± 5 1 
1 3 ± 0 6 
1 3 ± 0 2 
24 
3 9 + 0 7 
0 5 + 0 3 
2 5 ± 1 5 
0 7 ± 0 3 
1 0 + 0 1 
Scintigraphy and dosimetric analysis of the images 
On the images of two patients with ovarian carcinoma the tumour was visual­
ized (Figure 2). With an antibody dose of 0.1 mg tumour was imaged as early 
as 3 h p.ι In the third patient the ovarian tumour deposit with a diameter of 3 
cm was not visualized. This may well be due to activity in the urinary bladder. 
The presence of malignant tumour was surgically and histopathologically con­
firmed. The benign tumours of two patients (uterine myoma and serous cyst-
adenoma of theovary) did not show elevated uptake 
Table 2 Retention in organs based on ROI measurements (expressed as 
%ID, mean + SE) 
48 
1 2 ± 0 8 
0 2 ± 0.2 
1 2 ± 1 2 
0 3 ± 0 2 
0 7 
High 1 2 3 l uptake in the spleen was seen throughout the study in all patients. 
Drawing ROIs, uptake in various organs was calculated for all patients. The 
uptake in the normal tissues seemed not to be related to the administered 
protein dose. Therefore, the data of all five patients were pooled Mean reten­
tion in organs expressed as %ID is presented (Table 2). The uptake in the 
spleen was calculated to be 1 5 2 ± 3.8%ID at 4 h p.ι. Throughout the study 
the splenic uptake decreased to 1 2 ± 0.8%ID at 48 h ρ ι. Particularly at the 
early images (1 - 4 h ρ ι.) bone marrow was clearly depicted (Figure 3). Uptake 
in 2 lumbar vertebrae was 1.4 ± 0.5%ID at 4 h ρ ι. The bone marrow in these 
2 vertebrae constitutes 4.6% of all bone marrow (33). Therefore, total bone 
marrow uptake represented approximately 30%ID at 4 h p.ι , whereas at 48 h 
p.ι total bone marrow uptake was reduced to approximately 4.3%ID The liver 
showed some elevated uptake. The uptake was calculated to be 8.5 ± 5 1 % ID 
at 4 h p.ι The kidneys were hardly visible and, in agreement therewith, the 
calculated uptake was low with 1.3 ± 0.6%ID at 4 h p.ι Retention of the 
radiolabel in the urinary bladder was seen at all time points. Thyroid uptake was 
clearly visible at 24 h and 48 h p.ι., despite the intended blockade of iodine 
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uptake. From ROI measurements thyroid uptake was calculated to be approxi­
mately 1 0%ID throughout the study. 
Tissue uptake 
Uptake data of the five patients were pooled since no influence of the antibody 
dose was observed. Uptake in malignant tumour deposits at approximately 72 h 
p.ι. varied from 0.8 to 1.9%ID/kg, whereas uptake in benign tumour was 0.3 
and 0 6%ID/kg, respectively Uptake in background tissue (muscle) varied from 
0.1 to 0 6%ID/kg. The tumour-to-muscle ratio was 8, 3 and 3 for the patients 
with malignant tumours, whereas in the patients with benign tumours this ratio 
was 1.5 and 1, respectively. 
FA CS analysis 
FACS analysis revealed that at 10 minutes before the completion of the 30 mm 
antibody infusion virtually all CD3+ cells (both CD4+ as well as CD8 + ) were 
coated with ОС/TR F(ab')2 (Figure 4) Differential counting of the blood cells and 
the plasma indicated that less than 15% of the radioactivity was associated 
with the blood cells, indicating that the majority of the biMAb in the circulation 
was not cell-associated 
White blood cell differentiation 
The white blood cell differentiation showed relevant changes post infusion in 
four patients. Starting from half an hour post infusion the absolute number of 
lymphocytes decreased 6 to 21 times, recovering at 48 h ρ ι to pre infusion 
levels (Figure 5). The absolute number of granulocytes showed no consistent 
changes 
Cytokines 
Only the patients who received the 1.0 and 0.2 mg antibody dose, respectively, 
showed IL-2 concentrations above the detection limit of the assay shortly after 
the infusion. The maximum concentrations were measured 2 h p.ι . At 5 and 7 
h p.ι , respectively, the IL-2 concentrations were still elevated, while in the next 
samples obtained at the following day the concentrations had normalized to 
below the detection limit. Maximum serum levels of TNF-σ were also obtained 2 
h p.ι. (Figure 6A). The patients who received the higher doses (1.0 and 0.2 mg) 
demonstrated much higher TNF-σ peaks than those who received the lower 
dose (0.1 mg). The TNF-σ concentrations had normalized to pre-injection levels 
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A typical example of the FACS analysis of peripheral lymphocytes shows 
that immediately post infusion all peripheral C D 3 + cells are coated with 
ОС/TR. However, from 5 h post infusion onwards ОС/TR cannot be 
detected on the peripheral C D 3 + cells. 
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Figure 6A. TNF-σ serum levels before and after intravenous infusion of the biMAb 
ОС/TR F(ab')2 in patients suspected of having ovarian carcinoma. 
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Figure 6B. IL-2, IFN-κ and TNF-σ serum levels before and after intravenous infusion 
of 0.2 mg of the biMAb OCÍTR F(ab')2. 
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at approximately 24 h ρ ι in all patients. In the higher dose patients (1.0 and 
0 2 mg) serum IFN-κ levels peaked simultaneously with IL-2 and TNF-σ (Figure 
6B). The concentrations of IL-2 and TNF-σ correlated well with the clinical 
symptoms highest levels were obtained in the patients who experienced the 
most severe side effects (0 2 and 1 0 mg dose level) Moreover, at the 0 1 mg 
dose, the highest TNF-σ serum level was observed in the patient who expen 
enced fever 
HAMA response 
As soon as 1 and 3 weeks ρ ι , respectively, elevated HAMA titers were 
detected in the serum samples of the patients who received the 1 0 and 0 2 mg 
antibody dose, respectively One of the three patients recieving the 0 1 mg dose 
demonstrated apparent pre-existing HAMA, whereas no HAMA responses were 
observed in the other two patients. 
Discussion 
The present study was performed to investigate the applicability of ι v. adminis 
tration of the biMAb ОС/TR F(ab')2 i n patients suspected of having ovarian 
carcinoma The toxicity and pharmacokinetics associated with the systemic 
administration of this biMAb, and its potential to localize in ovarian tumour were 
studied 
After ι ν infusion tumour localization of ОС/TR F(ab')2 could be visualized on 
the planar images in two out of three patients with ovarian carcinoma Tumour-
to- muscle ratios varied from 3 to 8 in patients with malignant tumours, 
suggesting specific tumour retention. Buist et al reported that two days after 
ι ν injection of 1 mg of the parental MOv18 F(ab')2 tumour uptake was 2 4 ± 
1 4 %ID/kg, with mean tumour-to-background ratios of 4.0 ± 1 8 (32). Tumour 
uptake of the ОС/TR F(ab')2 was somewhat lower This could be either due to 
the monovalent anti-tumour reactivity or to its interaction with Τ cells Still, our 
findings suggest that the absolute tumour uptake obtained with ОС/TR F(ab')2 is 
the result of the ovarian carcinoma-specific MOv18 reactivity of this biMAb 
However, final proof on specific tumour uptake can only be obtained by compar­
ing the tumour uptake of the biMAb ОС/TR with that of a control biMAb with 
CD3-reactivity and an irrelevant other arm 
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Several investigational methods provided information on the interaction of 
ОС/TR F(ab')2 with CD3+ lymphocytes Early planar images showed high 
uptake in spleen and bone marrow in all patients FACS analysis revealed that 
during the ι ν infusion all peripheral CD3+ lymphocytes became coated with 
the biMAb After the completion of the infusion the number of biMAb coated 
lymphocytes decreased rather rapidly In addition, the white blood cell differenti 
ation showed a significant decrease in the number of lymphocytes starting 
immediately after the completion of the infusion Taken together, these findings 
suggest that the biMAb-coated lymphocytes leave the circulation and traffic to 
the lymphoid organs Analogously, Kroesen et al (34) described a rapid 
decrease of BIS-1 F(ab')2 biMAb-coated lymphocytes in blood after ι v. administ­
ration in renal cell cancer patients Their in vitro experiments indicated that this 
could not be attributed to internalization, supporting the hypothesis that T-cells 
loaded with biMAb leave the circulation 
In two patients side effects occurred as early as thirty minutes after the ι ν 
infusion of 1 О and 0 2 mg ОС/TR F(ab')2 Patients experienced chills, head 
ache, nausea and vomiting, diarrhoea, hypotension and fever until approximately 
20 h ρ ι The observed complex of symptoms suggested the acute release of 
cytokines after the infusion of ОС/TR F(ab')2 (35) Serum levels of IL-2, TNF-σ 
and IFN γ increased immediately after the infusion and reached maximum 
concentrations at approximately 2 h ρ ι The IL-2 and TNF-σ levels correlated 
well with the clinical condition of the patients: the highest levels and the 
strongest increase were observed in the patients who experienced the most 
severe adverse reactions 
Similar symptoms were observed in renal cell cancer patients after ι ν adminis­
tration of the biMAb BIS-1 F(ab')2 in combination with s с. injection of IL 2 (34) 
In these patients the TNF-σ levels also peaked at 2 h ρ ι These findings 
suggest that the symptoms observed in the two studies are not the result of 
intrinsic characteristics of a particular MAb, but the consequence of the anti-
CD3 χ anti-tumour antibody construct. 
A similar complex of symptoms has been reported after ι ν administration of 
the anti-CD3 MAb OKT3 in renal transplantation patients (36, 37) The serum 
cytokine levels showed a prompt increase of both TNF-σ and IFN-y In those 
studies it is thought that the acute symptoms are caused by cytokine release 
resulting from T-cell activation by the OKT3 MAb In vitro studies indicate that 
intracellular clustering of the CD3/TCR complex is a prerequisite for effective T-
cell activation with anti-CD3 MAbs (16, 17) However, this clustering can only 
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occur when the biMAb would be immobilized (e.g. via an intact Fc part or via an 
antibody-antigen interaction) (16, 17). The anti-tumour MAb MOv18 is reactive 
with an epitope with a very restricted expression on normal tissue (20, 24). It 
was therefore assumed that F(ab')2 fragments of the biMAb ОС/TR cannot 
induce such clustering except in the presence of tumour cells Theoretically, any 
cells expressing the MOv18 antigen could serve as a template for CD3/TCR 
complex clustering Assuming that a limited number of T-cells would have to be 
activated to produce cytokines in concentrations that could cause the observed 
side effects, this could have happened in any tissue of the body expressing the 
MOv18 epitope. 
It has been suggested that the presence of trace quantities of intact anti-CD3 in 
the biMAb preparations could induce T-cell activation (38). In our study this 
seems highly unlikely, since high performance liquid chromatography (HPLC) 
analysis of the ОС/TR F(ab')2 preparation confirmed the absence of any intact 
IgG molecules. 
Kroesen et al. (34) proposed that the increase in serum cytokine levels may be 
the result of local activation of T-cells at the site of the tumour after cross-
linking of the biMAb with tumour antigens. However, we also observed the 
syndrome in a patient without any known malignant tumour (patient number 
05) 
In conclusion, the concept of redirecting effector cells of the immune system 
towards tumour cells using bispecific antibodies is an attractive therapy concept 
for cancer patients In potential, the biMAb ОС/TR offers therapeutic perspec­
tives, since the i.p. administration of this biMAb, in combination with pre-
activated PBL, resulted in clinical responses. Toxicity of i.v administered biMAb 
seems to be dose-dependent, with evident clinical symptoms at 0.2 and 1.0 mg 
and only subclinical changes in leucocyte differentiation counts at the 0.1 mg 
dose. Repeated injections with 0.1 mg or even lower doses of biMAb may 
probably circumvent the toxicity but may still allow sufficient tumour uptake. 
Perhaps, ι ρ administration may serve as a continuous systemic infusion of low 
doses of biMAb. Further studies are required to better understand the mechan­
isms involved in T-cell activation and the effects at the site of the tumour after 
systemic administration of the bispecific antibody OC/TR. 
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chapter 9 
Summary and conclusions 
Currently, the first-line treatment of patients with advanced ovarian carcinoma 
consists of cytoreductive debulking surgery followed by platinum-based combi-
nation chemotherapy. Despite this aggressive approach, prognosis for the 
majority of patients is still poor. So far, no effective second-line treatment is 
available. Research continues to search for improvement of the established 
therapy regimens and to explore new treatment modalities During the last 
decades the possible applications of anti-tumour monoclonal antibodies (MAbs) 
has gained interest. 
In this thesis several aspects of ovarian cancer targeting with MAbs have been 
evaluated. In chapter 1 the most relevant literature is reviewed Besides an 
overview of the etiology, diagnosis and therapy of ovarian carcinoma, this 
chapter presents a number of aspects affecting tumour targeting with radio 
labelled and bispecific monoclonal antibodies (biMAbs) 
The uptake in tumour of radiolabelled MAb is influenced by many factors such 
as antibody form and radionuclide. Antibody fragments potentially have advan-
tages over intact IgG: a faster blood clearance, higher tumour-to-non-tumour 
tissue ratios, and lower immunogenicity. 
The feasibility of radioimmunoscintigraphy (RIS) with 99mTc - OV-TL 3 Fab' was 
studied in patients suspected of having ovarian cancer (chapter 2). No adverse 
reactions were observed in any of the patients Sensitivity of RIS in 36 surgical-
ly defined and histologically confirmed tumour deposits larger than 1 cm in 
diameter, was 53%, whereas computed tomography (CT) and ultrasonography 
(US) detected 6 1 % and 40%, respectively. The RIS procedure could be com-
pleted within 30 h, which is faster than the procedure with i n l n - DTPA - OV 
TL 3 F(ab')2 used in a previous study. However, the overall imaging perform 
ance was not improved as compared with 111ln-labelled F(ab')2 fragments Lower 
affinity together with faster blood clearance of the Fab' fragment seem to lead 
to lower (absolute) tumour uptake, which may reduce the detection rate 
One of the problems associated with the in vivo application of murine anti-
tumour MAbs is the potential development of human anti-mouse antibodies 
(HAMA). The humoral anti-OV-TL 3 response was analysed with an in-house 
OV TL 3 F(ab')2-based sandwich-type IRMA (chapter 3) The homologous IRMA 
demonstrated that 8 out of 20 (40%) patients had developed HAMA responses 
after a single injection of Fab' fragments and that 14 out of 73 (19%) had 
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developed HAMA responses after F(ab')2 administration. Analysis of the 
subclass of the measured HAMA indicated that IgG, IgM, as well as mixed 
responses occurred Remarkably, the proportion of HAMA-responders after 
injection of OV-TL 3 Fab' fragments was in the same order as the fraction of 
HAMA responders after F(ab')2 administration The kinetics of the HAMA 
responses showed great variations within the patient groups The relevance of 
the sampling time and frequency was demonstrated HAMA responses can be 
easily underestimated due to a low sampling frequency 
One of the major disadvantages of the use of 99mTc-labelled Fab' fragments in 
RIS is their relatively high kidney retention, hampering detection of tumour 
lesions in the upper abdomen The use of cleavable linkers to connect l 1 1 l n to 
MAbs has been described in order to reduce physiologic retention in normal 
organs such as liver, spleen and kidneys Analogously, a cleavable chelator, 
mercaptoacetyltnglycenne (RP-1), for labelling 9 9 mTc to MAbs was developed In 
chapter 4 our animal studies with this new cleavable linker are described In 
ovarian carcinoma bearing nude mice the biodistribution of directly labelled and 
RP-1-linked 9 9 nTc-labelled Fab' fragments of MAbs directed towards ovarian 
carcinoma was compared. Kidney uptake was significantly lower for the RP-1 
linked conjugates. Tumour uptake showed no differences between RP 1 
conjugates and directly labelled preparations 
As a prelude to radioimmunotherapy (RIT), the effect of the route of administra 
tion on the biodistribution of radioiodinated MAb was studied in mice with 
subcutaneous or intraperitoneal (ι ρ ) ovarian carcinoma xenografts (chapter 5) 
In this model dosimetric analysis of the biodistribution of both intravenously 
(i.v ) and ι p. administered radiolabeled MAb indicated that the estimated 
radiation dose that can be guided to solid ι p. tumour deposits was at least 
twice as high following i.p administration compared to ι ν administration 
These results suggest that the ι p. route of administration may be the best 
choice for therapeutic administration of radioiodinated MAbs. 
To assess the clinical potential of ι p. MAb-based RIT, pharmacokinetics, 
biodistribution, estimated radiation dose and toxicity associated with ι ρ 
administration of an escalating protein dose of chimeric MOv18 (cMOv18) IgG 
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labelled with a tracer dose of 1 3 1 l in patients suspected of having ovarian 
carcinoma, were studied (chapter 6). No side effects were observed at any dose 
level Scintigraphic images showed that the radioimmunoconjugate accumulated 
only in ovarian cancer tumours and not in normal tissues With ι ρ administra­
tion of 150 MBq (4 mCi) the radiation doses that could be guided to the large 
ovarian carcinoma tumour masses ranged from 0 3 to 1.5 Gy. With a 7400 
MBq (200 mCi) dose these tumours would absorb a radiation dose varying from 
15 to 76 Gy Extrapolation of the data from the present study to a dose of 
7400 MBq would result in an estimated radiation dose to small tumour deposits 
(1-2 cm in diameter) of at least 12 to 71 Gy. At this dose level (7400 MBq) the 
radiation dose to the marrow was estimated to be 2 4 - 3 1 Gy, indicating that 
reversible myelosuppression could occur These results indicate that with ι ρ 
administration of l 3 1 l cMOv18 IgG radiation doses may provide therapeutic 
effects especially in relatively small tumour deposits 
Bispecific MAbs (biMAbs), which are composed of an anti-tumour and an anti 
effector cell antibody, have been proposed as a new concept in cancer therapy 
In vitro studies as well as animal experiments with biMAbs have demonstrated 
effective and selective tumour cell lysis Preliminary clinical studies with loco-
regional administered biMAbs have indicated locoregional responses The applic­
ability of i.v therapy with the bispecific MAb ОС/TR was investigated in two 
studies The anti-tumour χ anti-T-cell biMAb ОС/TR is a biologically produced 
biMAb combining the anti-ovarian carcinoma activity of the MOv18 MAb with 
anti CD3/T-cell receptor complex (TCR) activity First, the in vitro binding 
characteristics of ОС/TR and its tumour targeting potential were studied in 
ovarian cancer-bearing mice (chapter 7) Scatchard analysis revealed that the 
affinity of the biMAb ОС/TR was 7-times lower than the affinity of the parental 
anti tumour antibody MOv18 Tumour uptake of ОС/TR was significantly higher 
than that of an irrelevant control MAb, indicating specific localization of the 
biMAb However, tumour uptake was significantly lower than the uptake of the 
parental MOv18 MAb Despite the loss of bivalent tumour binding, the biMAb 
can still localize in ovarian tumour deposits These results indicated that the first 
prerequisite of an effective therapeutic approach using systemically applied 
biMAb, ι e tumour localization, can be met 
To assess the clinical potential of systemic biMAb based cancer therapy we 
studied the tumour targeting potential, the biodistribution and toxicity associ-
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ated with systemic administration of ОС/TR F(ab')2 in patients suspected of 
having ovarian cancer (chapter 8). At antibody dose levels of more than 0.1 mg 
of ОС/TR F(ab')2 massive activation of T-cells with acute release of cytokines 
occurred, resulting in serious toxicity such as chills, headache, nausea and 
vomiting, hypotension and fever. Despite the interaction with T-cells, the 
biodistribution data suggested that the biMAb preferentially localized in ovarian 
cancer tumours following ¡.v. administration, thus offering therapeutic perspec-
tives. Repeated injections with 0.1 mg or even lower doses of biMAb may 
probably circumvent the toxicity but may still allow sufficient tumour uptake. 
Perhaps, i.p. administration may serve as a continuous systemic infusion of low 
doses of biMAb. Further studies are required to better understand the mechan-
isms involved in T-cell activation and the effects at the site of the tumour after 
systemic administration of biMAbs. 
Overall, preferential tumour localization of radiolabelled MAbs as well as biMabs 
was obtained after both i.v and i.p. administration. 
The precise role of RIS in the diagnosis of ovarian cancer has to be defined. The 
conventional imaging modalities US and CT lack tissue specificity, resulting in 
poor differentiation between benign and malignant tumours. RIS may provide 
specific information on the presence and localization of malignant tumour with a 
diameter of more than 1 cm. However, in ovarian cancer patients the sensitivity 
of RIS is similar to those of US and CT. RIS only deserves a role in the clinical 
practice in case accurate detection of residual or recurrent disease with a 
diameter of 1 cm or less can be provided. 
Therapy with radiolabelled MAbs is still in its infancy. Most likely, RIT in ovarian 
cancer patients will only be effective in patients with small volume disease. 
There might be a role for RIT as an adjuvant regimen in patients with minimal 
residual disease who are at high risk to develop recurrent disease. 
To improve ovarian cancer targeting, further research should be focused on 
improving tumour uptake. Developing MAbs with higher specificity and/or 
affinity may contribute to better results. Non-specific accumulation in urinary 
bladder, kidneys, and liver has to be reduced to a minimum in order to not 
hamper the detection of small primary and metastatic tumour deposits. The use 
of Mabs that are less immunogenic may allow multiple injections. Further 
research should be focused on defining the most suitable radionuclide for RIT 
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that delivers the optimum radiation dose to the tumour and that is associated 
with the lowest radiation dose to the bone marrow and other organs at risk. In 
addition, the optimal moment in the course of the disease to apply RIT should 
be defined. 
Systemic administration of anti-tumour χ anti-CD3 biMAb is associated with T-
cell activation, resulting in clinical toxicity which limits its applicability. Further 
research is needed to elucidate the many aspects involved in the concept of 
biMAbs. The availability of effector cells, the binding and activation of effector 
cells, and the biological activity of effector cells and the optimal strategy for 
clinical implementation need to be further investigated. 
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Samenvatting en conclusies 
De gangbare behandeling van patiënten met uitgezaaide eierstokkanker bestaat 
uit een operatie, gevolgd door chemotherapie Ondanks deze aggressieve 
benadering, zijn de vooruitzichten voor de meerderheid van deze patiënten 
somber Tot nu toe is er geen afdoende behandeling voor patiënten bij wie de 
ziekte terugkomt Onderzoek naar verbetering van bestaande behandelingen en 
onderzoek naar nieuwe behandelingsmogelijkheden gaat continu door Gedu-
rende de laatste jaren hebben de mogelijke toepassingen van "monoclonale 
antistoffen" in toenemende mate belangstelling gekregen 
Een monoclonale antistof is een eiwit dat in staat is heel speciaal één andere 
structuur (antigeen) te herkennen en te binden In voorgaande jaren zijn mono-
clonale antistoffen (MAbs) ontwikkeld die antigenen herkennen die voornamelijk 
voorkomen op kwaadaardige tumoren Zo zijn er ook MAbs die speciaal anti-
genen op eierstokkankercellen herkennen 
Na toediening zal een anti eierstokkanker MAb zich in het lichaam voornamelijk 
ophopen op die plaatsen waar zich eierstokkankercellen bevinden Door de MAb 
te merken met een radionuclide (= radioactieve stof), kan dit zichtbaar worden 
gemaakt door foto's te maken met een zogenaamde "gamma camera" Dit 
principe kan worden gebruikt voor de opsporing van eierstokkanker Voor 
behandeling van kanker zouden anti-kanker MAbs kunnen worden gekoppeld 
aan radionuclides chemotherapeutica of toxines Nadat de MAbs de kankercel-
len hebben herkend en hieraan zijn gebonden, kan het "meegedragen" middel 
zijn werk doen 
In dit proefschrift werden verschillende aspecten van het gericht leiden van 
MAbs naar eierstokkanker (targeting) geëvalueerd Hoofdstuk 1 geeft een 
overzicht van de meest relevante literatuur Naast een overzicht van de ont-
staanswijze, de opsporing en de behandeling van eierstokkanker, werden een 
aantal aspecten, die de tumor "targeting" met radioactief gemerkte en bispecifie 
ke MAbs beïnvloeden, besproken. 
De opname in tumor van radioactief gelabelde MAb wordt beïnvloed door vele 
factoren, zoals de vorm van de antistof en de keuze van het radionuclide 
Antistof fragmenten (F(ab')2, Fab') hebben een aantal voordelen boven intacte 
immunoglobulines (IgG), namelijk snellere bloedklarmg, hogere tumor/niet-tumor 
weefsel ratio's, en lagere immunogeniciteit 
De bruikbaarheid van radioimmunoscmtigrafie (RIS) met 99mTc - OV-TL 3 Fab' 
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werd bestudeerd in patiënten met eierstokkanker (hoofdstuk 2) In geen van de 
patiënten werden bijwerkingen waargenomen. Met RIS werd 53% van de 36 bij 
operatie gevonden tumoren groter dan 1 cm in diameter zichtbaar gemaakt, 
terwijl computed tomografie (CT) en ultrasonografie (US) respectievelijk 6 1 % en 
40% van de tumoren detecteerden De RIS procedure kon worden voltooid 
binnen 30 uur, wat sneller was dan de procedure met n i l n - DTPA - OV-TL 3 
F(ab')2 dat werd gebruikt in een eerdere studie Echter, de algehele kwaliteit van 
de afbeeldingen werd niet verbeterd in vergelijking met ^In-gemerkte F(ab')2 
fragmenten De lagere affiniteit van het Fab' fragment voor de tumor, in com-
binatie met de snellere bloedklaring, resulteerden in een lagere (absolute) tumor 
opname, wat ten koste ging van de detectie 
Eén van de problemen bij de toepassing van muize anti-tumor MAbs, is de 
mogelijke ontwikkeling van humane anti muize antistoffen (HAMA) De humorale 
anti OV-TL 3 reactie bij patiënten, waarbij intraveneus (via de bloedbaan) OV TL 
3 MAb werd toegediend, werd geanalyseerd met een immunofluorometrische 
bepalingsmethode (hoofdstuk 3) Met deze homologe immunofluorometrische 
test (IFMA) werd aangetoond, dat 8 van de 20 (40%) patiënten HAMA ontwik 
keiden na een éénmalige injectie van Fab' fragmenten en dat 14 van de 73 
(19%) patiënten HAMA ontwikkelden na toediening van F(ab')2 fragmenten 
Analyse van de subklasse van de gemeten HAMA het zien dat zowel IgG, IgM, 
als gemengde reacties optraden Opmerkelijk genoeg was het deel van de pati 
enten, die HAMA ontwikkelden na de injectie van OV-TL 3 Fab' fragmenten, 
vergelijkbaar met de fractie van HAMA-ontwikkelaars na F(ab')2 toediening De 
kinetiek van de HAMA ontwikkeling liet grote variaties zien binnen de patiënten 
groepen Het belang van het tijdstip van bloedafname en van de frequentie van 
de monsterafname werd aangetoond HAMA reacties kunnen eenvoudig worden 
onderschat ten gevolge van een te geringe bemonsteringsfrequentie 
Eén van de nadelen van het gebruik van 99mTc-gemerkte Fab' fragmenten voor 
RIS was de relatieve hoge opname van het radionuclide in de nieren, hetgeen de 
opsporing van tumoren in de bovenbuik bemoeilijkt In de literatuur is beschre 
ven dat de fysiologische ophoping in normale organen zoals lever, milt en nieren 
verminderd kan worden door afbreekbare verbindingen te gebruiken, zodat het 
radionuclide kan worden uitgescheiden Vergelijkbaar hiermee werd een splits 
bare chelator, mercaptoacetyltriglycenne (RP-1), ontwikkeld om 99mTc aan MAbs 
te koppelen In hoofdstuk 4 worden onze dierstudies met deze nieuwe splitsbare 
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verbinding beschreven. In muizen met tumoren werd de biodistributie ( = 
verdeling over het lichaam) van direkt gemerkte en RP-1-gekoppelde 9 9 mTc-Fab' 
fragmenten van MAbs, gericht tegen eierstokkanker, met elkaar vergeleken. De 
nier-opname was inderdaad lager voor de RP-1 gekoppelde verbindingen, terwijl 
de opname in de tumor gelijk bleef 
Als een inleiding tot radioimmunotherapie (RIT), werd het effect van de toedie­
ningsroute op de biodistributie van met 1 2 5 l - en 131l-gelabelde MAb bestudeerd in 
muizen met subcutane ( = onderhuidse) of intraperitoneale (ι ρ ) ( = in de 
buikholte) eierstokkanker (hoofdstuk 5) Dosimetriche analyse van de biodistri­
butie van gelijktijdig intraveneus (ι v.) en ι ρ toegediende MAb gaf aan, dat de 
geschatte stralingsdosis, die via OV-TL 3 F(ab')2 naar de solide ι ρ tumoren kan 
worden geleid, minstens twee keer zo hoog zal zijn na ι ρ toediening, in vergelij 
king met ι ν toediening Deze resultaten geven aan dat de ι ρ toedienings­
route wel eens de beste keus zou kunnen zijn voor behandeling met '^I-gemerk­
te MAbs. 
In patiënten met verdenking op eierstokkanker werd een studie uitgevoerd met 
chimeer ( = deels van de mens, deels van de muis afkomstig) MOv18 (cMOv18) 
IgG, gemerkt met een lage dosis 131l (hoofdstuk 6) De farmacokmetiek, biodis 
tribune, geschatte stralingsdosis en bijwerkingen van ι ρ toediening van een 
oplopende MAb dosis werd bestudeerd Op geen enkel dosisniveau werden 
bijwerkingen waargenomen Gamma-camera foto's lieten zien dat het radioim 
munoconjugaat alleen stapelde in eierstokkanker en niet in normale weefsels. 
Met ι ρ toediening van 150 MBq (4 mCi) varieerde de stralingsdosis, die naar de 
grote tumoren van de eierstokken geleid kon worden, van 0 3 tot 1 5 Gy Met 
een 7400 MBq (200 mCi) dosis zouden deze tumoren een stralingsdosis 
absorberen variërend van 1 5 tot 76 Gy Op een dergelijk dosis niveau (7400 
MBq) werd de stralingsdosis voor beenmerg geschat op 2 4 - 3 1 Gy, zodat nog 
geen onherstelbare schade aan het beenmerg zou optreden Deze resultaten 
vormen een aanwijzing dat ι ρ toediening van l 3 1 l - cMOv18 IgG, met name in 
relatief kleine tumoren, zou kunnen resulteren in stralingsdoses met een thera­
peutisch effect. 
Bispecifieke MAbs (biMAbs) zijn antistoffen die twee verschillende antigenen 
herkennen en kunnen binden BiMabs, samengesteld uit een anti-tumor antistof 
en een anti-immuunsysteem cel antistof, kunnen mogelijk worden toegepast in 
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de behandeling van kanker. In-vitro studies zowel als dierexperimenten met 
biMAbs hebben effectieve en selectieve tumorceldoding laten zien. In studies bij 
patiënten, waarbij biMAbs locoregionaal (= vlakbi] de tumor) werden toege-
diend, werden locoregionale responsen waargenomen De toepasbaarheid van 
ι v. therapie met de bispecifieke MAb ОС/TR werd onderzocht in twee studies 
De anti-tumor χ anti-T-cel biMAb ОС/TR is aan de ene kant gericht tegen 
eierstokkanker (MOv18) en aan de andere kant tegen het CD3/T-cel receptor 
complex (TCR) van T-lymfocyten. In eerste instantie werden de in-vitro bin 
dingskarakteristieken van ОС/TR en de mogelijkheid om in tumor te localiseren 
bestudeerd in eierstokkanker-dragende muizen (hoofdstuk 7). Scatchard analyse 
het zien dat de affiniteit van de biMAb ОС/TR voor de tumor 7 keer lager was 
dan de affiniteit van de oorspronkelijke anti-tumor antistof MOv18. Tumor 
opname van ОС/TR was significant hoger dan die van een irrelevante controle 
MAb, hetgeen duidt op specifieke localisatie van de biMAb. Echter, de tumor 
opname was significant lager dan de opname van de oorspronkelijke MOv18 
MAb Deze resultaten geven aan dat de biMAb, ondanks het verlies van de 
bivalente tumor binding, nog steeds kan localiseren in eierstokkanker. 
In patiënten met verdenking op eierstokkanker werd een studie uitgevoerd met 
de biMAb ОС/TR (hoofdstuk 8) De localisatie in tumor, biodistributie en 
bijwerkingen na i.v. toediening van ОС/TR F(ab')2 werden bestudeerd. Op 
antistof dosis niveaus van meer dan 0.1 mg trad activatie van T-cellen met 
acute afgifte van cytokines op, resulterend in ernstige toxiciteit zoals, koude 
rillingen, hoofdpijn, misselijkheid en braken, hypotensie en koorts. Ondanks de 
interactie met T-cellen, werd een relatief hoge opname in eierstokkanker 
tumoren gevonden na i.v. toediening, hetgeen therapeutische perspectieven 
biedt Met herhaalde injecties van 0.1 mg zou de toxiciteit mogelijk omzeild 
kunnen worden, terwijl voldoende tumor-opname mogelijk blijft. Misschien zou 
i.p. toediening kunnen fungeren als een continue systemische infusie van lage 
doses biMAb. 
De studies beschreven in dit proefschrift hebben laten zien dat specifieke tumor 
localisatie werd verkregen van radioactief gelabelde MAbs en biMAbs na zowel 
ι v. als i.p. toediening. 
De precieze rol van RIS in de diagnostiek van eierstokkanker dient nog te 
worden vastgesteld. De conventionele afbeeldende technieken US en CT missen 
weefsel specificiteit, resulterend in slechte differentiatie tussen benigne en 
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maligne tumoren. RIS zou specifieke informatie kunnen verschaffen over de aan-
wezigheid en localisatie van maligne tumor deposities met een diameter van 
meer dan 1 cm. Echter, in patiënten met eierstokkanker is de sensitiviteit van 
RIS vergelijkbaar met die van US en CT. RIS is een nogal belastende diagnosti-
sche procedure, daarom verdient RIS alleen een rol in de klinische praktijk, 
indien accurate detectie van resterende of recidiverende ziekte met een diameter 
van 1 cm of minder kan worden bereikt. 
Therapie met radioactief gelabelde MAbs staat nog in de kinderschoenen. 
Hoogstwaarschijnlijk zal RIT alleen effectief blijken te zijn in eierstokkanker 
patiënten met kleine tumor deposities. Mogelijk is er een rol weggelegd voor RIT 
als een aanvullende behandeling in patiënten met kleine tumoren. 
Om de "targeting" van eierstokkanker te verbeteren zal verder onderzoek gericht 
moeten zijn op de verbetering van de tumor-opname. Het ontwikkelen van MAbs 
met hogere specificiteit en/of affiniteit zou kunnen bijdragen tot een beter 
resultaat. Niet-specifieke opname in urineblaas, nieren en lever dient tot een 
minimum te worden gereduceerd om de detectie van kleine tumoren mogelijk te 
maken. Het gebruik van MAbs die minder immunogeen zijn zou multiple injecties 
mogelijk moeten maken. Verder onderzoek is nodig om te definiëren welk 
radionuclide het meest geschikt is voor RIT, te weten dat radionuclide, dat de 
optimale stralingsdosis afgeeft aan de tumor en tevens geassocieerd is met de 
laagste stralingsdosis voor het beenmerg en de andere risico organen. Tevens 
dient het optimale moment in het ziektebeloop voor het toepassen van RIT te 
worden vastgesteld. 
Bij systemische toediening van anti-tumor χ anti-CD3 biMAb treedt T-cel 
activatie op, resulterend in klinische toxiciteit, welke de toepasbaarheid beperkt. 
Verder onderzoek is nodig om de vele aspecten te verhelderen, die een rol 
spelen bij het toepassen van biMAbs. De beschikbaarheid van effector cellen, de 
binding en activatie van effector cellen, de biologische activiteit van effector 
cellen en de optimale strategie voor klinische implementatie dienen nader te 
worden onderzocht. 
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verwerking van de onderzoeksgegevens op rolletjes. Marjo en Wim, dank 
voor het inspringen als Emile er eens niet was. 
Antoi Meeuwis, Dirk-Jan Immerzeel en Peter Kok voor het maken van de 
scintigrafische foto's, zelfs in de weekenden en altijd in veelvoud. 
Drs. W.C.A.M. Buijs, beste Wil, je hebt mij de beginselen van de dosime-
trie weten uit te leggen. Lang leve het verval! 
Dr C.M.G. Thomas en Ing. M.F.G. Segers, beste Chris en Tijn, steeds 
waren jullie bereid HAMA's te bepalen en de lab-technische details nader 
te verklaren. 
De medewerkers van het Centraal Dierenlaboratorium, met name Gerrie 
Grutters, Hennie Eikholt en Yvette Brom, voor de prettige samenwerking 
tijdens de dierexperimenten. 
De verpleging van de afdeling Gynaecologie, voor de aanpassingen in de 
gewone gang van zaken en het verrichten van de extra handelingen. 
Het delen van de onderzoeks-frustraties met de leden van de promoven-
da-kring van de W A O maakte het mogelijk de boel te relativeren: gedeel-
de smart is nog altijd halve smart. 
Lieve familieleden en vrienden: jullie belangstelling en steun was onmis-
baar. 
Liefste Rob, zelfs als ik aanwezig was, was ik vaak "afwezig". Dankjewel 
voor je zorg, steun en geduld. 
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Curriculum vitae 
Coby Tibben werd op 15 november 1961 geboren te Zwartsluis. In 1980 
behaalde ZIJ het diploma Atheneum В aan het Carolus Clusius College te Zwolle. 
Na uitgeloot te zijn voor de studie Geneeskunde, begon ZIJ aan de Dagopleiding 
voor Educatief Werk "De Kopse Hof" te Nijmegen In 1981 kon ZIJ alsnog 
beginnen met de studie Geneeskunde aan de Katholieke Universiteit te Nijme­
gen Tijdens de wetenschappelijke stage werden de effecten van cyclophospha­
mide en cisplatinum combmatie-chemotherapie bij patiënten met gevorderd 
ovariumcarcinoom geëvalueerd. Het artsexamen werd behaald in november 
1989. Van mei tot november 1990 was ZIJ in deeltijd als arts-onderzoeker in 
dienst van de afdeling Obstetrie en Gynaecologie (hoofden: Prof.Dr Т.К.A.B. 
Eskes en Prof.Dr R. Rolland) van het Academisch Ziekenhuis Nijmegen St. 
Radboud te Nijmegen. Tijdens deze periode werd onderzoek verricht naar het 
effect van epimestrol op de hypothalame-hypofysaire as bij vrouwelijke proef­
personen. Van september 1990 tot november 1994 werkte ZIJ als arts-onderzoe­
ker binnen het onderzoeksproject "Monoclonale antistoffen tegen kanker 
geassocieerde antigenen, diagnostische en therapeutische mogelijkheden". 
Binnen dit project werd samengewerkt door de afdeling Nucleaire Geneeskunde 
(hoofd: Prof.Dr F.H.M. Corstens) en de afdeling Obstetrie en Gynaecologie van 
het Academisch Ziekenhuis Nijmegen St. Radboud te Nijmegen. Van februari tot 
juli 1994 was ZIJ als AGNIO klinisch werkzaam binnen de afdeling Obstetrie en 
Gynaecologie van het Academisch Ziekenhuis Nijmegen St. Radboud. In augus­
tus 1994 is ZIJ gehuwd met Rob Wiering. Sinds juli 1995 is ZIJ in opleiding tot 
gynaecoloog en is ZIJ werkzaam op de afdeling Obstetrie en Gynaecologie 
(hoofd: Dr J.M.J. Dony) van het Academisch Ziekenhuis Nijmegen St Radboud 
te Nijmegen. 
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Stellingen 
behorend bij het proefschrift 
Diagnostic and therapeutic targeting of ovarian cancer 
using monoclonal antibodies 
1 
Het tijdstip van bloedafname en de frequentie van de monsterafname bij de 
bepaling van humane anti-murine antistoffen (HAMA) is van groot belang· 
HAMA reacties kunnen eenvoudig worden onderschat ten gevolge van een te 
geringe bemonsteringsfrequentie (dit proefschrift). 
2 
BIJ ovariumcarcinoom patiënten leidt intraperitoneale toediening van radioimmu-
noconjugaten tot verminderde opname in normale weefsels, maar niet tot hogere 
tumor-opname (dit proefschrift) 
3 
Intraveneuze toediening van F(ab')2 fragmenten van de anti-tumor χ anti-T-cel 
bispecifieke monoklonale antistof ОС/TR leidt ook bij zeer lage doses tot acute 
activatie van T-cellen (dit proefschrift). 
4 
BIJ radioimmunoscintigrafie met OV-TL 3 voor detectie van ovariumcarcinoom in 
patiënten zal met gebruik van het F(ab')2 fragment, gemarkeerd met technetium-
99m of jodium-1 23, het meest optimale resultaat worden bereikt. 
5 
Toepassing van radioimmunotherapie met jodium-131 -gemarkeerd chimeer 
MOv18 zal waarschijnlijk alleen effectief zijn bij de behandeling van ovanumcar-
cinoompatienten met "minimal residual disease". 
6 
Het meest geschikte moment in het ziektebeloop voor het toepassen van 
radioimmunotherapie zal waarschijnlijk zijn na afloop van de eerstelijns chemo-
therapie. 
7 
Intraperitoneale toediening van ОС/TR F(ab')2 zou kunnen fungeren als een 
continue systemische infusie van lage doses bispecifieke monoklonale antistof, 
resulterend ¡η reductie van de toxiciteit. 
8 
De affiniteit van een antistof, zoals bepaald m een Scatchard analyse, is meer 
afhankelijk van de assay omstandigheden dan van de antistof. 
9 
Ter verbetering van de stadiëring en de behandeling van cervixcarcinoom zal het 
toucher-in-narcose waarschijnlijk vervangen gaan worden door geavanceerde 
radiologische technieken zoals MRI. 
10 
Een "fosfaatverzadigde" grond is niet met fosfaat verzadigd, doch alleen maar 
gevoelig voor fosfaat-uitspoeling. 
11 
De veelheid aan medische tv-programma's leidt bij (potentiële) patiënten niet tot 
een betere kijk op de mogelijkheden van de geneeskunde. 
12 
De beste manier om automobilisten over te halen gebruik te maken van het 
openbaar vervoer, is de files te laten bestaan en de parkeerruimte te beperken. 

